

42nd
ANNUAL GENERAL MEETING
FINANCIAL YEAR 2025-26



**MEDICO INTERCONTINENTAL
LIMITED**

(CIN: L24100GJ1984PLC111413)

CORPORATE INFORMATION

Board of Directors

Tanvi Shah	Chairperson and Non-Executive Director
Samir Shah	Managing Director
Ankur Dave	Independent Director
Priyank Sancheti	Independent Director
Parshwa Shah	Independent Director
Swati Shah	Non-Executive Director

Audit Committee

Ankur Dave	Chairman
Priyank Sancheti	Member
Tanvi Shah	Member

Stakeholders Relationship Committee

Ankur Dave	Chairman
Priyank Sancheti	Member
Tanvi Shah	Member

Nomination and Remuneration Committee

Ankur Dave	Chairman
Priyank Sancheti	Member
Tanvi Shah	Member

Chief Executive Officer

Dilipkumar Bhogilal Shah

Chief Financial Officer

Jay Sharadkumar Shah

Company Secretary & Compliance Officer

Puneeta Sharma

Statutory Auditors

V. Goswami & Co.
3, 2nd Floor, Manek Appt,
Nr. Jain Derasar Temple,
Above Dena Bank, Nehrunagar,
Ahmedabad-380015.

Secretarial Auditor

Agarwal & Mehta Company Secretaries LLP
34/401, Raghukul Apartments,
Sola Road, Naranpura, Ahmedabad,
Gujarat, India, 380063.

Registered Office

1-5th Floor, Adit Raj Arcade,
Nr. Karma Shreshtha Tower,
100 Ft Road, Satellite,
Ahmedabad, Gujarat - 380015, India.

Bankers

ICICI Bank
Standard Chartered Bank

Registrar & Transfer Agent

Purva Sharegistry (India) Pvt. Ltd.
9, Shivshakti Industrial Estate,
JR Boricha Marg, Opp. Kasturba Hospital,
Lower Parel (E), Mumbai- 400011.

Depositories

Central Depository Services (India) Limited

Marathon Futurex, A-wing, 25th Floor,
NM Joshi Marg, Lower Parel,
Mumbai- 400013.

National Securities Depository Limited

Trade World, A wing, 4th & 5th Floors,
Kamala Mills Compound, Lower Parel,
Mumbai- 400013.

S.N.	Particulars	Page No.
1	Message from Managing Director	2
2	Notice of AGM	3
3	Director's Report	42
4	Corporate Governance Report	64
5	Independent Auditors Report and Financials (Standalone)	81
6	Independent Auditors Report and Financials (Consolidated)	129

MESSAGE FROM MANAGING DIRECTOR

Dear Shareholders,

It gives me immense pleasure to connect with you through the Annual Report of Medico Intercontinental Limited for the Financial Year 2025-26. I would like to begin by expressing my sincere gratitude for your continued trust, encouragement, and support. Your confidence in the Company inspires us to pursue new opportunities and create sustainable value.



India's pharmaceutical and healthcare sector continues to demonstrate remarkable resilience and growth potential, driven by increasing healthcare awareness, innovation, and expanding market opportunities. We remain committed to leveraging these opportunities while creating long-term value for all our stakeholders.

A significant milestone during the year was our strategic investment in Calborn Lifescience Private Limited, wherein your Company acquired a 51% equity stake, making it a subsidiary of Medico Intercontinental Limited. Calborn Lifescience possesses a unique product portfolio, particularly in the Vitamin D3 segment, which offers promising opportunities in the nutraceutical and pharmaceutical markets.

As a manufacturing-focused entity, Calborn Lifescience is presently in its development and scaling phase. While the subsidiary has incurred losses during the current year, we view this as a natural part of the investment cycle associated with establishing manufacturing capabilities, achieving operational efficiencies, and building market presence. Such ventures typically require a gestation period of three to four years before realizing their full potential. We remain confident that with sustained efforts, strategic planning, and operational excellence, Calborn Lifescience will evolve into a profitable and valuable subsidiary, contributing meaningfully to the growth of your Company in the years ahead.

Building on our strong nationwide trading operations and strategic partnerships, we continue to focus on expanding our product portfolio, strengthening customer relationships, enhancing operational efficiencies, and exploring new avenues for growth. Our commitment to innovation, quality, and responsible business practices remains unwavering as we strive to create lasting value for our stakeholders.

As we look ahead, our focus will remain on unlocking the potential of our existing businesses, integrating and scaling our new investments, and capitalizing on emerging opportunities within the healthcare and pharmaceutical ecosystem. We are confident that our strategic initiatives will position the Company for sustained growth and enhanced shareholder value.

Our achievements would not have been possible without the dedication, passion, and hard work of our employees. On behalf of the Board of Directors, I express my sincere appreciation to our team members for their invaluable contributions. I also extend my gratitude to our customers, business partners, bankers, regulators, investors, and all stakeholders for their continued trust and support.

As we enter the new financial year, we do so with optimism, determination, and a clear vision for the future. Together, we will continue to build a stronger and more resilient organization capable of delivering sustainable growth and long-term value.

Thank you for your continued support.

Samir D Shah
Managing Director
DIN: 03350268

NOTICE

Notice is hereby given that the **42nd Annual General Meeting** of the Members of **Medico Intercontinental Limited** will be held on Wednesday, 30th September, 2026 at 02:00 P.M. through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements (Standalone & Consolidated) for the financial year ended 31st March, 2026 together with the Reports of Board of Directors and Auditors thereon.
2. To appoint Director in place of Mrs. Swati Jay Shah (DIN: 08420884), who retires by rotation and being eligible offers herself for reappointment.

SPECIAL BUSINESSES:

3. APPROVAL FOR ENTERING INTO RELATED PARTY TRANSACTIONS WITH OXFORD PHARMA:

To consider and, if thought fit, to pass with or without modification(s) the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to Regulations 2(1)(zc), 23(4) and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the applicable provisions of the Companies Act, 2013 read with the related rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and other applicable laws/statutory provisions, if any, and the Company’s Policy on Related Party Transactions, each as amended, the consent of the Members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the ‘Board’, which term shall be deemed to include any Committee constituted/empowered/to be constituted by the Board from time to time to exercise its powers conferred by this resolution) to continue with the existing contract(s)/ arrangement(s)/transaction(s) and/or enter into and/or carry out new contract(s)/ arrangement(s)/transaction(s) (whether by way of an individual transaction or transactions taken together or series of transactions or otherwise), as detailed in the Explanatory Statement, to be entered into and/or carried out and/or continued between / amongst the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) with **Oxford Pharma**, related party of the Company, on such terms and conditions as may be agreed upon between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) and **Oxford Pharma**, for an aggregate value not exceeding Rs. 25 crores during FY 2026-27, subject to such contract(s)/ arrangement(s)/ transaction(s) being carried out at arm’s length and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be necessary and expedient, including finalizing the terms and conditions, methods and modes in respect thereof and finalizing and executing necessary documents, including contract(s), scheme(s), agreement(s) and such other documents, file applications and make representations in respect thereof and seek approval from relevant authorities, including Governmental authorities in this regard and deal with any matters, take necessary steps as the Board may, in its absolute discretion deem necessary, desirable or expedient, to give effect to this resolution and to settle any question that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution.

RESOLVED FURTHER THAT the Board be and is hereby authorized to delegate all or any of the powers herein conferred, to any Director(s) or Chief Financial Officer or Company Secretary or any other Officer(s)/ Authorized Representative(s) of the Company, to do all such acts and take such steps, as may be considered necessary or expedient, to give effect to the aforesaid resolution.

RESOLVED FURTHER THAT all actions taken by the Board, or any person so authorized by the Board, in connection with any matter referred to or contemplated in the foregoing resolution, be and are hereby approved, ratified and confirmed in all respects.”

4. APPROVAL FOR ENTERING INTO RELATED PARTY TRANSACTIONS WITH LYF DISTRIBUTOR:

To consider and, if thought fit, to pass with or without modification(s) the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to Regulations 2(1)(zc), 23(4) and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the applicable provisions of the Companies Act, 2013 read with the related rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and other applicable laws/statutory provisions, if any, and the Company’s Policy on Related Party Transactions, each as amended, the consent of the Members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the ‘Board’, which term shall be deemed to include any Committee constituted/empowered/to be constituted by the Board from time to time to exercise its powers conferred by this resolution) to continue with the existing contract(s)/ arrangement(s)/transaction(s) and/or enter into and/or carry out new contract(s)/ arrangement(s)/transaction(s) (whether by way of an individual transaction or transactions taken together or series of transactions or otherwise), as detailed in the Explanatory Statement, to be entered into and/or carried out and/or continued between / amongst the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) with **LYF Distributor**, related party of the Company, on such terms and conditions as may be agreed upon between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) and **LYF Distributor**, for an aggregate value not exceeding Rs. 6 crores during FY 2026-27, subject to such contract(s)/arrangement(s)/ transaction(s) being carried out at arm’s length and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be necessary and expedient, including finalizing the terms and conditions, methods and modes in respect thereof and finalizing and executing necessary documents, including contract(s), scheme(s), agreement(s) and such other documents, file applications and make representations in respect thereof and seek approval from relevant authorities, including Governmental authorities in this regard and deal with any matters, take necessary steps as the Board may, in its absolute discretion deem necessary, desirable or expedient, to give effect to this resolution and to settle any question that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution.

RESOLVED FURTHER THAT the Board be and is hereby authorized to delegate all or any of the powers herein conferred, to any Director(s) or Chief Financial Officer or Company Secretary or any other Officer(s)/ Authorized Representative(s) of the Company, to do all such acts and take such steps, as may be considered necessary or expedient, to give effect to the aforesaid resolution.

RESOLVED FURTHER THAT all actions taken by the Board, or any person so authorized by the Board, in connection with any matter referred to or contemplated in the foregoing resolution, be and are hereby approved, ratified and confirmed in all respects.”

5. APPROVAL FOR ENTERING INTO RELATED PARTY TRANSACTIONS WITH MEDICO LAB:

To consider and, if thought fit, to pass with or without modification(s) the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to Regulations 2(1)(zc), 23(4) and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the applicable provisions of the Companies Act, 2013 read with the related rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and other applicable laws/statutory provisions, if any, and the Company’s Policy on Related Party Transactions, each as amended, the consent of the Members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the ‘Board’, which term shall be deemed to include any Committee constituted/empowered/to be constituted by the Board from time to time to exercise its powers conferred by this resolution) to continue with the existing contract(s)/ arrangement(s)/transaction(s) and/or enter into and/or carry out new contract(s)/ arrangement(s)/transaction(s) (whether by way of an individual transaction or transactions taken together or series of transactions or otherwise), as detailed in the Explanatory Statement, to be entered into and/or carried out and/or continued between / amongst the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) with **Medico LAB**, related party of the Company, on such terms and conditions as may be agreed upon between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) and **Medico LAB**, for an aggregate value not exceeding Rs. 6 crores during FY 2026-27, subject to such contract(s)/arrangement(s)/ transaction(s) being carried out at arm’s length and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be necessary and expedient, including finalizing the terms and conditions, methods and modes in respect thereof and finalizing and executing necessary documents, including contract(s), scheme(s), agreement(s) and such other documents, file applications and make representations in respect thereof and seek approval from relevant authorities, including Governmental authorities in this regard and deal with any matters, take necessary steps as the Board may, in its absolute discretion deem necessary, desirable or expedient, to give effect to this resolution and to settle any question that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution.

RESOLVED FURTHER THAT the Board be and is hereby authorized to delegate all or any of the powers herein conferred, to any Director(s) or Chief Financial Officer or Company Secretary or any other Officer(s)/ Authorized Representative(s) of the Company, to do all such acts and take such steps, as may be considered necessary or expedient, to give effect to the aforesaid resolution.

RESOLVED FURTHER THAT all actions taken by the Board, or any person so authorized by the Board, in connection with any matter referred to or contemplated in the foregoing resolution, be and are hereby approved, ratified and confirmed in all respects."

6. APPROVAL FOR ENTERING INTO RELATED PARTY TRANSACTIONS WITH CALBORN LIFESCIENCE PRIVATE LIMITED:

To consider and, if thought fit, to pass with or without modification(s) the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to Regulations 2(1)(zc), 23(4) and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the applicable provisions of the Companies Act, 2013 read with the related rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and other applicable laws/statutory provisions, if any, and the Company's Policy on Related Party Transactions, each as amended, the consent of the Members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the 'Board', which term shall be deemed to include any Committee constituted/empowered/to be constituted by the Board from time to time to exercise its powers conferred by this resolution) to continue with the existing contract(s)/ arrangement(s)/transaction(s) and/or enter into and/or carry out new contract(s)/ arrangement(s)/transaction(s) (whether by way of an individual transaction or transactions taken together or series of transactions or otherwise), as detailed in the Explanatory Statement, to be entered into and/or carried out and/or continued between / amongst the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) with **Calborn Lifescience Private Limited**, related party of the Company, on such terms and conditions as may be agreed upon between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) and **Calborn Lifescience Private Limited**, for an aggregate value not exceeding Rs. 130 crores during FY 2026-27, subject to such contract(s)/arrangement(s)/ transaction(s) being carried out at arm's length and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be necessary and expedient, including finalizing the terms and conditions, methods and modes in respect thereof and finalizing and executing necessary documents, including contract(s), scheme(s), agreement(s) and such other documents, file applications and make representations in respect thereof and seek approval from relevant authorities, including Governmental authorities in this regard and deal with any matters, take necessary steps as the Board may, in its absolute discretion deem necessary, desirable or expedient, to give effect to this resolution and to settle any question that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution.

RESOLVED FURTHER THAT the Board be and is hereby authorized to delegate all or any of the powers herein conferred, to any Director(s) or Chief Financial Officer or Company Secretary or any other Officer(s)/ Authorized Representative(s) of the Company, to do all such acts and take such steps, as may be considered necessary or expedient, to give effect to the aforesaid resolution.

RESOLVED FURTHER THAT all actions taken by the Board, or any person so authorized by the Board, in connection with any matter referred to or contemplated in the foregoing resolution, be and are hereby approved, ratified and confirmed in all respects.”

7. APPROVAL FOR ENTERING INTO RELATED PARTY TRANSACTIONS WITH Mr. SAMIR D SHAH:

To consider and, if thought fit, to pass with or without modification(s) the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to Regulations 2(1)(zc), 23(4) and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the applicable provisions of the Companies Act, 2013 read with the related rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and other applicable laws/statutory provisions, if any, and the Company's Policy on Related Party Transactions, each as amended, the consent of the Members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the 'Board', which term shall be deemed to include any Committee constituted/empowered/to be constituted by the Board from time to time to exercise its powers conferred by this resolution) to continue with the existing contract(s)/ arrangement(s)/transaction(s) and/or enter into and/or carry out new contract(s)/ arrangement(s)/transaction(s) (whether by way of an individual transaction or transactions taken together or series of transactions or otherwise), as detailed in the Explanatory Statement, to be entered into and/or carried out and/or continued between / amongst the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) with **Mr. Samir D Shah**, related party of the Company, on such terms and conditions as may be agreed upon between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies) and/or joint venture(s) and **Mr. Samir D Shah**, for an aggregate value not exceeding Rs. 18.50 crores during FY 2026-27, subject to such contract(s)/arrangement(s)/ transaction(s) being carried out at arm's length and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be necessary and expedient, including finalizing the terms and conditions, methods and modes in respect thereof and finalizing and executing necessary documents, including contract(s), scheme(s), agreement(s) and such other documents, file applications and make representations in respect thereof and seek approval from relevant authorities, including Governmental authorities in this regard and deal with any matters, take necessary steps as the Board may, in its absolute discretion deem necessary, desirable or expedient, to give effect to this resolution and to settle any question that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution.

RESOLVED FURTHER THAT the Board be and is hereby authorized to delegate all or any of the powers herein conferred, to any Director(s) or Chief Financial Officer or Company Secretary or any other Officer(s)/ Authorized Representative(s) of the Company, to do all such acts and take such steps, as may be considered necessary or expedient, to give effect to the aforesaid resolution.

RESOLVED FURTHER THAT all actions taken by the Board, or any person so authorized by the Board, in connection with any matter referred to or contemplated in the foregoing resolution, be and are hereby approved, ratified and confirmed in all respects.”

**By order of the Board of Directors
For Medico Intercontinental Limited**

**Place : Ahmedabad
Date : August 14, 2026**

**Sd/-
Puneeta Sharma
Company Secretary
Membership No.: A42989**

Notes:

1. The AGM will be held on Wednesday, 30th September, 2026 at 02:00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with the applicable provision of the Companies Act, 2013 read with MCA latest Circular No. 03/2025 dated September 22, 2025, read with Circulars dated April 8, 2020, April 13, 2020, May 5, 2020, and subsequent circulars issued in this regard, (collectively referred to as 'MCA Circulars') allowing, inter-alia, conducting of AGMs through Video Conferencing / Other Audio-Visual Means ('VC / OAVM') facility till further orders, in accordance with the requirements provided in paragraphs 3 and 4 of the MCA General Circular dated May 5, 2020. The SEBI also vide its Circular No. SEBI/HO/CFD/CFD-PoD-2/P/ CIR/2024/133 dated October 3, 2024 ('SEBI Circular') has provided certain relaxations from compliance with certain provisions of the Listing Regulations. In compliance with these Circulars, provisions of the Act and the Listing Regulations. In compliance with these Circulars, provisions of the Act and Listing Regulations, the 42nd AGM of the Company is being conducted through VC / OAVM facility, without the physical presence of Members at a common venue. The deemed venue for the 42nd AGM shall be the Registered Office of the Company.

As the AGM shall be conducted through VC / OAVM, the facility for appointment of Proxy by the Members is not available for this AGM and hence the Proxy Form and Attendance Slip including Route Map are not annexed to the Notice.

2. However, in pursuance of Section 112 and Section 113 of the Companies Act, 2013, representatives of the members such as the President of India or the Governor of a State or body corporate can attend the AGM through VC/OAVM and cast their votes through e-voting.
3. Body Corporates whose Authorized Representatives are intending to attend the meeting through VC/OAVM are requested to send to the Company on their email ID **mail@medicointercontinental.com** a duly certified copy of the Board Resolution authorizing their representative(s) to attend and vote on their behalf at the Annual General Meeting, pursuant to Section 113 of the Companies Act, 2013.
4. In compliance with the aforementioned provisions of the Act and the Listing Regulations, electronic copy of the Integrated Annual Report for the financial year 2025-26 is being sent to all the Members whose e-mail addresses are registered with the Company / Depository Participant(s) ('DPs') for communication purposes. Additionally, in accordance with Regulation 36(1)(b) of the Listing Regulations, the Company is also sending a letter to Members whose e-mail ids are not registered with Company / RTA / DPs providing the weblink of Company's website from where the Integrated Annual Report for the financial year 2025-26 can be accessed.

In case any Member is desirous of obtaining hard copy of the Integrated Annual Report for the financial year 2025-26 and Notice of the 42nd AGM of the Company, he / she may send request to the Company at **mail@medicointercontinental.com** mentioning Folio No. / DP ID and Client ID.

Members who have questions or are seeking clarifications on the Integrated Annual Report or on the proposals as contained in the Notice, are requested to send e-mail to the Company at **mail@medicointercontinental.com** 14 days in advance before the date of the meeting. This would enable the Company to compile the information and provide the replies at the meeting. The Company will be able to answer only those questions at the meeting which are received in advance as per the above process. The Company will allot time for Members to express their views or give comments during the meeting. The Members who wish to speak at the meeting need to register themselves as a speaker by sending an e-mail from their registered e-mail ID mentioning their name, DP ID and Client ID / Folio number and Mobile number, on e-mail ID **mail@medicointercontinental.com** 14 days in advance before the date of the meeting. Depending on the availability of time, the Company reserves the right to restrict the number of speakers at the meeting.

5. The Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 ('the Act') with respect to Item no. 3 to 7 forms part of the Notice. The Board of Directors has considered and decided to include Item No. 3 to 7 as given above as Special Business in the forthcoming AGM as it is unavoidable in nature. The relevant details as set out under Item No. 3 to 7 of the Notice pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations') and Secretarial Standard - 2 on General Meetings issued by the Institute of Company Secretaries of India ('SS-2') in respect of the Directors seeking appointment / reappointment at this AGM, are also part of the Notice. The directors have furnished consent / declaration for their appointment / re-appointment as required under the Companies Act, 2013 and the Rules there under.

6. Those Shareholders (Physical or Demat) whose email IDs are not registered can get their email ID registered on the website of our RTA i.e., <https://www.purvashare.com/>
7. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
8. The Register of Members and Share Transfer Books of the Company will remain closed from Thursday, 24th September, 2026 to Wednesday, 30th September, 2026 (both days inclusive) in terms of provisions of Section 91 of the Companies Act, 2013.
9. Pursuant to the provisions of the Act and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 and Amendment Rules 2017 notified by the Ministry of Corporate Affairs, the Company is required to transfer all shares in respect of which dividend has not been paid or claimed by the Members for seven consecutive years or more in the name of Investor Education and Protection Fund (IEPF) Suspense Account. As the Company has declared and paid dividend first time in the financial year i.e., F.Y. 2022-23, therefore details related to these provisions are not applicable to the Company.
10. The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act, the Register of Contracts or Arrangements in which the Directors are interested under Section 189 of the Act and all other documents referred to in the Notice and Explanatory Statements, shall be available for inspection in accordance with the applicable statutory requirements based on the requests received by the Company at mail@medicointercontinental.com.
11. The business set out in the Notice will be transacted through electronic voting system and the Company is providing facility for voting by electronic means. Instructions and other information relating to e-voting are given in the Notice under Note no. 30 and 31.
12. In case of joint holders attending the Meeting, only such joint holder who is higher in the order of names will be entitled to vote.
13. The Annual Report along with the Notice of AGM will be placed on the Company's website on www.medicointercontinental.com.
14. Members of the Company holding shares either in physical form or in Dematerialized forms as on Benpos date i.e. 28th August, 2026 will receive Annual Report for the financial year 2025-26 through electronic mode.
15. Members are requested to address all the correspondence to the Registrar and Share Transfer Agents, Purva Sharegistry (India) Private Limited, Unit: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg, Opp., Lower Parel (East), Mumbai-400011.
16. Members are requested to quote their Folio No. or DP ID / Client ID, in case shares are in physical / dematerialized form, as the case may be, in all correspondence with the Company / Registrar and Share Transfer Agent.
17. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020, May 05, 2020, September 25, 2023 and September 19, 2024, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
18. The Board of Directors of the Company has appointed Mr. Yash Mehta, a Practicing Company Secretary, Ahmedabad, as Scrutinizer for conducting the voting process of remote e-Voting and e-Voting during AGM in a fair and transparent manner. The results of the e-Voting shall be declared to the Stock Exchanges within the timeframe prescribed under the Act and the Listing Regulations.
19. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to atleast 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee,

Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

20. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.medicointercontinental.com. The Notice can also be accessed from the websites of the Stock Exchange i.e. BSE Limited at www.bseindia.com. The AGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e. www.evotingindia.com.
21. Members may also note that the Notice of the 42nd AGM and the Annual Report 2025-26 will be available on the Company's website www.medicointercontinental.com. The physical copies of the documents will also be available at the Company's registered office for inspection during normal business hours on working days. Members who require e-communication, or have any other queries, may write to us at: - mail@medicointercontinental.com.
22. As per the SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020; Circular No. SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022; and Circular No. SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023 ("SEBI Circulars") and Circular No. SEBI/HO/DDHS/DDHS-PoD-1/P/CIR/2025/83 dated June 05, 2025 read with MCA General Circular 20/2020 dated 05th May, 2020, MCA General Circular 09/2023 dated 25th September, 2023 and MCA Circular No. 09/2024 dated September 19, 2024; the Annual Report will be sent through electronic mode to those Members whose email IDs are registered with the Registrar and Share Transfer Agent of the Company/ Depository participant.
23. SEBI has mandated that securities of listed companies can be transferred only in dematerialized form. In view of the above and to avail various benefits of dematerialization, Members are advised to dematerialize shares held by them in physical form, for ease in portfolio management.

SEBI introduced a special, time-bound window from July 7, 2025, to January 6, 2026, for the re-lodgment of physical share transfer requests that were previously rejected or returned before April 1, 2019. This initiative allowed Members to transfer and dematerialize shares that faced procedural or documentation issues, aiming to resolve long-standing legacy, non-disputed ownership cases. In order to further facilitate the investors to get rightful access to their securities, SEBI has opened another special window for transfer and dematerialization of physical securities which were sold / purchased before April 1, 2019. This special window is open for a period of 1 (one) year from February 5, 2026 to February 4, 2027 and is available for such transfer requests which were previously submitted and were rejected or returned before April 1, 2019 due to deficiency of documents, process or otherwise. The Members who are eligible for this are requested to take advantage of this special window and have the shares transferred in their name(s).

24. SEBI, vide its circular dated November 3, 2021 (subsequently amended by circulars dated December 14, 2021, March 16, 2023 and November 17, 2023) mandated that the security holders (holding securities in physical form), whose folio(s) do not have PAN or Contact Details or Mobile Number or Bank Account Details or Specimen Signature updated, shall be eligible for any dividend payment in respect of such folios, only through electronic mode with effect from April 1, 2024, only upon furnishing the PAN, contact details including mobile number, bank account details and specimen signature.

Members are requested to submit PAN, or intimate all changes pertaining to their bank details, mandates, nominations, power of attorney, change of address, change of name, e-mail address, contact numbers, specimen signature (as applicable) etc., to their DPs in case of holding in dematerialized form or to Company's RTA through Form ISR-1, Form ISR-2 and Form ISR-3 (as applicable) available at <https://medicointercontinental.com/investors/faqs/> in case of holdings in physical form.

25. As per the provisions of the Act and applicable SEBI Circular, Members holding shares in physical form may file nomination in the prescribed Form SH-13 with RTA or make changes to their nomination details through Form SH-14 and Form ISR-3. In respect of shares held in dematerialized form, the nomination form may be filed with the respective DPs. For relevant forms, please visit the Company's website at <https://medicointercontinental.com/investors/faqs/>
26. Members may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated the listed companies to issue securities in dematerialized form only, while processing Investor service requests, viz. issue of duplicate securities certificate; renewal/ exchange of securities

certificate; endorsement; sub-division/ splitting of securities certificate; consolidation of securities certificates/ folios; transmission and transposition. Further SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/ CIR/2022/65 dated May 18, 2022 has simplified the procedure and standardized the format of documents for transmission of securities.

In furtherance of the Government of India's initiatives on "Ease of Doing Business" and "Ease of Doing Investment", SEBI has dispensed with the requirement of issuance of Letter of Confirmation ('LOC') for effecting direct credit of securities to the dematerialized account of investors. This change aims to speed up the process significantly and will be effective from April 2, 2026. LOCs issued earlier remain valid for dematerialization within 120 days. Under the new framework, investors must already hold a demat account and submit a duly attested, recent Client Master List along with prescribed forms. RTA, Companies and Depositories are required to complete verification and credit securities directly into the demat account within 30 days of the receipt of such request.

Accordingly, Members are requested to make service requests to the Company through e-mail mail@medicointercontinental.com or by writing to the Company's RTA at support@purvashare.com by submitting a duly filled and signed Form ISR-4 & ISR-5, as the case may be along with recent Client Master List. The said forms can be downloaded from the Company's website at <https://medicointercontinental.com/investors/faqs/>.

27. Members holding shares in physical form, in identical order of names, in more than one folio are requested to send to the Company's RTA, the details of such folios together with the share certificates along with the requisite KYC documents for consolidating their holdings in one folio. Requests for consolidation of share certificates shall be processed in dematerialized form as stated above.
28. SEBI vide Circular No. SEBI/HO/OIAE/OIAE_IAD-1/P/ CIR/2023/131 dated July 31, 2023 (updated as on December 20, 2023) has specified that a Member shall first take up his / her / their grievance with the listed entity by lodging a complaint directly with the concerned listed entity and if the grievance is not redressed satisfactorily, the Member may, in accordance with the SCORES guidelines, escalate the same through the SCORES Portal in accordance with the process laid out therein. Only after exhausting all available options for resolution of the grievance, if the Member is not satisfied with the outcome, he / she / they can initiate dispute resolution through the Online Dispute Resolution ('ODR') Portal. Members are requested to take note of the same.
29. The Annual Report 2025-26, the Notice of the 42nd AGM and instructions for e-voting, are being sent by electronic mode to all the members whose email addresses are registered with the Company / Depository Participant(s), unless a member has requested for a physical copy of the documents. For members who have not registered their email addresses and requested for a physical copy of the documents, the said documents are being sent by the permitted mode.
30. **E – Voting Facility:** The remote e-Voting period will begin on Sunday, September 27, 2026 at 9:00 a.m. and will end on Tuesday, September 29, 2026 at 5:00 p.m. During this period, Members of the Company holding shares either in physical form or dematerialized form as on cut-off date, i.e., Wednesday, September 23, 2026, may exercise their vote electronically. The e-Voting module shall be disabled by CDSL for voting thereafter.

A person whose name is recorded in the Register of Members or in the Beneficial Owners maintained by Depositories as on the cut-off date i.e., Wednesday, September 23, 2026 shall be entitled to avail the facility of remote e-Voting as well as e-Voting system during the AGM. Voting rights shall be reckoned on the paid-up value of shares registered in the name of the Member / Beneficial Owner (in case of shares held in dematerialized form) as on the cut-off date i.e., Wednesday, September 23, 2026. The voting right of Members shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Wednesday, September 23, 2026.

A person who is not a member as on the cut-off date should treat this Notice for information purposes only.

31. THE INSTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING AND E-VOTING DURING AGM AND JOINING MEETING THROUGH VC/OAVM ARE AS UNDER:

Step 1: Access through Depositories CDSL/ NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

- i. The voting period begins on Sunday, 27th September, 2026 at 9:00 A.M. and ends on Tuesday, 29th September, 2026 at 5:00 P.M. During this period, shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of Wednesday, September 23, 2026 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- ii. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- iii. Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts / websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1: Access through Depositories CDSL/ NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- iv. In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242** dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode CDSL / NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	1) Users who have opted for CDSL's Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & My Easi New (Token) Tab.
	2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.
	3) If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option.

Type of shareholders	Login Method
	4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders holding securities in demat mode with NSDL Depository	1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS" Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting 4) For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Type of shareholders	Login Method
Individual Shareholders (holding securities in demat mode) login through their Depository Participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911.
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at 022 - 4886 7000 and 022 - 2499 7000

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

v. Login method for e-Voting and joining virtual meeting for **Physical shareholders and shareholders other than individual holding in Demat form.**

- The shareholders should log on to the e-voting website www.evotingindia.com.
- Click on "Shareholders" module.
- Now enter your User ID
 - For CDSL: 16 digits beneficiary ID,
 - For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- Next enter the Image Verification as displayed and Click on Login.
- If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
- If you are a first-time user follow the steps given below:

	For Shareholders holding shares in Demat Form other than Individual and Physical Form
PAN	Enter your 10-digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) - Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.

Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. - If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).
---	--

- vi. After entering these details appropriately, click on "SUBMIT" tab.
- vii. Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- viii. For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- ix. Click on the EVSN for the relevant <Medico Intercontinental Limited> on which you choose to vote.
- x. On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/ NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- xi. Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- xii. After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- xiii. Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- xiv. You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- xv. If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- xvi. There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- xvii. Additional Facility for Non – Individual Shareholders and Custodians – For Remote Voting only.**
 - Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to **www.evotingindia.com** and register themselves in the "Corporates" module.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to **helpdesk.evoting@cdslindia.com**.
 - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
 - The list of accounts linked in the login will be mapped automatically & can be delinked in case of any wrong mapping.
 - It is mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
 - Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz;

yash.ymassociates@gmail.com or mail@medicointercontinental.com respectively, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for Remote e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast **14 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at **mail@medicointercontinental.com**. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **14 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at **mail@medicointercontinental.com**. These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES:

1. **For Physical shareholders** - please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to RTA of the Company at **support@purvashare.com**.
2. **For Demat shareholders** - Please update your email id & mobile no. with your respective Depository Participant (DP).
3. **For Individual Demat shareholders** - Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to **helpdesk.evoting@cdslindia.com** or contact at toll free no. 1800 21 09911.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurax,

Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 21 09911.

31. The Scrutinizer shall after the conclusion of voting at the general meeting, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than two (2) days of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favor or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
33. The Result declared along with the Scrutinizers' Report shall be placed on the Company's website on or before 2nd October, 2026 and on the website of CDSL immediately after the results are declared by the Chairman or any other person authorized by him and the Company shall, simultaneously, forward the results to the concerned Stock exchange where its equity shares are listed.

**By order of the Board of Directors
For Medico Intercontinental Limited**

**Place : Ahmedabad
Date : August 14, 2026**

**Sd/-
Puneeta Sharma
Company Secretary
Membership No.: A42989**

PROOF

Explanatory Statement pursuant to Section 102 (1) of the Companies Act, 2013:

The following statement sets out all the material facts relating the Resolution Nos. 3 to 7 to be passed as mentioned in the accompanying Notice:

In terms of Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') as amended, material related party transactions require prior approval of the shareholders through ordinary resolutions, even if such transactions are in the ordinary course of business of the Company and at an arm's length basis.

As per the Listing Regulations, where the annual consolidated turnover is upto Rs. 20,000 Crores, any transaction with a related party shall be considered material, if the transaction(s) entered into/to be entered into individually or taken together with the previous transactions during a financial year, exceeds 10% of the annual consolidated turnover of the Listed Entity, as per the last audited financial statements of the Company and shall require prior approval of Members by means of an ordinary resolution.

The said limits are applicable even if the transactions are in the ordinary course of business of the concerned company and at an arm's length basis. Further, as per Regulation 2(1)(zc) of the Listing Regulations, the definition of Related Party Transaction ('RPT') includes a transaction involving a transfer of resources, services or obligations between a listed entity or any of its subsidiaries on one hand and a related party of the listed entity or any of its subsidiaries on the other hand, regardless of whether a price is charged or not.

Accordingly, Resolution Nos. 3 to 7 are placed for approval of the Members of the Company.

ITEM NO. 3:

Background, details and benefits of the transaction

Oxford Pharma is a pharmaceutical manufacturing unit in which Mr. Samir Shah, Managing Director of the Company, holds a 50% ownership interest and therefore Oxford Pharma is an enterprise significantly influenced by Directors of the Company.

Our Company (Medico Intercontinental Limited) is primarily engaged in the trading of pharmaceutical products and requires timely procurement of pharmaceutical products in bulk quantities to ensure uninterrupted supply to its customers and vendors. Oxford Pharma possesses adequate manufacturing facilities, production capacity and infrastructure to meet the Company's operational requirements and quality standards.

Considering the Company's business requirements, procurement of products from Oxford Pharma enables the Company to ensure consistent availability of products, timely execution of orders and continuity of supply. Further, owing to the ownership and management involvement of the Managing Director in Oxford Pharma, the Company derives certain operational and commercial advantages, including priority in manufacturing schedules, timely delivery of goods and assured availability of products. These benefits assist the Company in efficiently servicing its customers and fulfilling commitments to its vendors within stipulated timelines.

The transactions between the Company and Oxford Pharma help streamline business operations, ensure uninterrupted availability of pharmaceutical products and support efficient management of the Company's supply chain requirements. The proposed transactions are expected to contribute to operational efficiency, business continuity and enhanced customer satisfaction.

The management has provided the Audit Committee with the relevant details of various proposed related party transactions (RPTs), including the nature of transactions, material terms and basis of pricing. All Independent Directors on the Audit Committee, after reviewing all necessary information, have granted approval for entering into the RPTs with Oxford Pharma for an aggregate value of Rs. 25 Crores during FY 2026-27. The Audit Committee has noted the said transactions with Oxford Pharma will be in ordinary course of business of the Company and are in the best interests of the Company and its shareholders.

The Audit Committee has reviewed the certificate provided by CEO & Managing Director and Chief Financial Officer of the Company, as required under the RPT Industry Standards.

Details of the proposed RPTs between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies), and/or joint venture(s) with Oxford Pharma, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular dated November 11, 2024 and last updated on January 30, 2026 are as follows:

Minimum information to be provided to the Audit Committee and shareholder for approval of Related Party Transactions as per RPT Industry Standards:

S.N.	Particulars of the information	Information provided by the management	
Part A: Minimum information of the proposed RPT			
A (1) Basic details of the related party			
1.	Name of the related party	Oxford Pharma, a Partnership Firm	
2.	Country of incorporation of the related party	India	
3.	Nature of business of the related party	Manufacturing of Pharmaceutical Products	
A (2) Relationship and ownership of the related party			
1.	Relationship between the listed entity (in case of transaction involving the subsidiary) and the related party – including nature of its concern (financial or otherwise) and the following:	Oxford Pharma is an Enterprise significantly influenced by the Management of the Company. Mr. Samir D Shah, Managing Director of the Company is a 50% partner in Oxford Pharma.	
	Shareholding of the listed entity, whether direct or indirect, in the related party.	NA	
	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity.	Not Applicable	
	Shareholding of the related party, whether direct or indirect, in the listed entity	Nil	
A (3) Details of previous transactions with the related party			
1.	Total amount of all the transactions undertaken by the listed entity with the related party during the last financial year.	Details of the transactions by the Company with Oxford Pharma:	
		Nature of transactions in FY 24-25	Amount (in Lakhs)
		Purchase of Goods	953.22
		Sale of Goods	470.42
2.	Total amount of all the transactions undertaken by the listed entity with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	Rs. 400 Lakhs	
3.	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity during the last financial year.	No	
A (4) Amount of the proposed transactions (All types of transactions taken together)			
1.	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders.	Nature of transactions	Amount (in Lakhs)
		Purchase of Goods	1500.00
		Sale of Goods	1000.00
		Total	2500.00
2.	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes	

S.N.	Particulars of the information	Information provided by the management	
3.	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year.	Purchase of Goods = 17.65% Sale of Goods = 11.76%	
4.	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Purchase of Goods = 14.55% Sale of Goods = 14.55%	
5.	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	Purchase of Goods = 50.00% Sale of Goods = 33.33%	
6.	Financial performance of the related party for the immediately preceding financial year.	Particulars for previous FY 24-25	Amount (Rs. in Lakhs)
		Turnover	2464.59
		Profit After Tax	44.81
		Net worth	134.90
A (5) Basic details of proposed transactions to be approved			
1.	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Nature of transactions	Amount (in Lakhs)
		Purchase of Goods	1500.00
		Sale of Goods	1000.00
		Total	2500.00
2.	Details of the proposed transaction	Purchase and Sales of Pharmaceutical Products	
3.	Tenure of the proposed transaction (tenure in number of years or months to be specified)	1 Year (FY 2026-27)	
4.	Whether omnibus approval is being sought?	Yes	
5.	Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	The aggregate value of transactions up to the aforesaid limit of Rs. 25 Crores shall apply during FY 2026-27. Approval of the Members is being sought for material RPTs for FY 2026-27.	
6.	Justification for the transaction	Please refer to, 'Background, details and benefits of the transaction', which forms part of the / explanatory statement to the Resolution No. 3.	
7.	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly.	Mr. Samir D Shah, Managing Director of the Company and Director of the Subsidiaries are 50% partner in Oxford Pharma.	
	a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party	Mr. Samir D Shah 50% partnership (No Shareholding)	
8.	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA	
9.	Other information relevant for decision making.	All relevant information forms a part of this disclosure setting out requisite facts.	

S.N.	Particulars of the information	Information provided by the management
Part B: Additional Information		
B (1) Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances		
1.	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	NA
2.	Basis of determination of price	The Company has considered prevailing market conditions, product quality, manufacturing capacity, delivery timelines, and commercial terms before entering into the proposed transaction. Since Oxford Pharma is an established manufacturing unit with whom the Company has an ongoing business relationship and operational advantages, including priority production and timely delivery of goods, formal bids/quotations were not invited from multiple parties for this transaction. The transaction is proposed considering the business exigencies, continuity of supply, and the overall benefit to the Company. The pricing and terms of the transaction are reviewed by the management and are considered to be at arm's length and in the ordinary course of business.
3.	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	
	a. Amount of trade advance	NA
	b. Tenure	NA
	c. Whether same is self-liquidating?	NA

The said transactions, being a material RPT, require prior approval of the Members of the Company in accordance with Regulation 23 of the Listing Regulations.

Members may note that in terms of the provisions of the Listing Regulations, the related parties as defined thereunder (whether such related party(ies) are a party to the aforesaid transactions or not), shall not vote to approve Resolution under Item No. 3.

Except as mentioned above, none of the Directors and KMPs of the Company and/or their respective relatives are, in any way, concerned or interested either directly or indirectly, financially or otherwise in the Resolution set out at Item No. 3 of the accompanying Notice.

Based on the review and approval of the Independent Directors on the Audit Committee, the Board of Directors recommends the Ordinary Resolution contained in Item No. 3 of the accompanying Notice to the Members for approval.

ITEM NO. 4:

Background, details and benefits of the transaction

LYF Distributor is a pharmaceutical trading firm in which Directors of one of the Wholly Owned Subsidiaries are partners therefore LYF Distributor is an enterprise significantly influenced by Directors of the Company.

LYF is the sole distributor for the products marketed by Evagrace Pharma Private Limited, the Wholly Owned Subsidiary (WOS) of the Company. Through its established distribution network, market reach, and customer base, LYF has significantly contributed towards expanding the market presence and sales volume of the products of the WOS.

Due to the active involvement and distribution efforts of LYF, the turnover and business operations of the WOS have

increased substantially. The transactions are undertaken on an arm's length basis and provide commercially beneficial margins to the Company and its subsidiary.

Accordingly, the proposed RPT is considered to be in the best interests of the Company and its public shareholders as it supports business growth, enhances market penetration, increases revenue generation, and ensures efficient distribution of products in the ordinary course of business.

The management has provided the Audit Committee with the relevant details of various proposed related party transactions (RPTs), including the nature of transactions, material terms and basis of pricing. All Independent Directors on the Audit Committee, after reviewing all relevant information, have granted approval for entering into RPTs with LYF Distributor, for an aggregate value of Rs. 6 Crores during FY 2026-27. The Audit Committee has noted that the said transactions with LYF Distributor will be in the ordinary course of business and are in the best interests of the Company and its shareholders.

The Audit Committee has reviewed the certificate provided by CEO & Managing Director and Chief Financial Officer of the Company, as required under the RPT Industry Standards.

Details of the proposed RPTs between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies), and/or joint venture(s) with LYF Distributor, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular dated November 11, 2024 and last updated on January 30, 2026 are as follows:

Minimum information to be provided to the Audit Committee and shareholder for approval of Related Party Transactions as per RPT Industry Standards:

S.N.	Particulars of the information	Information provided by the management	
Part A: Minimum information of the proposed RPT			
A (1) Basic details of the related party			
1.	Name of the related party	LYF Distributor, a Partnership Firm	
2.	Country of incorporation of the related party	India	
3.	Nature of business of the related party	Trading of Pharmaceutical Products	
A (2) Relationship and ownership of the related party			
1.	Relationship between the listed entity (in case of transaction involving the subsidiary) and the related party – including nature of its concern (financial or otherwise) and the following:	Enterprises Significantly Influenced by Directors of the Wholly Owned Subsidiary of the Company. Mr. Krushant Parekh, Mr. Pavankumar Varma and Mr. Yogendra Rathod, Directors of the Wholly Owned Subsidiary of the Company are partners (100%) of LYF Distributors	
	Shareholding of the listed entity, whether direct or indirect, in the related party.	NA	
	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity.	Not Applicable	
	Shareholding of the related party, whether direct or indirect, in the listed entity	Nil	
A (3) Details of previous transactions with the related party			
1.	Total amount of all the transactions undertaken by the listed entity with the related party during the last financial year.	Details of the transactions by the Company with LYF Distributor:	
		Nature of transactions in FY 24-25	Amount (in Lakhs)
		Sale of Goods	256.95

S.N.	Particulars of the information	Information provided by the management	
2.	Total amount of all the transactions undertaken by the listed entity with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	Rs. 100 Lakhs	
3.	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity during the last financial year.	No	
A (4) Amount of the proposed transactions (All types of transactions taken together)			
1.	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders.	Nature of transactions	Amount (in Lakhs)
		Sale of Goods	600.00
		Total	600.00
2.	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes	
3.	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year.	7.06%	
4.	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	86.95%	
5.	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	100%	
6.	Financial performance of the related party for the immediately preceding financial year.	Particulars for previous FY 24-25	Amount (Rs. in Lakhs)
		Turnover	261.54
		Profit After Tax	-2.13
		Net worth	17.22
A (5) Basic details of proposed transactions to be approved			
1.	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Nature of transactions	Amount (in Lakhs)
		Sale of Goods	600.00
		Total	600.00
2.	Details of the proposed transaction	Sales of Pharmaceutical Products	
3.	Tenure of the proposed transaction (tenure in number of years or months to be specified)	1 Year	
4.	Whether omnibus approval is being sought?	Yes	
5.	Value of the proposed transaction during a financial year.	The aggregate value of transactions up to the aforesaid limit of Rs. 6 Crores shall apply during	

S.N.	Particulars of the information	Information provided by the management
	If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	FY 2026-27. Approval of the Members is being sought for material RPTs for FY 2026-27.
6.	Justification for the transaction	Please refer to, 'Background, details and benefits of the transaction', which forms part of the / explanatory statement to the Resolution No. 4.
7.	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party	No promoter(s) / Director(s) / Key Managerial Personnel of the listed entity have any interest in the transaction. Directors of the Subsidiary Company are partners of LYF Distributors; therefore, indirect interest is there.
8.	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
9.	Other information relevant for decision making.	All relevant information forms a part of this disclosure setting out requisite facts.
Part B: Additional Information		
B (1) Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances		
1.	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	NA
2.	Basis of determination of price	The Company evaluated the distribution capabilities, market reach, existing customer network, operational efficiency, and commercial terms before entering into the proposed transaction. LYF has an established distribution network and proven track record in marketing and distributing the products of Evagrace Pharma Private Limited, which has significantly contributed to the growth in turnover of the WOS. Considering the existing business relationship, operational efficiency, and continuity of business operations, formal bids/ quotations were not invited from multiple distributors for the proposed transaction. The transaction is proposed in the ordinary course of business and on an arm's length basis, and the pricing/commercial terms are reviewed and approved by the management to ensure that they are fair and beneficial to the Company and its public shareholders.
3.	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	
	a. Amount of trade advance	NA
	b. Tenure	NA
	c. Whether same is self-liquidating?	NA

The said transactions, being a material RPT, require prior approval of the Members of the Company in accordance with Regulation 23 of the Listing Regulations.

Members may note that in terms of the provisions of the Listing Regulations, the related parties as defined thereunder (whether such related party(ies) are a party to the aforesaid transactions or not), shall not vote to approve Resolution under Item No. 4.

Except as mentioned above, none of the Directors and KMPs of the Company and/or their respective relatives are, in any way, concerned or interested either directly or indirectly, financially or otherwise in the Resolution set out at Item No. 4 of the accompanying Notice.

Based on the review and approval of the Independent Directors on the Audit Committee, the Board of Directors recommends the Ordinary Resolution contained in Item No. 4 of the accompanying Notice to the Members for approval.

ITEM NO. 5:

Background, details and benefits of the transaction

Medico LAB is a pharmaceutical trading firm in which Company is a 50% partner and therefore Medico LAB is a Joint Venture of the Company.

Medico LAB is a Joint Venture entity of the Company having an established market presence and its own customer base for pharmaceutical products. In addition to its own products, Medico LAB is also engaged in marketing and selling the Company's products through its existing distribution and sales network.

Through this arrangement, the Company is able to expand its market reach, increase product penetration, and enhance sales opportunities in regions and customer segments serviced by Medico LAB. The transaction also enables the Company to achieve better business volumes and operational synergies.

The proposed transactions are undertaken on an arm's length basis and provide commercially viable margins to the Company.

Accordingly, the proposed RPT is considered to be in the best interests of the Company and its public shareholders as it contributes towards revenue growth, improved market access, and overall profitability of the Company in the ordinary course of business.

The management has provided the Audit Committee of the Directors ("Audit Committee") with the relevant details of various proposed related party transactions (RPTs), including the nature of transactions, material terms and basis of pricing. The Audit Committee, after reviewing the relevant information, has approved the proposed transactions, for an aggregate value of Rs. 6 Crores during FY 2026-27. The Audit Committee has noted that the said transactions are in the ordinary course of business and are in the best interests of the Company and its shareholders.

The Audit Committee has reviewed the certificate provided by CEO & Managing Director and Chief Financial Officer of the Company, as required under the RPT Industry Standards.

Details of the proposed RPTs between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies), and/or joint venture(s) with Medico LAB, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular dated November 11, 2024 and last updated on January 30, 2026 are as follows:

Minimum information to be provided to the Audit Committee and shareholder for approval of Related Party Transactions as per RPT Industry Standards:

S.N.	Particulars of the information	Information provided by the management
Part A: Minimum information of the proposed RPT		
A (1) Basic details of the related party		
1.	Name of the related party	Medico LAB, a Partnership Firm
2.	Country of incorporation of the related party	India
3.	Nature of business of the related party	Trading of Pharmaceutical Products
A (2) Relationship and ownership of the related party		
1.	Relationship between the listed entity (in case of transaction involving the subsidiary) and the related	Enterprises Significantly Influenced by Directors of the Company

S.N.	Particulars of the information	Information provided by the management	
	party – including nature of its concern (financial or otherwise) and the following:	The Company is holding 50% partnership in Medico LAB	
	Shareholding of the listed entity, whether direct or indirect, in the related party.	NA	
	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity.	50%	
	Shareholding of the related party, whether direct or indirect, in the listed entity	Nil	
A (3) Details of previous transactions with the related party			
1.	Total amount of all the transactions undertaken by the listed entity with the related party during the last financial year.	Details of the transactions by the Company with Medico LAB:	
		Nature of transactions in FY 24-25	Amount (in Lakhs)
		Purchase of Goods	8.49
		Sale of Goods	308.16
		Interest Income	12.34
2.	Total amount of all the transactions undertaken by the listed entity with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	Purchase of Goods = 10 Lakhs Sale of Goods = 7.5 Lakhs	
3.	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity during the last financial year.	No	
A (4) Amount of the proposed transactions (All types of transactions taken together)			
1.	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders.	Nature of transactions	Amount (in Lakhs)
		Purchase of Goods	100.00
		Sale of Goods	450.00
		Interest Income	50.00
		Total	600.00
2.	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes	
3.	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year.	Purchase of Goods = 1.17% Sale of Goods = 5.29% Interest Income = 0.60%	
4.	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Purchase of Goods = 0.60% Sale of Goods = 7.27% Interest Income = 0.90%	

S.N.	Particulars of the information	Information provided by the management	
5.	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	Purchase of Goods = 16.86% Sale of Goods = 75.88% Interest Income = 8.43%	
6.	Financial performance of the related party for the immediately preceding financial year.	Particulars for previous FY 24-25	Amount (Rs. in Lakhs)
		Turnover	564.19
		Profit After Tax	20.40
		Net worth	309.10
A (5) Basic details of proposed transactions to be approved			
1.	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Nature of transactions	Amount (in Lakhs)
		Purchase of Goods	100.00
		Sale of Goods	450.00
		Interest Income	50.00
		Total	600.00
2.	Details of the proposed transaction	Purchase & Sale of Pharmaceuticals Products and Interest Income on Invested Capital	
3.	Tenure of the proposed transaction (tenure in number of years or months to be specified)	1 Year	
4.	Whether omnibus approval is being sought?	Yes	
5.	Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	The aggregate value of transactions up to the aforesaid limit of Rs. 6 Crores shall apply during FY 2026-27. Approval of the Members is being sought for material RPTs for FY 2026-27.	
6.	Justification for the transaction	Please refer to 'Background, details and benefits of the transaction', which forms part of the explanatory statement to the Resolution No. 5.	
7.	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party	NA	
8.	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA	
9.	Other information relevant for decision making.	All relevant information forms a part of this disclosure setting out requisite facts.	
Part B: Additional Information			
B (1) Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances			
1.	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	NA	

S.N.	Particulars of the information	Information provided by the management
2.	Basis of determination of price	The Company evaluated the business credentials, market reach, customer base, operational capabilities, and commercial terms of Medico LAB before entering into the proposed transaction. Considering the strategic business relationship, operational synergies, and the established distribution network of Medico LAB for marketing and selling the Company's products, formal bids/ quotations were not invited from multiple parties for the proposed transaction. The transaction is undertaken in the ordinary course of business and on an arm's length basis. The pricing and commercial terms are periodically reviewed by the management to ensure that the transactions are fair, commercially reasonable, and in the best interests of the Company and its public shareholders.
3.	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	
	a. Amount of trade advance	NA
	b. Tenure	NA
	c. Whether same is self-liquidating?	NA
B (3) Disclosure only in case of transactions relating to investment made by the Listed entity or its Subsidiary (including interest income received from the investment made)		
1.	Source of funds in connection with the proposed transaction. <i>Note: This item of disclosure is not applicable to listed banks/ NBFCs/insurance companies/ housing finance companies.</i>	NA
2.	Where any financial indebtedness is incurred to make investment, specify the following: <i>Note: This item of disclosure is not applicable to listed banks/ NBFCs /insurance companies/housing finance companies.</i> a. Nature of indebtedness b. Total cost of borrowing c. Tenure d. Other details	NA
3.	Purpose for which funds shall be utilized by the investee company.	NA
4.	Material terms of the proposed transaction	Interest on capital contributed by the Company to the partnership firm (Medico LAB), payable at the rate of 12% per annum (or such lower rate as may be permissible under the partnership deed and applicable law), on the outstanding capital contribution, in accordance with the terms of the partnership deed.

The said transactions, being a material RPT, require prior approval of the Members of the Company in accordance with Regulation 23 of the Listing Regulations.

Members may note that in terms of the provisions of the Listing Regulations, the related parties as defined thereunder (whether such related party(ies) are a party to the aforesaid transactions or not), shall not vote to approve Resolution under Item No. 5.

Except as mentioned above, none of the Directors and KMPs of the Company and/or their respective relatives are, in any way, concerned or interested either directly or indirectly, financially or otherwise in the Resolution set out at Item No. 5 of the accompanying Notice.

Based on the review and approval of the Independent Directors on the Audit Committee, the Board of Directors recommends the Ordinary Resolution contained in Item No. 5 of the accompanying Notice to the Members for approval.

ITEM NO. 6:

Background, details and benefits of the transaction

Calborn Lifescience Private Limited, Subsidiary of the Company in which Company holds 51% stake.

The proposed Related Party Transactions ("RPTs") are in the ordinary course of business and are undertaken on an arm's length basis. The holding company acts as the sole selling agent for the subsidiary, facilitating the marketing and sale of the subsidiary's products.

Entering into such transactions enables the subsidiary to leverage the holding company's established market presence, distribution network, customer relationships, and operational expertise, thereby enhancing business efficiency, revenue generation, and overall commercial growth. Accordingly, the proposed RPTs are considered to be in the best interests of the listed entity and its public shareholders.

The management has provided the Audit Committee of Directors ("Audit Committee") with the relevant details of various proposed related party transactions (RPTs), including the nature of transactions, material terms and basis of pricing. All Independent Directors on the Audit Committee, after reviewing all relevant information, have granted approval for entering into RPTs with Calborn Lifescience Private Limited for an aggregate value upto Rs. 130 Crores during FY 2026-27. The Audit Committee has noted that the said transactions with Calborn Lifescience Private Limited will be in the ordinary course of business and are in the best interests of the Company and its shareholders.

The Audit Committee has reviewed the certificate provided by CEO & Managing Director and Chief Financial Officer of the Company, as required under the RPT Industry Standards.

Details of the proposed RPTs between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies), and/or joint venture(s) with Calborn Lifescience Private Limited, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular dated November 11, 2024 and last updated on January 30, 2026 are as follows:

Minimum information to be provided to the Audit Committee and shareholder for approval of Related Party Transactions as per RPT Industry Standards:

S.N.	Particulars of the information	Information provided by the management
Part A: Minimum information of the proposed RPT		
A (1) Basic details of the related party		
1.	Name of the related party	Calborn Lifescience Private Limited, Subsidiary of the Company
2.	Country of incorporation of the related party	India
3.	Nature of business of the related party	Manufacturing of API (Cholecalciferol – Vitamin D3)
A (2) Relationship and ownership of the related party		
1.	Relationship between the listed entity (in case of transaction involving the subsidiary) and the related party – including nature of its concern (financial or otherwise) and the following:	Subsidiary The Company is holding 51% stake in Calborn Lifescience Private Limited

S.N.	Particulars of the information	Information provided by the management	
	Shareholding of the listed entity, whether direct or indirect, in the related party.	51%	
	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity.	Not Applicable	
	Shareholding of the related party, whether direct or indirect, in the listed entity	Nil	
A (3) Details of previous transactions with the related party			
1.	Total amount of all the transactions undertaken by the listed entity with the related party during the last financial year.	Details of the transactions by the Company with the Subsidiary:	
		Nature of transactions in FY 24-25	Amount (in Lakhs)
		Not Applicable as this is the first-year post Calborn Lifescience Private Limited became Subsidiary of the Company.	
2.	Total amount of all the transactions undertaken by the listed entity with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	Purchase of Goods = 400 Lakhs Sale of Goods = 100 Lakhs Loan Given = 500 Lakhs	
3.	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity during the last financial year.	No	
A (4) Amount of the proposed transactions (All types of transactions taken together)			
1.	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders.	Nature of transactions	Amount (in Lakhs)
		Purchase of Goods	5500.00
		Sale of Goods	1000.00
		Loan Given	5000.00
		Interest Income	500.00
		Investment	1000.00
		Total	13000.00
2.	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes	
3.	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year.	Purchase of Goods = 64.71% Sale of Goods = 11.76% Loan given = 58.82% Interest Income = 5.88% Investment = 11.76%	
4.	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Purchase of Goods = 100% Sale of Goods = 18.18% Loan given = 90.90% Interest Income = 9.09% Investment = 18.18%	

S.N.	Particulars of the information	Information provided by the management	
5.	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	Purchase of Goods = 550.00% Sale of Goods = 100.00% Loan given = 500.00% Interest Income = 50.00% Investment = 100.00%	
6.	Financial performance of the related party for the immediately preceding financial year.	Particulars for previous FY 24-25	Amount (Rs. in Lakhs)
		Not Applicable as this is the first-year post Calborn Lifescience Private Limited became Subsidiary of the Company.	
A (5) Basic details of proposed transactions to be approved			
1.	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Nature of transactions	Amount (in Lakhs)
		Purchase of Goods	5500.00
		Sale of Goods	1000.00
		Loan Given	5000.00
		Interest Income	500.00
		Investment	1000.00
		Total	13000.00
2.	Details of the proposed transaction	As mentioned above	
3.	Tenure of the proposed transaction (tenure in number of years or months to be specified)	1 Year	
4.	Whether omnibus approval is being sought?	Yes	
5.	Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	The aggregate value of transactions up to the aforesaid limit of Rs. 130 Crores shall apply during FY 2026-27. Approval of the Members is being sought for material RPTs for FY 2026-27.	
6.	Justification for the transaction	Please refer to 'Background, details and benefits of the transaction', which forms part of the explanatory statement to the Resolution No. 6.	
7.	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party	NA	
8.	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA	
9.	Other information relevant for decision making.	All relevant information forms a part of this disclosure setting out requisite facts.	
Part B: Additional Information			
B (1) Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances			
1.	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	NA	

S.N.	Particulars of the information	Information provided by the management
2.	Basis of determination of price	Since the holding company is acting as the sole selling agent of the subsidiary, competitive bids / quotations were not invited for the proposed transaction. The arrangement is based on the long-standing business relationship, operational synergies, and the holding company's established distribution and marketing network, which enables efficient sales facilitation for the subsidiary. Accordingly, no separate bidding process was undertaken for the proposed transaction.
3.	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	
	a. Amount of trade advance	NA
	b. Tenure	NA
	c. Whether same is self-liquidating?	NA
B (2) Disclosure only in case of transactions relating to loans and advances (other than trade advances) or inter-corporate deposits given by the listed entity or its subsidiary		
1.	Source of funds in connection with the proposed transaction. <i>Note: This item of disclosure is not applicable to listed banks/ NBFCs/insurance companies/ housing finance companies.</i>	Internal arrangements by the Company through trade receivables or any other business funds generated internally.
2.	Where any financial indebtedness is incurred to make investment, specify the following: <i>Note: This item of disclosure is not applicable to listed banks/ NBFCs /insurance companies/housing finance companies.</i> a. Nature of indebtedness b. Total cost of borrowing c. Tenure d. Other details	Not Applicable
3.	Rate of interest at which the listed entity or its subsidiary is borrowing from its bankers/ other lenders. <i>Note:</i> (1) <i>This item of disclosure is not applicable to listed banks/ NBFCs/insurance companies/ housing finance companies.</i> (2) <i>Disclosure shall be made of borrowings undertaken by the listed entity with a comparable maturity profile to the loan/ICD being granted by the listed entity</i>	10.00% p.a. to 12.00 % p.a.
4.	Proposed interest rate to be charged by listed entity or its subsidiary from the related party.	12.00% p.a
5.	Maturity / due date	Repayable on demand
6.	Repayment schedule & terms	Repayable on demand

S.N.	Particulars of the information	Information provided by the management
7.	Whether secured or unsecured?	Unsecured
8.	If secured, the nature of security & security coverage ratio	NA
9.	The purpose for which the funds will be utilized by the ultimate beneficiary of such funds pursuant to the transaction.	Business purpose mainly working capital requirements.
B (3) Disclosure only in case of transactions relating to investment made by the Listed entity or its Subsidiary (including interest income received from the investment made/ inter corporate loan provided)		
1.	Source of funds in connection with the proposed funds transaction. <i>Note: This item of disclosure is not applicable to listed banks/ NBFCs/insurance companies/ housing finance companies.</i>	As may be determined at the time of taking funds.
2.	Where any financial indebtedness is incurred to make investment, specify the following: <i>Note: This item of disclosure is not applicable to listed banks/ NBFCs /insurance companies/housing finance companies.</i> a. Nature of indebtedness b. Total cost of borrowing c. Tenure d. Other details	As may be determined at the time of taking funds.
3.	Purpose for which funds shall be utilized by the investee company.	Principle business activities.
4.	Material terms of the proposed transaction	As may be determined at the time of taking funds.
B (4) Disclosure only in case of guarantee (including performance guarantee in nature of security/ contractual commitment or which could have an impact in monetary terms on the issuer of such guarantee), surety, indemnity or comfort letter, by whatever name called, made or given by the listed entity or its subsidiary.		
1.	(a) Rationale for giving guarantee, surety, indemnity or comfort letter (b) Whether it will create a legally binding obligation on listed entity? Yes or No	Bank guarantee to the Mehsana Urban Bank of the Subsidiary Company. Yes
2.	Material covenants of the proposed transaction including: (i) commission, if any to be received by the listed entity or its subsidiary; (ii) contractual provisions on how the listed entity or its subsidiary will recover the monies in case such guarantee, surety, indemnity or comfort letter is invoked.	NA
3.	The value of obligations undertaken by the listed entity or any of its subsidiary, for which a guarantee, surety, indemnity or comfort letter has been provided by the listed entity or its subsidiary.	Upto an amount of Rs. 28.91 Cr

S.N.	Particulars of the information	Information provided by the management
	Additionally, any provisions required to be made in the books of account of the listed entity or any of its subsidiary shall also be specified.	
C (1) Transactions relating to any loans and advances (other than trade advance) or inter-corporate deposits given by the listed entity or its subsidiary.		
1.	Latest credit rating of the related party. <i>Note: Standalone rating to be provided while option to provide structured obligation rating (SO rating) and credit enhancement rating (CE rating), if any</i>	Subsidiary has initiated process with Crisil for obtaining credit rating and the same is under Process.
2.	Default on borrowings, if any, over the last three financial years, by the related party from the listed entity or any other person and value of subsisting default. <i>Note: This information may be provided to the extent it is available in the public domain or as may be provided by the related party upon request.</i> In addition, state the following: a) Whether the account of the related party has been classified as a non-performing asset (NPA) by any of its bankers and whether such status is currently subsisting; b) Whether the related party has been declared a "wilful defaulter" by any of its bankers and whether such status is currently subsisting; c) Whether the related party is undergoing or facing any application for commencement of an insolvency resolution process or liquidation; d) Whether the related party, not being an MSME, suffers from any of the disqualifications specified under Section 29A of the Insolvency and Bankruptcy Code, 2016.	NA
C (2) Disclosure only in case of material transactions relating to any investment made by the listed entity or its subsidiary.		
1.	Latest credit rating of the related party <i>Note:</i> 1. Standalone rating to be provided while option to provide structured obligation rating (SO rating) and credit enhancement rating (CE rating), if any 2. This shall be applicable in case of investment in debt securities	Subsidiary has initiated process with Crisil for obtaining credit rating and the same is under Process.
	Whether any regulatory approval is required. If yes, whether the same has been obtained.	Not Applicable
C (3) Disclosure only in case of transactions relating to any guarantee (including performance guarantee in nature of security/contractual commitment or which could have an impact in monetary terms on the issuer of such guarantee), surety, indemnity or comfort letter, by whatever name called, made or given by the listed entity or its subsidiary.		
1.	If guarantee, performance guarantee (in nature of security/contractual commitment or which could have an	Under process of obtaining credit rating.

S.N.	Particulars of the information	Information provided by the management
	impact in monetary terms on the issuer of such guarantee), surety, indemnity or comfort letter is given in connection with the borrowing by a related party, provide latest credit rating of the related party <i>Note:</i> a. <i>Standalone rating to be provided while option to provide structured obligation rating (SO rating) and credit enhancement rating (CE rating), if any.</i> b. <i>This information may be provided to the extent it is available in the public domain or as may be provided by the related party upon request.</i>	
2.	Details of solvency status and going concern status of the related party during the last three financial years: FY 2025-26 FY 2024-25 FY 2023-24	Going concern in current FY (The entity became a subsidiary of the Company during the current financial year; accordingly, the going concern assessment is applicable from the current financial year.)
3.	The value of obligations undertaken by the listed entity or any of its subsidiary, for which a guarantee, performance guarantee (in nature of security/contractual commitment or which could have an impact in monetary terms on the issuer of such guarantee) surety, indemnity or comfort letter has been provided by the listed entity or its subsidiary. Additionally, any provisions required to be made in the books of account of the listed entity or any of its subsidiary shall also be specified.	Upto an amount of Rs. 28.91 Cr
4.	Default on borrowings, if any, over the last three financial years, by the related party from the listed entity or any other person and value of subsisting default. <i>Note: This information may be provided to the extent it is available in the public domain or as may be provided by the related party upon request.</i> In addition, state the following: a) Whether the account of the related party has been classified as a non-performing asset (NPA) by any of its bankers and whether such status is currently subsisting; b) Whether the related party has been declared a "wilful defaulter" by any of its bankers and whether such status is currently subsisting; c) Whether the related party is undergoing or facing any application for commencement of an insolvency resolution process or liquidation; d) Whether the related party, not being an MSME, suffers from any of the disqualifications specified under Section 29A of the Insolvency and Bankruptcy Code, 2016.	Not Applicable

S.N.	Particulars of the information	Information provided by the management
	Justification as to why the proposed transaction is in the interest of the listed entity, basis for determination of price and other material terms and conditions of RPT.	The proposed Related Party Transactions (“RPTs”) are in the ordinary course of business and are undertaken on an arm’s length basis. The holding company acts as the sole selling agent for the subsidiary, facilitating the marketing and sale of the subsidiary’s products. Entering into such transactions enables the subsidiary to leverage the holding company’s established market presence, distribution network, customer relationships, and operational expertise, thereby enhancing business efficiency, revenue generation, and overall commercial growth. Accordingly, the proposed RPTs are considered to be in the best interests of the listed entity and its public shareholders.

The said transactions, being a material RPT, require prior approval of the Members of the Company in accordance with Regulation 23 of the Listing Regulations.

Members may note that in terms of the provisions of the Listing Regulations, the related parties as defined thereunder (whether such related party(ies) are a party to the aforesaid transactions or not), shall not vote to approve Resolution under Item No. 6.

Except as mentioned above, none of the Directors and KMPs of the Company and/or their respective relatives are, in any way, concerned or interested either directly or indirectly, financially or otherwise in the Resolution set out at Item No. 6 of the accompanying Notice.

Based on the review and approval of the Independent Directors on the Audit Committee, the Board of Directors recommends the Ordinary Resolution contained in Item No. 6 of the accompanying Notice to the Members for approval.

ITEM NO. 7:

Background, details and benefits of the transaction

Mr. Samir D Shah, Managing Director of the Company. The Company proposes to enter into the Related Party Transactions (“RPTs”) with Mr. Samir Shah, Managing Director of the Company, considering his significant contribution towards the growth and operations of the Company and its subsidiary.

The proposed transactions are in the best interests of the Company and its public shareholders as they facilitate efficient business operations, strategic decision-making, and overall business growth.

Further, the said transactions are undertaken in the ordinary course of business and are conducted on an arm’s length basis, ensuring that the terms are comparable to those prevailing in similar transactions with unrelated parties. The management have reviewed the proposed arrangements and is of the view that the transactions are fair, commercially beneficial, and aligned with the long-term growth objectives of the Company and its subsidiary, thereby safeguarding the interests of the public shareholders.

The management has provided the Audit Committee of Directors (‘Audit Committee’) with the relevant details of various proposed related party transactions (RPTs), including the nature of transactions, material terms and basis of pricing. All Independent Directors on the Audit Committee, after reviewing all relevant information, have granted approval for entering into RPTs with Mr. Samir D Shah for an aggregate value upto Rs. 18.50 Crores during FY 2026-27. The Audit Committee has noted that the said transactions with Mr. Samir D Shah will be in the ordinary course of business and are in the best interests of the Company and its shareholders.

The Audit Committee has reviewed the certificate provided by CEO & Managing Director and Chief Financial Officer of the Company, as required under the RPT Industry Standards.

Details of the proposed RPTs between the Company and/or its subsidiary(ies), wholly owned subsidiary(ies), and/or joint venture(s) with Mr. Samir D Shah, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular dated November 11, 2024 and last updated on January 30, 2026 are as follows:

Minimum information to be provided to the Audit Committee and shareholder for approval of Related Party Transactions as per RPT Industry Standards:

S.N.	Particulars of the information	Information provided by the management	
Part A: Minimum information of the proposed RPT			
A (1) Basic details of the related party			
1.	Name of the related party	Mr. Samir D Shah	
2.	Country of incorporation of the related party	India	
3.	Nature of business of the related party	Pharmaceutical and Real estate Industry	
A (2) Relationship and ownership of the related party			
1.	Relationship between the listed entity (in case of transaction involving the subsidiary) and the related party – including nature of its concern (financial or otherwise) and the following:	Managing Director of the Company holding 46.40% shares in the Company	
	Shareholding of the listed entity, whether direct or indirect, in the related party.	Not Applicable	
	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity.	Not Applicable	
	Shareholding of the related party, whether direct or indirect, in the listed entity	46.40%	
A (3) Details of previous transactions with the related party			
1.	Total amount of all the transactions undertaken by the listed entity with the related party during the last financial year.	Details of the transactions by the Company with the Subsidiary:	
		Nature of transactions in FY 24-25	Amount (in Lakhs)
		Remuneration paid	60.00
		Rent paid	4.80
		Interest paid	0.52
		TOTAL	65.32
2.	Total amount of all the transactions undertaken by the listed entity with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	Remuneration = 15 Lakhs Rent = 1.20 Lakhs	
3.	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity during the last financial year.	No	
A (4) Amount of the proposed transactions (All types of transactions taken together)			
1.	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders.	Nature of transactions	Amount (in Lakhs)
		Remuneration paid	240.00
		Rent paid	10.00
		Interest paid	100.0
		Loan taken	1500.00
		Total	1850.00

S.N.	Particulars of the information	Information provided by the management	
2.	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes	
3.	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year.	Remuneration paid = 2.82% Rent paid = 0.12% Interest paid = 1.18% Loan taken = 17.65%	
4.	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	Remuneration paid = 4.36% Rent paid = 1.09% Interest paid = 18.18% Loan taken = 27.27%	
5.	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	NA	
6.	Financial performance of the related party for the immediately preceding financial year.	Particulars for previous FY 24-25	Amount (Rs. in Lakhs)
		Related party being Individual, these figures are not applicable	
A (5) Basic details of proposed transactions to be approved			
1.	Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)	Nature of transactions	Amount (in Lakhs)
		Remuneration paid	240.00
		Rent paid	10.00
		Interest paid	100.00
		Loan taken	1500.00
		Total	1850.00
2.	Details of the proposed transaction	As mentioned above	
3.	Tenure of the proposed transaction (tenure in number of years or months to be specified)	1 Year	
4.	Whether omnibus approval is being sought?	Yes	
5.	Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	The aggregate value of transactions up to the aforesaid limit of Rs. 18.50 Crores shall apply during FY 2026-27. Approval of the Members is being sought for material RPTs for FY 2026-27.	
6.	Justification for the transaction	Please refer to, 'Background, details and benefits of the transaction', which forms part of the explanatory statement to the Resolution No. 7.	
7.	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly.	Mr. Samir D Shah, Managing Director, holding 46.40% shares in the Company.	
	a. Name of the director / KMP	Mr. Samir D Shah	
	b. Shareholding of the director / KMP, whether direct or indirect, in the related party	NA	

S.N.	Particulars of the information	Information provided by the management
8.	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
9.	Other information relevant for decision making.	All relevant information forms a part of this disclosure setting out requisite facts.
Part B: Additional Information		
B (1) Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances		
1.	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	NA
2.	Basis of determination of price	Considering the nature of the transaction and the involvement of Mr. Samir Shah, Managing Director of the Company, the services/transactions are of a specialized and strategic nature and are closely linked to the operational requirements of the Company and its subsidiary. Accordingly, comparative bids/quotations from external parties were not considered feasible. However, the Audit Committee and the Board have reviewed the terms of the proposed transaction and confirmed that the same are at arm's length, in the ordinary course of business, and comparable with prevailing market practices. The transaction is considered commercially beneficial and in the best interest of the Company and its public shareholders.
3.	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	
	a. Amount of trade advance	NA
	b. Tenure	NA
	c. Whether same is self-liquidating?	NA
B (2) Disclosure only in case of transactions relating to loans and advances (other than trade advances) or inter-corporate deposits given by the listed entity or its subsidiary		
1.	Source of funds in connection with the proposed transaction. Note: This item of disclosure is not applicable to listed banks/ NBFCs/insurance companies/ housing finance companies.	Not Applicable as Loan and advances not given by the listed entity, instead Loan will be provided by Mr. Samir D Shah to Company, if required
2.	Where any financial indebtedness is incurred to make investment, specify the following: Note: This item of disclosure is not applicable to listed banks/ NBFCs /insurance companies/housing finance companies. a. Nature of indebtedness b. Total cost of borrowing c. Tenure d. Other details	Not Applicable

S.N.	Particulars of the information	Information provided by the management
3.	Rate of interest at which the listed entity or its subsidiary is borrowing from its bankers/ other lenders. Note: (1) This item of disclosure is not applicable to listed banks/ NBFCs/insurance companies/ housing finance companies. (2) Disclosure shall be made of borrowings undertaken by the listed entity with a comparable maturity profile to the loan/ICD being granted by the listed entity	10.00% p.a. to 12.00% p.a.
4.	Proposed interest rate to be charged by listed entity or its subsidiary from the related party.	Not Applicable
5.	Maturity / due date	Not Applicable
6.	Repayment schedule & terms	Not Applicable
7.	Whether secured or unsecured?	Unsecured
8.	If secured, the nature of security & security coverage ratio	NA
9.	The purpose for which the funds will be utilized by the ultimate beneficiary of such funds pursuant to the transaction.	Business purpose mainly working capital requirements.
C (1) Transactions relating to any loans and advances (other than trade advance) or inter-corporate deposits given by the listed entity or its subsidiary.		
1.	Latest credit rating of the related party. <i>Note: Standalone rating to be provided while option to provide structured obligation rating (SO rating) and credit enhancement rating (CE rating), if any</i>	NA
2.	Default on borrowings, if any, over the last three financial years, by the related party from the listed entity or any other person and value of subsisting default. Note: This information may be provided to the extent it is available in the public domain or as may be provided by the related party upon request. In addition, state the following: a) Whether the account of the related party has been classified as a non-performing asset (NPA) by any of its bankers and whether such status is currently subsisting; b) Whether the related party has been declared a "wilful defaulter" by any of its bankers and whether such status is currently subsisting; c) Whether the related party is undergoing or facing any application for commencement of an insolvency resolution process or liquidation; d) Whether the related party, not being an MSME, suffers from any of the disqualifications specified under Section 29A of the Insolvency and Bankruptcy Code, 2016.	NA

S.N.	Particulars of the information	Information provided by the management
C (2) Disclosure only in case of material transactions relating to any investment made by the listed entity or its subsidiary.		
1.	Latest credit rating of the related party Note: 3. Standalone rating to be provided while option to provide structured obligation rating (SO rating) and credit enhancement rating (CE rating), if any 4. This shall be applicable in case of investment in debt securities	Not Applicable
	Whether any regulatory approval is required. If yes, whether the same has been obtained.	Not Applicable

The said transactions, being a material RPT, require prior approval of the Members of the Company in accordance with Regulation 23 of the Listing Regulations.

Members may note that in terms of the provisions of the Listing Regulations, the related parties as defined thereunder (whether such related party(ies) are a party to the aforesaid transactions or not), shall not vote to approve Resolution under Item No. 7.

Except as mentioned above, none of the Directors and KMPs of the Company and/or their respective relatives are, in any way, concerned or interested either directly or indirectly, financially or otherwise in the Resolution set out at Item No. 7 of the accompanying Notice.

Based on the review and approval of the Independent Directors on the Audit Committee, the Board of Directors recommends the Ordinary Resolution contained in Item No. 7 of the accompanying Notice to the Members for approval.

**By order of the Board of Directors
For Medico Intercontinental Limited**

**Place : Ahmedabad
Date : August 14, 2026**

**Sd/-
Puneeta Sharma
Company Secretary
Membership No.: A42989**

Details of Director Seeking Re-appointment at the Annual General Meeting

Disclosure required under Regulation 36 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard - 2 in respect of Directors seeking appointment / reappointment:

Name of the Director	Swati Jay Shah
DIN	08420884
Nationality	Indian
Date of Appointment on Board	29/05/2019
Qualification	LLM and PhD in Law
Shareholding in company	-
List of Directorships held in other Companies (excluding foreign, private and Section 8 Companies)	NA
Memberships of Audit and Stakeholders' Relationship Committees across Public Companies	-
Remuneration paid or sought to be paid	-
Relationship with other Directors/KMP	Wife of Mr. Jay Shah, CFO of the Company.
Nature of Expertise	Mrs. Swati Shah, aged 33 years, is having LLM and PhD in Law and having an experience of Legal field which will be helpful for the Company in case of any legal matters which may arise in future.
Brief Resume	Mrs. Swati Shah, aged 33 years, is having LLM and PhD in Law and having an experience of Legal field.
Skills and Capabilities of an Independent Director required for the role and the manner in which the person meets such requirements	-

**By order of the Board of Directors
For Medico Intercontinental Limited**

**Place : Ahmedabad
Date : August 14, 2026**

**Sd/-
Puneeta Sharma
Company Secretary
Membership No.: A42989**

DIRECTORS' REPORT

Dear Members,

The Board of Directors hereby submits the report of the business and operations of your Company ("the Company" or "MIL"), along with Audited Financial Statements for the financial year ended 31st March, 2026. The Consolidated performance of the Company and its subsidiaries have been referred to wherever required.

1. FINANCIAL PERFORMANCE OF THE COMPANY:

(Rs. In Lakhs, except per equity share data)

Particulars	Standalone		Consolidated	
	For the year ended 31st March		For the year ended 31st March	
	2026	2025	2026	2025
Revenue from Operations	5446.08	6712.98	8408.41	9531.53
Other Income	234.54	50.77	127.04	41.71
Total Income	5680.62	6763.75	8535.45	9573.23
Less: Total Expenses	(5132.80)	(6283.41)	(8110.82)	(8713.12)
Profit/Loss before Depreciation, Finance Costs, Exceptional items and Tax expenses	547.82	480.34	424.63	860.11
Less: - Depreciation/Amortization/ Impairment	(69.35)	(55.57)	(542.75)	(78.69)
Profit/Loss before Finance Costs, Exceptional items and Tax expenses	478.47	424.77	(118.12)	781.42
Less: - Finance Costs	(166.83)	(67.22)	(815.92)	(99.31)
Profit/Loss before Exceptional items and Tax expenses	311.64	357.55	(934.04)	682.11
Add/(Less): - Exceptional Items	0.00	0.00	0.00	0.00
Profit/Loss before Tax expenses	311.64	357.55	(934.04)	682.11
Less: - Tax Expense (Current & Deferred)	(93.28)	(100.97)	(175.06)	(186.58)
Profit/Loss for the year (1)	218.36	256.58	(1109.10)	495.53
Other Comprehensive Income/Loss (2)	0.00	0.00	0.00	0.00
Total (1+2)	218.36	256.58	(1109.10)	495.53
Earnings Per Share (Basic & Diluted)	2.18	2.57	-3.20	5.06

2. RESULT OF OPERATIONS & STATE OF COMPANY'S AFFAIR:

Standalone: The total income of the Company was Rs. 5680.62 Lakhs during current year as against Rs. 6763.75 Lakhs in the previous year. The Company has reported net profit of Rs. 218.36 Lakhs during the year under review as against profit of Rs. 256.58 Lakhs in the previous year. Your Company has performed well and your Directors are relentlessly striving for the betterment of the business and simultaneously your Directors are optimistic about the future and expect the business to perform much better in the forthcoming years.

Consolidated: During the financial year under review, the Company recorded total income of Rs. 8,535.45 Lakhs on a consolidated basis as against Rs. 9,573.23 Lakhs in the previous financial year.

The Company reported a consolidated net loss (including share of profit/(loss) of Associates and Joint Ventures) of Rs. 1,098.04 Lakhs during the year under review as compared to a net profit of Rs. 505.73 Lakhs in the previous year. The decline in profitability was primarily attributable to losses incurred by a subsidiary in which the Company acquired a 51% stake during the year. The subsidiary operates in the manufacturing sector and possesses a differentiated and unique product portfolio. As the acquisition was completed during the current year, the business is presently in a growth and stabilization phase, and management expects that the benefits of operational integration, capacity utilization, and market development initiatives will accrue over time.

Net profit/(loss) and total comprehensive income attributable to the owners of the Parent stood at Rs. (320.07) Lakhs for the current year as against Rs. 505.73 Lakhs in the previous year.

The management remains focused on improving operational efficiencies, strengthening the performance of the subsidiary, and creating long-term value for all stakeholders

3. CHANGE IN THE NATURE OF THE BUSINESS:

There is no change in the nature of the business during the year under review.

4. SHARE CAPITAL:

During the year under review, Authorized capital of the Company has been increased, details of the same are as follows:

Share Capital of the Company as on March 31, 2025 was as follows:

Authorized Capital - Rs. 20,00,00,000/- (Rupees Twenty Crores only) divided into 2,00,00,000 (Two Crores Only) Equity Shares of Rs. 10 each.

Issued, Subscribed and Paid-Up Capital - Rs. 10,00,00,000/- (Rupees Ten Crores only) divided into 1,00,00,000 (One Crore Only) Equity Shares of Rs. 10 each.

Share Capital of the Company as on March 31, 2026 was as follows:

Authorized Capital - Rs. 20,00,00,000/- (Rupees Twenty Crores only) divided into 2,00,00,000 (Two Crores Only) Equity Shares of Rs. 10 each.

Issued, Subscribed and Paid-Up Capital - Rs. 10,00,00,000/- (Rupees Ten Crores only) divided into 1,00,00,000 (One Crore Only) Equity Shares of Rs. 10 each.

5. DIVIDEND:

The Board of Directors has not recommended any dividend for the financial year ended on March 31, 2026 as the Board have considered it financially prudent in the long-term interest of the company so as to reinvest the profits into the business of the company and to build its strong reserve base and assure the growth of the Company in long run.

6. UNPAID / UNCLAIMED DIVIDEND:

Members are hereby informed that under the Act, the Company is required to transfer the dividend which remains unpaid or unclaimed for a period of seven consecutive years or more to the IEPF. The Company has declared dividend for the first time in previous year 2022-23, therefore, there is no such amount of Unpaid or Unclaimed dividend to be transferred to Investor Education and Protection Fund (IEPF).

Amount of Unpaid / Unclaimed Dividend has been transferred into the unpaid Dividend a/c as per the requirement of Companies Act, 2013.

Members who have not encashed the dividend warrants so far in respect of the aforesaid period(s) are requested to make their claim to Purva Shareregistry (India) Private Limited, RTA. Further, the Company sends a voluntary reminder to the shareholders who have not claimed their dividends, on an annual basis.

7. TRANSFER TO RESERVES:

During the period under review, the company has transferred profit of Rs. 218.36 Lakhs to the Reserves of the Company.

8. MATERIAL CHANGES AND COMMITMENTS AFFECTING FINANCIAL POSITION BETWEEN THE END OF THE FINANCIAL YEAR AND DATE OF REPORT:

There were no Material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the Company and the date of the report.

9. DEPOSIT:

The company has not accepted any deposits from the public and as such, no amount on account of principal or interest on deposits from public was outstanding as on the date of the balance sheet for the Financial Year 2025-2026.

Further, for exempted deposits, Company has filed Form DPT-3 as on March 31, 2026 as per the notification issued by the Ministry of Corporate Affairs (MCA) within due course of time.

10. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE U/S 186 OF THE COMPANIES ACT, 2013:

The particulars of loans, guarantees and investments have been disclosed in the financial statements which also form part of this report.

11. CORPORATE SOCIAL RESPONSIBILITY:

The company has not developed and implemented any Corporate Social Responsibility Initiatives as per the provisions of section 135(1) of the Companies Act, 2013 read with Companies (Corporate Social Responsibility Policy) Rules, 2014 as the aforesaid provisions are not applicable to the Company.

12. CONSERVATION OF ENERGY, RESEARCH AND DEVELOPMENT, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The particulars as prescribed under sub-section (3)(m) of section 134 of the Companies Act, 2014 read with Rule 8(3) of Companies (Accounts) Rules, 2014 are annexed herewith at “Annexure-I”.

13. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:

The Board has adopted policies and procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company’s policies, safeguarding of its assets, prevention and detection of fraud, error reporting mechanisms, accuracy and completeness of the accounting records and timely preparation of reliable financial disclosures. The details with respect to internal control systems and internal Audit has been briefed in Management Discussion and Analysis Report, which is annexed herewith as “Annexure-II”.

14. POLICY ON DIRECTORS’ APPOINTMENT AND REMUNERATION AND OTHER DETAILS:

The current policy is to have an appropriate mix of Executive, Non-Executive and Independent Directors to maintain the independence of the Board, and separate its functions of governance and management.

Further, pursuant to Corporate Governance provisions, the Board of Directors framed and approved the Nomination and Remuneration Policy of the Company which now captures and explains the principles of the overall remuneration including short-term incentive and the long-term incentive payable to the Executive Directors, Key Managerial Personnel, Senior Management, and other employees of the Company.

The Policy also provides guidance on selection and nomination of Directors to the Board of the Company and appointment of the Senior Management Personnel of the Company. The remuneration paid to the Executive Directors, Key Managerial Personnel and Senior Management is in accordance with the Nomination and Remuneration Policy formulated in accordance with Section 178 of the Act and the Listing Regulations.

Details pertaining to composition and re-constitution of the Nomination and Remuneration Committee are included in the Report on Corporate Governance. All the recommendations made by the Nomination and Remuneration Committee were accepted by the Board.

15. DIRECTORS:

To comply with the requirement of the Companies Act, 2013 and Articles of Association of the Company, Mrs. Swati Jay Shah shall retire by rotation at the forthcoming Annual General Meeting. Being eligible, she offers herself for re-appointment.

There were no changes occurred during the year under review.

16. KEY MANAGERIAL PERSONNEL:

Mr. Samir Shah continues to be the Managing Director of the Company.

Mr. Dilipkumar Bhogilal Shah continues to be the Chief Executive Officer of the Company.

Mr. Jay Sharadkumar Shah continues to be the Chief Financial Officer of the Company.

Ms. Puneeta Sharma (PAN: *****48E), Company Secretary & Compliance Officer of the Company resigned from the Company w.e.f. 22nd April, 2025 and re-appointed as Company Secretary & Compliance Officer of the Company w.e.f. 14th July, 2025.

17. INDEPENDENT DIRECTOR’S DECLARATION:

The Company has received necessary declaration from each independent director under Section 149(7) of the Companies Act, 2013, that he / she meets the criteria of independence as laid down in Section 149(6) of the Companies Act, 2013.

18. BOARD EVALUATION:

In terms of provisions of Companies Act, 2013 read with rules issued there under and SEBI (LODR) Regulations 2015, the Board of Directors on recommendation of the Nomination and Remuneration Committee, have evaluated the effectiveness of the Board/Director's for the Financial Year 2025-26.

The performance and functioning of the board were evaluated by the board after seeking inputs from all the directors on the basis of the criteria such as the board composition and structure, effectiveness of board processes, information and functioning, etc.

The committees of the Board were assessed after seeking inputs from the committee members on the basis of the criteria such as the composition of committees, effectiveness of committee meetings, etc.

The board and the nomination and remuneration committee reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. In addition, the Chairperson was also evaluated on the key aspects of her role.

Separate meeting of independent directors has been held on February 14, 2026 for the FY 2025-26 to evaluate the performance of non-independent directors, performance of the board as a whole and performance of the Chairperson.

19. NUMBER OF MEETINGS OF THE BOARD:

During the year, the Board met **07 (Seven)** times to deliberate on various matters. The dates, attendance of the Directors and other details of the meetings are given in the Report on Corporate Governance. The maximum interval between any two meetings did not exceed 120 days, as prescribed by the Act and Listing Regulations.

20. AUDIT COMMITTEE:

Details pertaining to composition and re-constitution of the Audit Committee are included in the Report on Corporate Governance. All the recommendations made by the Audit Committee were accepted by the Board.

21. STAKEHOLDERS RELATIONSHIP COMMITTEE (SRC):

Details pertaining to composition and re-constitution of the Stakeholders and Relationship Committee are included in the Report on Corporate Governance.

22. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES:

Particulars of contracts or arrangements with related parties referred to in section 188(1) of the Companies Act, 2013 read with Rule 8(2) of Companies (Accounts) Rules, 2014 in prescribed Form AOC-2 is annexed herewith at **Annexure III**.

23. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES:

During the period under review, the Company is having 4 (four) Wholly Owned Subsidiary Companies and 1 (One) Subsidiary Company namely:

1. Ritz Formulations Private Limited
2. Sungrace Pharma Private Limited
3. Azillian Healthcare Private Limited
4. Evagrace Pharma Private Limited
5. Calborn Lifescience Private Limited (Subsidiary)

Therefore, provisions of section 129(3) of the Companies Act, 2013 relating to preparation of consolidated financial statements are applicable to the Company. Further, we have prepared the consolidated financial Statements of the Company, which forms part of this Annual Report.

A Statement containing salient features of the financial statement of our subsidiaries in the prescribed format AOC-1 as appended as **Annexure IV**. In accordance with Section 136 of the Companies Act, 2013, the audited financial statements including the consolidated financial statements and related information of the Company are available on our website www.medicointercontinental.com.

Further, the Company has one Joint Venture namely:

1. Medico Lab

Further, the Company does not have any Associate Company.

24. VIGIL MECHANISM / WHISTLE BLOWER POLICY:

As per the provision of Section 177(9) of the Act and Regulation 22 of the Listing Regulations, the Company is required to establish a Vigil Mechanism. The Company's Code of Conduct, Whistle blower and other Governance Policies lay out the principles of highest ethical standards. The details of the Whistle blower Policy are provided in the Report on Corporate Governance forming part of this Report.

25. PARTICULARS OF EMPLOYEES U/S 197(12) OF THE COMPANIES ACT, 2013:

The Information & Statement of Particulars of employees pursuant to Section 197 of the Companies Act, 2013 and Rule 5 (1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed as **Annexure V**.

26. DIRECTORS' RESPONSIBILITY STATEMENT:

In terms of section 134(5) of the Companies Act, 2013, your Directors state that: -

- (a) in the preparation of the annual accounts, the applicable accounting standards have been followed;
- (b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- (c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) the Directors have prepared the annual accounts on a going concern basis.
- (e) the Directors have laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively
- (f) the Directors have devised proper system to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

27. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

During the period under review, no material orders have been passed by the regulators or courts or tribunals impacting the going concern status and company's operation in future.

28. AUDITORS & AUDITORS' REPORT:

Statutory Auditors

Pursuant to the provisions of section 139 of the Companies Act, 2013, the members at the annual general meeting of the Company held on 27th September, 2024 re-appointed V Goswami & Co, Chartered Accountants, Ahmedabad (Firm Registration No. **128769W**) as statutory auditors of the Company for the second term of 5 consecutive years i.e., from the conclusion of Fortieth Annual General Meeting till the conclusion of Forty Fifth Annual General Meeting, covering one term of five consecutive years.

They have confirmed their eligibility under Section 141 of the Companies Act, 2013 and the Rules framed there under for appointment as Auditors of the Company.

The Auditors' Report for FY 2025-26 does not contain any qualification, reservation or adverse remark. The Auditors' Report is enclosed with the financial statements in this Annual Report.

Secretarial Auditor

In terms of the amended provisions of Regulation 24A of the Listing Regulations, the Board of Directors, based on the recommendation of the Audit Committee, appointed M/s. Agarwal & Mehta, Company Secretaries LLP (LLPIN: AAN-6741) as the Secretarial Auditors of the Company for a term of 5 (five) consecutive years from the financial year 2025-26 up to financial year 2029-30. The said appointment was approved by the Members at the Forty-First AGM of the Company held on 30th September, 2025.

The Secretarial Audit Report (Form No. MR - 3) of the Company given by the Secretarial Auditors for the financial year ended March 31, 2026 is enclosed as **Annexure-VI** to this Report. The Secretarial Audit Report of your Company does not contain any qualification, reservation or adverse remark.

The Company has undertaken an audit for the financial year ended March 31, 2026 for all applicable compliances as per SEBI Regulations and Circulars / Guidelines issued thereunder. The Annual Secretarial Compliance Report pursuant to Regulation 24A of the Listing Regulations has been submitted to the Stock Exchanges on April 16, 2026 within the statutory timelines.

Further, as per the applicable provisions of Corporate Governance, there is a requirement to undertake Secretarial Audit of material unlisted subsidiaries. One of the subsidiaries of the Company, Azillian Healthcare Private Limited is a material subsidiary; therefore, the Company has appointed Yash Mehta & Associates, Practicing Company Secretary (Membership No. F12143 & COP 16535) to undertake the Secretarial Audit of the Company. Secretarial Audit Report for the FY 2025-26 issued by him in the prescribed form MR-3 is annexed as **Annexure-VII** to this report.

The Secretarial Audit Report of the Company and its material unlisted subsidiary Company does not contain any qualification, reservation or adverse remark.

Internal Auditor

MJV & Co, Chartered Accountants, Ahmedabad was re-appointed as an Internal Auditor of the Company for the Financial Year 2025-26 and the consent regarding such appointment was received from the auditor in this regard.

Cost Records and Cost Audit

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148(1) of the Companies Act, 2013 are not applicable to our Company.

29. REPORTING OF FRAUDS BY AUDITORS:

During the year under review, neither the statutory auditors nor the secretarial auditor has reported to the audit committee under section 143(12) of the Companies Act, 2013, any instances of fraud committed against the Company by its officers or employees, the details of which would need to be mentioned in the Board's Report.

30. ANNUAL RETURN:

Pursuant to Section 92(3) and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return as on March 31, 2026 is hosted on the website of your Company at **www.medicointercontinental.com**.

31. CORPORATE GOVERNANCE REPORT:

In compliance with Regulation 34 read with Schedule V(C) of the Listing Regulations, a Report on Corporate Governance along with a Certificate of Compliance as required under Schedule V(E) of the Listing Regulations from the Practicing Company Secretary forms part of this Report.

32. MANAGERIAL DISCUSSION AND ANALYSIS:

In terms of the provisions of Regulation 34(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Management's discussion and analysis is set out in this Annual Report & marked as **Annexure-II**.

The state of the affairs of the business along with the financial and operational developments has been discussed in detail in the Management Discussion and Analysis Report.

33. RISK MANAGEMENT POLICY:

Risk Management is the process of identification, assessment and prioritization of risks followed by coordinated efforts to minimize, monitor and mitigate/control the probability and/or impact of unfortunate events or to maximize the realization of opportunities. The Company has laid down a comprehensive Risk Assessment and Minimization Procedure which is reviewed by the Board from time to time. These procedures are reviewed to ensure that executive management controls risk through means of a properly defined framework. The major risks have been identified by the Company and its mitigation process/measures have been formulated in the areas such as business, project execution, event, financial, human, environment and statutory compliance.

34. INFORMATION REQUIRED UNDER SEXUAL HARASSMENT OF WOMEN AT WORK PLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013:

Your Company adopts a zero-tolerance approach towards sexual harassment at workplace. Your Company has in place a Prevention of Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The POSH Policy of the Company is available on the website of the Company.

An Internal Committee has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy. All employees (permanent, contractual, temporary, trainees) are covered under this Policy.

During the year 2026, the Company did not receive any complaint of alleged sexual harassment. As on March 31, 2026 no complaints related to sexual harassment are pending for disposal.

Continuous awareness in this area has been created to provide a safe workplace to all its employees. During the year, the Company organized sensitization and awareness programs vide inductions for new joiners, e-learning modules for all employees' trainees, associates including sending emailers, creating standees and posters to sensitize all employees to conduct themselves in a professional manner.

35. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

The Company has neither made any application nor any proceedings pending under The Insolvency and Bankruptcy Code, 2016 during the year under review. Therefore, there are no details required to be disclosed, as the said clause is not applicable as on year ended 31st March, 2026.

36. PROHIBITION OF INSIDER TRADING

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has adopted a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information to ensure prohibition of Insider Trading in the Organization. The said Code are available on Company's website.

The 'Trading Window' is closed when the Compliance Officer determines that a Designated Person or class of Designated Persons can reasonably be expected to have possession of Unpublished Price Sensitive Information. The Company Secretary of the Company has been designated as Compliance Officer to administer the Code of Conduct and other requirements under SEBI (Prohibition of Insider Trading) Regulations, 2015.

37. GREEN INITIATIVES:

Electronic Copies of the Annual Report 2025-26 and the notice of the 42nd AGM are sent to all members whose email addresses are registered with the Company / depository participant(s). For members who have not registered their email addresses, Company has provided facility to register/update the email addresses with the RTA of the Company on <https://www.purvashare.com/>. For members who have not registered their email addresses and ask for physical copies, physical copies are sent in the permitted mode.

38. CAUTIONARY STATEMENT:

Statement in the Annual Report, particularly those which relate to Management Discussion and Analysis, describing the Company's objectives, projections, estimates and expectations, may constitute forward looking statements within the meaning of applicable laws and regulations. Although the expectations are based on reasonable assumptions, the actual results might differ.

39. APPRECIATION / ACKNOWLEDGMENTS:

Your Directors place on record their deep appreciation to employees at all levels for their hard work, dedication and commitment. The enthusiasm and unstinting efforts of the employees have enabled the Company to be as industry leaders.

The Board places on record its appreciation for the support and co-operation your Company has been receiving from its business partners and others associated with the Company. It will be the Company's endeavour to build and nurture strong links with the trade based on mutuality of benefits, respect for and co-operation with each other, consistent with consumer interests. The Directors also take this opportunity to thank all Investors, Clients, Vendors, Banks, Government and Regulatory Authorities for their continued support.

**For and on behalf of the Board
Medico Intercontinental Limited**

**Place : Ahmedabad
Date : August 14, 2026**

**Sd/-
Samir Shah
Managing Director
DIN: 03350268**

**Sd/-
Tanvi Shah
Director
DIN: 08192047**

CONSERVATION OF ENERGY & TECHNOLOGY ABSORPTION

The particulars as per the Companies (Accounts) Rules, 2014 regarding conservation of energy, technology absorption is as under:

(A) CONSERVATION OF ENERGY

Steps taken or impact on conservation of energy	N.A.
The steps taken by the company for utilizing alternate sources of energy	
The capital investment on energy conservation equipment's	

(B) TECHNOLOGY ABSORPTION

- Efforts made towards technology absorption: N.A.
- Benefits derived like product improvement, cost reduction, product development or import substitution: N.A.
- In case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-

Detail of technology imported	N.A.
Year of Import	
Has technology been fully absorbed	
If not fully absorbed, areas, where this has not taken place, reasons there for and future plans of action.	

4. Expenses incurred on Research and Development

During the period under review particulars regarding expenditures on research and development are as under:

Particulars	N.A.
Capital Expenditures	
Recurring Expenditures	
Total	
Total Research and development expenses as % of turnover	

For and on behalf of the Board
 Medico Intercontinental Limited

Place : Ahmedabad
 Date : August 14, 2026

Sd/-
 Samir Shah
 Managing Director
 DIN: 03350268

Sd/-
 Tanvi Shah
 Director
 DIN: 08192047

Management Discussion and Analysis Report (MDAR)

In terms of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 the Management Discussion and Analysis Report (MDAR) is structured as follows:

- Economic Outlook
- Industry structure and developments
- Opportunities
- Segment-wise or product-wise performance
- Outlook
- Threats, Risk and Concerns
- Internal Control System
- Financial and operational performance
- Material Development in Human Resources
- details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in key financial ratios, along with detailed explanations therefore, including:
 - (i) Debtors Turnover
 - (ii) Inventory Turnover
 - (iii) Interest Coverage Ratio
 - (iv) Current Ratio
 - (v) Debt Equity Ratio
 - (vi) Operating Profit Margin
 - (vii) Net Profit Margin
 or sector-specific equivalent ratios, as applicable.
- details of any change in Return on Net Worth as compared to the immediately previous financial year along with a detailed explanation thereof.

Some Statements in this discussion may be forward looking. The Company's actual results, performance or achievements can thus differ materially from those projected in any such forward-looking statements in the management discussion and analysis on account of various factors such as changes in Government regulations, tax regimes, impact of competition, etc.

- Economic Outlook:

Amid persistent global economic headwinds, India stands out as one of the fastest-growing major economies. According to the First Advance Estimates of Gross Domestic Product 2025-26, India's GDP growth is projected at 7.4% in FY 2025-26, compared to 6.5% in FY 2024-25. Robust private consumption, tax reforms, and resilient manufacturing and services activity are supporting the growth trajectory. Despite rising trade tensions and policy uncertainty, India's economic outlook remains resilient, with growth estimated at 6.5% in FY 2026-27 and 6.6% in FY 2027-28. Key drivers include easing inflationary pressures, rapid infrastructure development and digitization, a recovery in exports and private investments, and favorable policy reforms, among others.

(Source: pib.gov.in; economictimes.indiatimes.com)

- Industry Structure and Developments:

Indian Pharmaceutical Industry

The Indian pharmaceutical industry was valued at approximately USD 55 billion in 2025 and is expected to reach USD 120-130 billion by 2030, growing at a CAGR of 11-13%. Growth will be driven by a combination of expanding healthcare access, growing demand for treatments across both acute and chronic conditions, digital transformation, and continued reliance on affordable generic medicines. India ranks as the third-largest pharmaceutical producer globally, by volume, and the 14th largest by value, contributing around 1.72% to India's

GDP. The strength of the industry lies in its well-established generics ecosystem, cost-effective manufacturing, and a large pool of skilled scientists and engineers. India's pharmaceutical sector has a strong export presence, supplying medicines to over 200 countries worldwide, with the United States (US) being its largest export destination. Pharmaceutical exports have grown steadily from USD 15 billion in FY 2013-14 to USD 27.9 billion in FY 2023-24 and USD 30.47 billion in FY 2024-25. Generic drugs account for 20% of global exports in terms of volume, positioning the country as the largest provider of generic medicines globally.

(Source: *pib.gov.in* and *IBEF*)

In the Union Budget 2026-27, the government launched the Biopharma SHAKTI (Strategy for Healthcare Advancement), with an outlay of Rs. 10,000 crores over the next five years, aimed at positioning India as a global hub for biopharmaceutical manufacturing and innovation. This initiative reflects the growing shift in India's disease burden toward non-communicable diseases, such as diabetes, underscoring the importance of biologic medicines in improving patient outcomes.

Looking ahead, the Indian Pharmaceutical industry is poised for robust growth, with the market projected to reach USD 450 billion by 2047. This expansion will be supported by favorable government policies, rising prevalence of chronic diseases, increasing foreign investments, and a strong focus on the manufacturing of high-quality pharmaceutical products.

GROWTH DRIVERS

Increase in Chronic Diseases: Rising incidences of chronic diseases such as hypertension, diabetes, respiratory ailments, and cardiovascular diseases on account of rapid urbanization, aging population, adoption of sedentary lifestyles, and poor dietary habits are expected to boost demand for pharmaceutical products.

Improving Affordability: Increasing income levels and affluence are prompting individuals to seek high-quality healthcare services, including better hospitals, medicines, and treatment.

Expanding Insurance Coverage: Health insurance penetration in India continues to deepen, supported by greater participation from private insurers and broader therapy coverage. The government's Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) health insurance scheme is driving healthcare access for patients.

Government Support and Incentives: Supportive government policies, such as the Production Linked Incentive (PLI) scheme, stringent quality and regulatory standards, and focus on chronic diseases, are further propelling the pharmaceutical industry's growth.

Company performance: Until the previous financial year, the Company was primarily engaged in the trading of pharmaceutical products. During the year under review, the Company expanded its business operations by acquiring a 51% equity stake in Calborn Lifescience Private Limited, thereby making it a subsidiary of the Company.

This strategic acquisition marks the Company's entry into the pharmaceutical manufacturing segment, strengthening its presence across the healthcare value chain. Calborn Lifescience Private Limited is engaged in the manufacturing of a unique portfolio of Vitamin D3 products and has established itself as one of the leading manufacturers in this niche segment. Notably, Calborn is recognized as the second manufacturer in India for this product category, providing the Company with a competitive advantage and opportunities for growth in the domestic and international markets.

The acquisition aligns with the Company's long-term strategy of diversifying its operations, enhancing value addition, and creating a stronger and more integrated business model. The Company expects this expansion into manufacturing to contribute positively to its future growth, profitability, and market positioning.

During the current financial year, the total income of the Company was Rs. 5680.62 Lakhs during current year as against Rs. 6763.75 Lakhs in the previous year. The Company has reported net profit of Rs. 218.36 Lakhs during the year under review as against profit of Rs. 256.58 Lakhs in the previous year. Your Board is looking more confident to increase revenue and profit in coming years.

– Opportunities and Threats:

Being a Trading company, our company is exposed to specific risks that are particular to its business and the environment within which it operates including interest rate volatility, economic cycle, and market risk. Further, venturing into new verticals and products shall also expose your company to risk. However, these also give an opportunity to exponentially grow the business.

– **Business Performance:**

During the current financial year, the total income of the Company was Rs. 5680.62 Lakhs during current year as against Rs. 6763.75 Lakhs in the previous year. The Company has reported net profit of Rs. 218.36 Lakhs during the year under review as against profit of Rs. 256.58 Lakhs in the previous year. Your Board is looking more confident to increase revenue and profit in coming years.

– **Outlook:**

With the current promoters and management at the helm, your company is hopeful about the expansion of the business operations. Improving economic scenarios, growing consumption and demand shall create more opportunities.

It is expected that the economic conditions shall improve.

– **Risks and areas of concern:**

Our strength is our determination and team work, weakness is the low equity base, opportunities are multiples and threats are the vibrations in the economy and government policies.

In any business, risks and prospects are inseparable. As a responsible management, the Company's principal Endeavour is to maximize returns. The Company continues to take all steps necessary to minimize its expenses through detailed studies and interaction with experts.

– **Internal control systems and their adequacy:**

The Company has carried out the internal audit and has ensure that recording and reporting are adequate and proper, the internal controls exist in the system and that sufficient measures are taken to update the internal control system. The system also ensures that all transactions are appropriately authorized, recorded and reported. Exercises for safeguarding assets and protection against unauthorized use are undertaken from time to time. The Company's audit Committee reviewed the internal control system. All efforts are being made to make the internal control systems more effective. All these measures are continuously reviewed by the management and as and when necessary, improvements are affected.

– **Material developments in human resources/industrial relations front, including number of people employed:**

The company had sufficient numbers of employees at its registered office. The company recognizes the importance of human value and ensures that proper encouragement both moral and financial is extended to employees to motivate them. The company enjoyed excellent relationship with workers and staff during the year under review.

– **details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in key financial ratios, along with detailed explanations therefore, including:**

There were following changes in the below-mentioned ratios which may or may not be 25% or more as compared to the immediately previous financial year:

- (i) Debtors Turnover – 2.68:1 as compared to 3.56:1 of previous year.
- (ii) Inventory Turnover – 18.07:1 as compared to 14.93:1 of previous year.
- (iii) Interest Coverage Ratio – 2.87:1 as compared to 6.32:1 of previous year.
- (iv) Current Ratio – 2.37:1 as compared to 5.31:1 of previous year.
- (v) Debt Equity Ratio – 0.65:1 as compared to 0.52:1 of previous year.
- (vi) Operating Profit Margin (%) – 16.11% as compared to 16.47% of previous year.
- (vii) Net Profit Margin (%) – 4.01% as compared to 3.82% of previous year.

or sector-specific equivalent ratios, as applicable.

– **details of any change in Return on Net Worth as compared to the immediately previous financial year along with a detailed explanation thereof – 0.09:1 as compared to 0.08:1 of previous year.**

– **Cautionary Statement:** Certain statements in the above Report may be forward looking and are stated as required by the legislations in force. The actual results may be affected by various factors that differ from what is anticipated in terms of future performance and the outlook presented above.

FORM NO. AOC- 2

(Pursuant to Clause (h) of Sub-Section (3) of Section 134 of the Companies Act, 2013 and Rule 8(2) of the Companies (Accounts) Rules, 2014)

This Form pertains to the disclosure of particulars of contracts / arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto:

- 1. Details of contracts or arrangements or transactions not at arm's length basis:** The details of contracts or arrangement not at arm's length basis with its related parties during the financial year 2025-26 are as follows:

(Amount in Rs.)

Name of Related Party and Nature of Relationship	Nature of contracts/ arrangement / transactions	Duration of contracts / arrangement / transactions	Salient terms of contracts / arrangements / transactions including the value, if any	Date(s) of approval by the Board, if any	Amount paid as advance, if any
Medico Healthcare	Office Rent Paid	1 Year	Rs. 8,82,720	30.05.2025	NA
Ritz Formulations Private Limited	Purchase and Sale of Goods	1 Year	Rs. 2,62,97,275	30.05.2025	NA
Sungrace Pharma Private Limited	Purchase and Sale of Goods	1 Year	Rs. 1,22,06,956	30.05.2025	NA
Evagrace Pharma Private Limited	Purchase and Sale of Goods	1 Year	Rs. 2,63,77,106	30.05.2025	NA
Azillian Healthcare Private Limited	Purchase and Sale of Goods	1 Year	Rs. 81,17,154	30.05.2025	NA
Oxford Pharma	Purchase and Sale of Goods	1 Year	Rs. 9,89,50,053	30.05.2025	NA
Samir D Shah	Remuneration and office rent paid	1 Year	Rs. 63,00,000	30.05.2025	NA
Jay S Shah	Remuneration	1 Year	Rs. 8,74,032	30.05.2025	NA
Diya Shah	Salary	1 Year	Rs. 7,52,258	30.05.2025	NA
Medico Lab	Purchase and Sale of Finished Goods and Interest to Partners	1 Year	Rs. 3,53,60,459	30.05.2025	NA
Calborn Lifescience Private Limited	Purchase and Sales of Goods and Interest Income	1 Year	Rs. 10,59,75,445	30.05.2025	NA

- 2. Details of material contracts or arrangement or transactions at arm's length basis:** There were no material contracts or arrangements or transactions entered with its related parties which are at arm's length during financial year 2025-26.

**For and on behalf of the Board
Medico Intercontinental Limited**

**Place : Ahmedabad
Date : August 14, 2026**

**Sd/-
Samir Shah
Managing Director
DIN: 03350268**

**Sd/-
Tanvi Shah
Director
DIN: 08192047**

Annexure - IV

FORM NO. AOC- 1

(Pursuant to first proviso of Sub-Section (3) of Section 129 of the Companies Act, 2013 and Rule 5 of the Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries or associate companies or joint ventures

Part A Subsidiaries
(Rs. in thousands*)

S.No.	Particulars	Subsidiary I	Subsidiary II	Subsidiary III	Subsidiary IV	Subsidiary V
1	Name of the Subsidiary	Ritz Formulations Private Limited	Sungrace Pharma Private Limited	Azillian Healthcare Private Limited	Evagrace Pharma Private Limited	Calborn Lifescience Private Limited
2	The date since when subsidiary was acquired	21/01/2019	25/01/2019	08/05/2019	27/03/2019	07/04/2025
3	Reporting period for the subsidiary concerned, if different from the holding company's reporting period.	NA	NA	NA	NA	NA
4	Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries.	NA	NA	NA	NA	NA
5	Share Capital	250.00	260.00	2,200.00	100.00	38785.72
6	Reserves and Surplus	24,089.58	24,333.09	1,08,243.43	12,694.60	-337208.17
7	Total Assets	41,842.47	40,183.12	1,43,478.72	31,624.70	507170.27
8	Total Liabilities	41,842.47	40,183.12	1,43,478.72	31,624.70	507170.27
9	Investments	100.01	100.01	0	0	5.10
10	Total Income	64,297.52	47,819.62	1,92,836.66	69,060.77	97475.23
11	Profit before taxation	5,366.32	5,248.13	21,244.67	4,888.15	-160209.09
12	Provision for taxation / Total Tax Expense	1,363.39	1,339.69	5,620.37	1,293.77	-1439.06
13	Profit after taxation	4,002.93	3,908.43	15,624.30	3,594.38	-158770.03
14	Proposed Dividend	NA	NA	NA	NA	NA
15	Extent of Shareholding	100%	100%	100%	100%	51%

*** Amounts in Financials of subsidiaries are in thousands therefore figures mentioned hereinabove are in thousands.**

- Names of subsidiaries which are yet to commence operations : NIL
- Names of subsidiaries which have been liquidated or sold during the year : NIL

Part B Associates and Joint Ventures**Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures**

The Company has invested in one partnership firm namely Medico Lab which is Joint venture of the Company. Further, the Company does not have any Associates.

(Rs. in thousands*)

No.	Name of Joint Venture	Medico Lab
1.	Latest audited Balance Sheet Date	31/03/2026
2.	Date on which the Associate or Joint Venture was associated or acquired	09/04/2024
3.	Shares of Associate or Joint Ventures held by the company on the year end	NA
	No. of Shares	-
	Amount of Investment in Associates or Joint Venture	Rs. 22,792.07
	Extent of Holding (in percentage)	50%
4.	Description of how there is significant influence	Company is holding 50% stake in Medico Lab
5.	Reason why the associate/Joint venture Is not consolidated.	Company holds a 50% stake in the partnership firm Medico Lab. Since Company's ownership interest is limited to 50%, it does not have a controlling interest in the entity. Accordingly, Medico Lab is not consolidated in the financial statements, as consolidation requires a controlling interest of more than 50%
6.	Net worth attributable to shareholding as per latest audited Balance Sheet	Rs. 25,116.43
7.	Profit or Loss for the year	Rs. 2211.79
	i. Considered in Consolidation	Rs. 1105.90
	ii. Not Considered in Consolidation	Rs. 1105.90

- Names of associates or joint ventures which are yet to commence operations : NIL
- Names of associates or joint ventures which have been liquidated or sold during the year : NIL

For and on behalf of the Board
Medico Intercontinental Limited

Place : Ahmedabad
 Date : August 14, 2026

Sd/-
 Samir Shah
 Managing Director
 DIN: 03350268

Sd/-
 Tanvi Shah
 Director
 DIN: 08192047

Sd/-
 Jay Sharadbhai Shah
 Chief Financial Officer

Sd/-
 Puneeta Sharma
 Compliance Officer

Annexure - V

Information of Particulars of employees pursuant to Section 197 of the Companies Act, 2013 and Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

S.N.	PARTICULARS	REMARKS								
1.	The ratio of the remuneration of each director to the median remuneration of the employees of the company for the financial year.	20:1								
2	The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year.	Following is the % increase in remuneration of Director, CFO, CEO, and Company Secretary during the period under review: <table><tr><td>Managing Director</td><td>0</td></tr><tr><td>Chief Financial Officer</td><td>8.33%</td></tr><tr><td>Chief Executive Officer</td><td>0</td></tr><tr><td>Company Secretary</td><td>25.00%</td></tr></table>	Managing Director	0	Chief Financial Officer	8.33%	Chief Executive Officer	0	Company Secretary	25.00%
Managing Director	0									
Chief Financial Officer	8.33%									
Chief Executive Officer	0									
Company Secretary	25.00%									
3	The percentage increase in the median remuneration of employees in the financial year.	10.86%								
4	The number of permanent employees on the rolls of company.	41								
5	The explanation on the relationship between average increase in remuneration and company performance. PROOF	The average increase in remuneration of employees during the financial year was 10.86%, which was in line with the Company's performance, market compensation trends, annual performance appraisal outcomes, individual merit, and the need to attract and retain talent. The remuneration revision reflects the Company's compensation philosophy of rewarding performance while maintaining overall cost efficiency.								
6	Variations in the market capitalization of the company, price earnings ratio as at the closing date of the current financial year and previous financial year and percentage increase over decrease in the market quotations of the shares of the company in comparison to the rate at which the company came out with the last public offer in case of listed companies, and in case of unlisted companies, the variations in the net worth of the company as at the close of the current financial year and previous financial year.	Market Capitalization: <table><tr><td>As on 31st March, 2025</td><td>Rs. 35.47 Cr</td></tr><tr><td>As on 31st March, 2026</td><td>Rs. 25.20 Cr</td></tr></table> Price Earnings Ratio: <table><tr><td>As on 31st March, 2025</td><td>Rs. 13.80</td></tr><tr><td>As on 31st March, 2026</td><td>Rs. 11.70</td></tr></table>	As on 31st March, 2025	Rs. 35.47 Cr	As on 31st March, 2026	Rs. 25.20 Cr	As on 31st March, 2025	Rs. 13.80	As on 31st March, 2026	Rs. 11.70
As on 31st March, 2025	Rs. 35.47 Cr									
As on 31st March, 2026	Rs. 25.20 Cr									
As on 31st March, 2025	Rs. 13.80									
As on 31st March, 2026	Rs. 11.70									

S.N.	PARTICULARS	REMARKS
7	Average percentile increases already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration.	During the financial year ended 31st March, 2026, the average increase in the remuneration of employees other than the managerial personnel was 10.86%. There was no increase in the remuneration of the Managing Director & CEO during the year. The remuneration of the Chief Financial Officer was increased by 8.33%, which is broadly in line with the average increase granted to other employees. The remuneration of the Company Secretary was increased by 25%, primarily on account of no remuneration revision having been granted in the previous year and considering the individual's performance, increased responsibilities, and contribution to the Company. Accordingly, the increase does not represent an exceptional circumstance but is based on merit and business considerations.
8	The key parameters for any variable component of remuneration availed by the directors	Nil
9	The ratio of the remuneration of the highest paid director to that of the employees who are not directors but receive remuneration in excess of the highest paid director during the year	NA
10	Affirmation that the remuneration is as per the remuneration policy of the company	Yes

Form No. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED ON MARCH 31, 2026

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
MEDICO INTERCONTINENTAL LIMITED
CIN: L24100GJ1984PLC111413
1-5th Floor, Adit Raj Arcade Nr Karma Shreshtha Tower,
100 Ft Rd, Satellite, Ahmedabad, Gujarat - 380015 India.

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **MEDICO INTERCONTINENTAL LIMITED** ("Company") for the financial year ended March 31, 2026 ("period under review"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms, returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, the explanations and clarifications given to us and the representations made by the Management, we hereby report that in our opinion, the company has, during the period under review covering the financial year ended on **March 31, 2026** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and Compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed with regulatory authorities and other records maintained by the Company for the period under review, according to the provisions of:

- 1) The Companies Act, 2013 (the Act) and the Rules made thereunder including any Amendment and re-enactment thereof ("Act");
- 2) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
- 3) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- 4) Foreign Exchange Management Act, 1999 and the rules and regulations made there under is not applicable as there were no instances of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings during the period under review;
- 5) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"):
 - (a) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - (b) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (c) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (d) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015;
 - (e) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (Not applicable to the Company during the period under review)
 - (f) The Securities and Exchange Board of India (Buy Back of Securities) Regulations 2018; (Not applicable to the Company during the period under review)
 - (g) Rules, Regulations, Circulars, Orders, Notifications and Directives issued under the above statute to the extent applicable.

The following other laws applicable to the Company: *

1. The Drugs and Cosmetics Act, 1940 and The Drugs and Cosmetics Rules, 1945.
2. The Narcotic Drugs and Psychotropic Substances (Amendment) Act, 2014 and the Narcotic Drugs and Psychotropic Substances Rules, 1985.

3. The Company has complied with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules and Regulations made under the Act, to the extent it is applicable.
4. Drugs (Prices Control) Order, 2013.

*Note: Compliances with respect to other laws has been Confirmed by the Management of the Company.

We have also examined compliance with the applicable clauses of the following:

- i. Secretarial Standards with regard to the Meeting of Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India.
- ii. The Company has not declared any dividend during the period under review; therefore, Secretarial Standards on Dividend (SS-3) was not applicable.

Auditor's Responsibility

We further state that, it is our responsibility to express an opinion on the compliance with the applicable laws and maintenance of records based on audit.

The audit was conducted in accordance with applicable Standards and we have complied with statutory and regulatory requirements and the Audit was planned and performed to obtain reasonable assurance about compliance with applicable laws and maintenance of Records.

Due to the inherent limitations of an audit including internal, financial and operating controls, there is an unavoidable risk that some Misstatements or material non-compliances may not be detected, even though the audit is properly planned and performed in accordance with the Standards.

We further report that the Board of Directors of the Company is duly constituted. The changes in the composition of Board that took place during the period under review were carried out in compliance of the provisions of Act. Adequate notice is given to all the Directors to schedule the Board Meetings in advance in due compliances of law. Agenda and detailed notes on agenda were also sent in advance and a system exists for seeking and obtaining further information and clarification on the agenda items before the meeting and for meaningful participation at the meeting.

Decisions at the meetings of Board of Directors / Committees of the Company were carried through on the basis of majority. We were informed that there were no dissenting views by any members of Board / Committee in the meetings held during the period under review that were required to be captured and recorded as part of minutes.

We further report that there are adequate systems and processes in the Company to commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that there were following major instances happened during the period under review:

Appointment and Resignation of Company Secretary:

- a. Ms. Puneeta Sharma resigned from the position of Company Secretary of the Company with effect from April 22, 2025.
- b. Ms. Puneeta Sharma appointed as Company Secretary of the Company with effect from July 14, 2025.

There were no other instances of:

- a) Public issue / Right issue of Shares / Debentures / Sweat Equity etc:
- b) Redemption of Securities.
- c) Merger / amalgamation / Reconstruction etc.
- d) Foreign Technical Collaboration.

For, Agarwal & Mehta Company Secretaries LLP
ICSI Unique Code No.: L2018GJ004600

Sd/-
YASH MEHTA
PARTNER
FCS: 12143
COP: 16535

Date : 14.08.2026
Place : Ahmedabad

PEER REVIEW NO.: 6717/2025
UDIN: F012143H00111252

This report is to be read with our letter of even date which is annexed as "ANNEXURE A" and forms an integral part of this report.

“ANNEXURE A”

To,
The Members,
MEDICO INTERCONTINENTAL LIMITED
CIN: L24100GJ1984PLC111413
1-5th Floor, Adit Raj Arcade Nr Karma Shreshtha Tower,
100 Ft Rd, Satellite, Ahmedabad, Gujarat - 380015 India.

Our report of even date is to be read along with this letter:

1. Maintenance of Secretarial records is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain responsible assurance about the correctness of the contents of secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we follow provide a responsible basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the company.
4. Wherever required, we have obtained the management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to verification of procedures on test basis.
6. The secretarial audit report is neither an assurance as to the future viability of the company nor the efficacy or effectiveness with which the management has conducted the affairs of the company.

For, Agarwal & Mehta Company Secretaries LLP
ICSI Unique Code No.: L2018GJ004600

Date : 14.08.2026
Place : Ahmedabad

Sd/-
YASH MEHTA
PARTNER
FCS: 12143
COP: 16535
PEER REVIEW NO.: 6717/2025
UDIN: F012143H001111252

Form No. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED ON MARCH 31, 2026

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
AZILLIAN HEALTHCARE PRIVATE LIMITED
CIN: U24230GJ2005PTC047259
60, 61 & 66, Skyline Infra Hub, B/H Intas Pharma Matoda Patia,
Changodar, Taluka Sanand, Ahmedabad, Gujarat - 382213.

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **AZILLIAN HEALTHCARE PRIVATE LIMITED** ("Company") for the financial year ended March 31, 2026 ("period under review"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms, returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, the explanations and clarifications given to us and the representations made by the Management, we hereby report that in our opinion, the company has, during the audit period covering the financial year ended on **March 31st, 2026** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and Compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the period under review according to the provisions of:

- 1) The Companies Act, 2013 (the Act) and the Rules made thereunder including any Amendment and re-enactment thereof ("Act");
- 2) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder is not applicable as there were no instances of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings during the period under review;

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards with regard to the Meeting of Board of Directors (SS-1), General Meetings (SS-2) issued by The Institute of Company Secretaries of India.
- (ii) The Company has not declared any dividend during the period under review; therefore, Secretarial Standards on Dividend (SS-3) was not applicable.

Auditor's Responsibility

The responsibility of the Auditor is to express opinion on the compliance with the applicable laws and maintenance of records based on audit. The audit was conducted in accordance with applicable Standards and those Standards require that the Auditor comply with statutory and regulatory requirements and plan and perform the audit to obtain reasonable assurance about compliance with applicable laws and maintenance of Records.

Due to the inherent limitations of an audit including internal, financial and operating controls, there is an unavoidable risk that some Misstatements or material non-compliances may not be detected, even though the audit is properly planned and performed in accordance with the Standards.

We further report that:

During the year under review, the Company has **COMPLIED** with all the material aspects of the provisions of the Act, Rules, Regulations, Guidelines and Standards etc. as mentioned above. The Board of Directors of the Company is duly constituted.

Adequate notice is given to all the Directors to schedule the Board Meetings in advance in due compliances of law. Decisions at the meetings of Board of Directors of the Company were carried through on the basis of majority. We were informed that there were no dissenting views by any members of Board in the meetings held during the year under review that were required to be captured and recorded as part of minutes.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

There were no other instances of:

- a) Public issue / Right issue of Shares / Debentures / Sweat Equity etc
- b) Redemption / Buy – Back of Securities.
- c) Merger / amalgamation / Reconstruction etc.
- d) Foreign Technical Collaboration.

**FOR YASH MEHTA & ASSOCIATES
COMPANY SECRETARIES**

**Date : 25.07.2026
Place : Ahmedabad**

**Sd/-
YASH MEHTA
PROPRIETOR
FCS: 12143
COP: 16535**

**PEER REVIEW NO: 7925/2026
UDIN: F012143H000938805**

This report is to be read with our letter of even date which is annexed as “ANNEXURE A” and forms an integral part of this report.

“ANNEXURE A”

To,
The Members,

AZILLIAN HEALTHCARE PRIVATE LIMITED

CIN: U24230GJ2005PTC047259

60, 61 & 66, Skyline Infra Hub, B/H Intas Pharma Matoda Patia,
Changodar, Taluka Sanand, Ahmedabad, Gujarat - 382213.

Our report of even date is to be read along with this letter:

1. Maintenance of Secretarial records is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain responsible assurance about the correctness of the contents of secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we follow provide a responsible basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the company.
4. Wherever required, we have obtained the management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to verification of procedures on test basis.
6. The secretarial audit report is neither an assurance as to the future viability of the company nor the efficacy or effectiveness with which the management has conducted the affairs of the company.

**FOR YASH MEHTA & ASSOCIATES
COMPANY SECRETARIES**

Sd/-
YASH MEHTA
PROPRIETOR
FCS: 12143
COP: 16535
PEER REVIEW NO: 7925/2026
UDIN: F012143H000938805

Date : 25.07.2026
Place : Ahmedabad

CORPORATE GOVERNANCE REPORT

Company's philosophy on Code of Governance

Medico Intercontinental Limited ("the Company") believes that good Corporate Governance fosters long-term corporate goals and enhances stakeholders' value. Every day at Medico, we share a common focus "to provide Quality products & to maintain high standards in formulations and practicing high code of ethics in marketing". This means being exemplary in how we do business and unlock our innovation potential because when it comes to building trust, the actions we take and decisions we make speak louder than words. Our Code of Conduct is our constitution, supporting each of us to maximize opportunities while minimizing risks; to make bold and ethical decisions that activate our purpose; and to keep our end users i.e., patients and customers at the heart of all we do.

We implement policies and guidelines, communicate and train all stakeholders to develop a culture of compliance at every level of the organization. Conducting the operations with ethics and integrity is fundamental to the Company's philosophy and business ambitions. The Company will continue to foster responsible growth, creating long-term value for our stakeholders and business partners. The Company continues to be in compliance with the provisions of Corporate Governance as set out in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board of Directors

The Board is at the helm of the governance structure at the Company. The Board has a good, diverse, and optimum mix of Executive and Non-Executive Directors. With the number of Non-Executive and Independent Directors more than one-half of the total number of Directors, the composition is in line with the applicable provisions of Companies Act, 2013 ("the Act") and Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). As on date of this Report, the Board consists of six Directors comprising one Executive Director, two Non-Executive Directors and three Independent Directors with the Chairperson of the Board being a Non-Executive Director. The composition of the Board represents optimum combination of the knowledge, experience and skills which are required by the Board to discharge its responsibilities effectively.

As on the date of this report, Mrs. Tanvi Samirbhai Shah, Non-Executive Director is the Chairperson of the Board, Mr. Ankur Amiram Dave, Independent Director is the Chairperson of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee of the Company.

Mr. Ankur Amiram Dave, Mr. Parshwa Kaushal Shah and Mr. Priyank Lalitbhai Sancheti are the Independent Directors of the Company. Mrs. Swati Jay Shah and Mrs. Tanvi S Shah are the Non-Executive Directors of the Company. Mr. Samir D Shah is the Managing Director, Mr. Dilipkumar B Shah is the Chief Executive Officer, Mr. Jay S Shah is the Chief Financial Officer and Ms. Puneeta Sharma is the Company Secretary & Compliance Officer of the Company.

Changes in Directorate

During the year under review, there were no changes occurred in the Board of Directors.

The Directors take active part in the deliberations at the Board and Committee Meetings by providing valuable guidance and advice to the Management on various aspects of business, policy direction, governance, compliance, etc. and play a critical role on strategic issues and add value in the decision-making process of the Board of Directors.

The maximum tenure of Independent Directors is in compliance with the Act and the Listing Regulations. All the Independent Directors have confirmed that they meet the criteria as mentioned in Regulation 16(1)(b) of the Listing Regulations and section 149(6) of the Act. The Independent Directors provide an annual confirmation that they meet the criteria of Independence. Based on the confirmations/ disclosures received from the Independent Directors, the Board is of the opinion that the Independent Directors fulfill the conditions specified in the Listing Regulations and are Independent of the Management.

As of March 31, 2026, Mr. Samir D Shah, Managing Director hold shareholding of 46.40% and Mr. Dilipkumar Shah, Chief Executive Officer of the Company hold 10.74% Equity Shares of the Company. Mr. Jay S Shah, Chief Financial Officer of the Company holds shareholding of 0.51% in the Company. The Company has obtained a certificate from M/s. Agarwal & Mehta Company Secretaries LLP, Ahmedabad confirming that none of the Directors on Board of the Company are debarred or disqualified from being appointed or continuing as Director of the Company by the Securities and Exchange Board of India (SEBI) and Ministry of Corporate Affairs or any such authority. The certificate forms part of this Report.

During the year ended March 31, 2026, 7 (Seven) Board meetings were held on April 07, 2025, April 22, 2025, May 30, 2025, July 14, 2025, August 14, 2025, November 14, 2025 and February 14, 2026.

The constitution of the Board and attendance details during the Financial Year ended March 31, 2026, is given below:

S.N.	Name of Director	DIN	Category
1.	Tanvi Samirbhai Shah	08192047	Chairperson / Non-Executive Director
2.	Samir Dilipkumar Shah	03350268	Managing Director
3.	Ankur Amiram Dave	01059786	Independent Director
4.	Priyank Lalitbhai Sancheti	09784354	Independent Director
5.	Swati Jay Shah	08420884	Non-Executive Director
6.	Parshwa Kaushal Shah	07400081	Independent Director

S.N.	Name of Member	No of Meetings held	No. of Meetings attended
1.	Tanvi Samirbhai Shah	7	7
2.	Samir Dilipkumar Shah	7	7
3.	Ankur Amiram Dave	7	7
4.	Priyank Lalitbhai Sancheti	7	7
5.	Swati Jay Shah	7	7
6.	Parshwa Kaushal Shah	7	7

Board processes:

1. A detailed agenda, setting out the business to be transacted at the meeting(s), supported by detailed notes and presentations, if any, is sent to each Director at least seven days before the date of the Board Meeting(s) and of the Committee meeting(s) except where meetings have been convened at a shorter notice to transact urgent business.
2. The Directors are provided with the VC facility to participate in the meetings of the Board and of Committees. The Directors participated in the Meeting of the Board and Committees through ~~VC facility~~ / physically.
3. All material information is circulated to the Directors before the meeting, including minimum information required to be made available to the Board as prescribed under Part A of Schedule II of the Listing Regulations. The Board also, inter-alia, periodically reviews strategy and business plans, annual operating and capital expenditure budget(s), investment(s), compliance reports of applicable laws, as well as steps taken by your Company to rectify instances of non-compliances, if any, minutes of the Committees of the Board, approval of quarterly / half-yearly / annual results, safety and risk management, transactions pertaining to purchase / disposal of property (ies), divestments, etc.
4. The Company has well-established framework for the meetings of the Board and its Committees to enable decision making process at the meetings in an informed and efficient manner. The Directors have unrestricted access to all the information pertaining to the Company.
5. The Board has constituted Audit Committee, Nomination and Remuneration Committee and the Stakeholders Relationship Committee. Each of the Committees deal with matters as mandated by the statutory regulations and plays a very crucial role in the overall governance structure. All the Committees have specific terms of reference approved by the Board which outlines the composition, scope, powers & duties and responsibilities. At each Board meeting, the Chairperson of respective Committees briefs the Board on matters discussed by the Committee at their respective meetings. The minutes of the meeting of all Committees are placed before the Board for review. During the year, all recommendations of the Committees of the Board which were mandatorily required have been accepted by the Board.
6. The Company Secretary attends the meetings of the Board and its Committees and is inter-alia, responsible for recording the minutes of such meetings. The draft minutes of the Board and its Committees are sent to the Chairperson and Members for their comments in accordance with the Secretarial Standards. The Company

adheres to the provisions of the Act, Secretarial Standards and Listing Regulations with respect to convening and holding the meetings of the Board of Directors, its Committees and the General Meetings of the members of the Company.

Meeting of the Independent Directors:

The Independent Directors of the Company meet without the presence of the Executive Directors and other Non-Executive Director or any other Management Personnel. These Meetings are conducted to enable the Independent Directors to, inter-alia, discuss matters pertaining to review of performance of Executive and Non-Independent Directors and the Board of Directors as a whole, assess the quality, quantity, and timeliness of flow of information between the Company Management and the Board that is necessary for the Board to perform their duties effectively. During the year ended March 31, 2026, the Independent Directors met once on February 14, 2026. Mr. Ankur Amiram Dave Chaired the meeting.

Familiarization Programme for Directors:

Familiarization Programmes are conducted for Independent Directors to enable them to understand their roles, rights and responsibilities. Presentations are also made at the Board meetings which facilitates them to clearly understand the business of the Company and the environment in which the Company operates. Regulatory updates are provided with necessary documents required for them to have a good understanding of Company's operations, businesses and the industry as a whole. Further, they are periodically updated on material changes in regulatory framework and its impact on the Company. When a Director is inducted on the Board, a detailed induction program is conducted including organization structure, ethics and compliance practices, key therapies and products in which the Company operates, human resources overview like talent acquisition initiatives, performance management, succession planning, Company policies, etc.

The details of such familiarization policy for Independent Director(s) are put up on the website of the Company and can be accessed on the website of the Company at https://medicointercontinental.com/wp-content/uploads/2026/05/Policy-on-Familiarization-Programme-for-Independent-Directors_including-hour-details_F.pdf

Committees of the Board:

Audit Committee:

The Audit Committee comprises of three Directors of which, two Independent Directors and one Non-Executive Director, with the Chairperson being an Independent Director. All the members of the Committee have relevant accounting or related financial management expertise.

The terms of reference of the Audit Committee are wide and cover all the matters specified for Audit Committee under Regulation 18 read with Part C of Schedule II to the Listing Regulations and the Act.

The terms of reference of the Audit Committee include inter-alia, overseeing the Company's financial reporting process and disclosure of financial information to ensure that the financial statements are correct, sufficient and credible; reviewing and examining with management the quarterly and annual financial results and the auditors' report thereon before submission to the Board for approval; reviewing management discussion and analysis of financial condition and results of operations; reviewing, approving or subsequently modifying any related party transactions in accordance with the Company's policy on Related Party Transaction; recommending the appointment, remuneration and terms of appointment of Statutory Auditors of the Company and approval for payment of any other services; reviewing and monitoring the auditor's independence and performance and effectiveness of audit process; reviewing management letters / letters of internal control weaknesses issued by the Statutory Auditors; reviewing with management, Statutory Auditors and Internal Auditor, the adequacy of internal control systems; reviewing the adequacy of internal audit function and discussing with Internal Auditor any significant finding and reviewing the progress of corrective actions on such issues; evaluating internal financial controls and risk management systems; reviewing the functioning of the Code of the Company and Whistle-Blowing Mechanism; and review of internal controls pertaining to compliances under the Insider Trading Regulations.

Audit Committee meetings held for consideration of financial results, approving related party transactions, valuation reports of assets/ businesses, risk assessment, controls and internal audit and control reports pertaining to the Company.

The meetings of the Audit Committee are also attended by the Head of Accounts, the Statutory Auditors, and the Company Secretary. The Audit Committee meets the Statutory Auditors in absence of the Management.

During the year ended March 31, 2026, 4 (Four) Audit Committee meetings were held on May 30, 2025, August 14, 2025, November 14, 2025 and February 14, 2026.

The constitution of the Audit Committee and attendance details during the Financial Year ended March 31, 2026, is given below:

S.N.	Name of Director	DIN	Category
1	Mr. Ankur Dave	01059786	Chairman / Independent Director
2	Mr. Priyank Lalitbhai Sancheti	09784354	Member / Independent Director
3	Mrs. Tanvi Shah	08192047	Member / Non-Executive Director

Four meetings of the Audit committee were held during the year. The dates on which the said meetings were held: May 30, 2025, August 14, 2025, November 14, 2025 and February 14, 2026.

S.N.	Name of Member	No of Meetings held	No. of Meetings attended
1	Mr. Ankur Dave	4	4
2	Mr. Priyank Lalitbhai Sancheti	4	4
3	Mrs. Tanvi Shah	4	4

Ms. Puneeta Sharma, Company Secretary of the Company acts as the Secretary and Compliance Officer to the meetings of the Audit Committee.

Nomination and Remuneration Committee:

The Nomination & Remuneration Committee comprises of three Directors of which, two Independent Directors and one Non-Executive / Non-Independent Director, with the Chairperson being an Independent Director.

The terms of reference of the Committee are in line with the requirements of Regulation 19 read with Part D of Schedule II to the Listing Regulations and the which Act include:

1. Formulate and recommend Nomination and Remuneration Policy to the Board.
2. For every appointment of an Independent Director, the Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an Independent Director. The person recommended to the Board for appointment as an Independent Director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
 - a) use the services of an external agencies, if required;
 - b) consider candidates from a wide range of backgrounds, having due regard to diversity; and
 - c) consider the time commitments of the candidates
3. Identify the candidates who are qualified to become Directors.
4. Identify the persons who are qualified to become Senior Management as per the Nomination and Remuneration Policy.
5. Recommend to the Board the appointment and removal of the Directors and Senior Management.
6. Review and approve the remuneration policies and annual payments to Directors; make sure that the remuneration to Senior Management and other employees are as per the remuneration policy.
7. Recommend to the Board, all remuneration, in whatever form, payable to Senior Management.
8. Lay down the process for evaluation of the performance of Board, its committees and individual Director and review its implementation and compliance.
9. Devise and review Board Diversity Policy.
10. Review the succession policies and plans for Directors and Senior Management.
11. Decide whether to extend or continue the term of appointment of the Independent Director, on the basis of the report of performance evaluation of Independent Directors.

During the year ended March 31, 2026, 2 (Two) Nomination and Remuneration Committee meetings were held on July 14, 2025 and August 14, 2025.

The constitution of the Nomination and Remuneration Committee and attendance details during the financial year ended March 31, 2026, is given below:

S.N.	Name of Director	DIN	Position
1	Mr. Ankur Dave	01059786	Chairman / Independent Director
2	Mr. Priyank Lalitbhai Sancheti	09784354	Member / Independent Director
3	Mrs. Tanvi Shah	08192047	Member / Non-Executive Director

Two meetings of the Nomination and Remuneration committee were held during the year. The dates on which the said meeting was held: July 14, 2025 and August 14, 2025.

S.N.	Name of Member	No of Meetings held	No. of Meetings attended
1	Mr. Ankur Dave	2	2
2	Mr. Priyank Lalitbhai Sancheti	2	2
3	Mrs. Tanvi Shah	2	2

Ms. Puneeta Sharma, Company Secretary of the Company acts as the Secretary and Compliance Officer to the meetings of the Nomination and Remuneration Committee.

Nomination and Remuneration Policy

The Nomination and Remuneration Policy of the Company are performance driven and is designed to motivate employees, recognize their achievements, and promote excellence in performance.

During the year under review, the Board framed the Nomination and Remuneration Policy. Overall, the policy provides guidance on:

- (1) Selection and nomination of Directors to the Board of the Company;
- (2) Appointment of the Senior Management Personnel of the Company; and
- (3) Remuneration of Directors, Key Management Personnel and other employees.

The Policy is available on Company's website at <https://medicointercontinental.com/investors/policies/>

Board Selection Criteria / list of core skills / expertise / competencies identified in the context of the business.

The Nomination and Remuneration Committee has approved the Nomination and Remuneration Policy which sets out criteria for inducting Board members:

- The candidate shall have appropriate skills and experience in one or more fields of management, sales, marketing, medical, finance, HR, law, public administrative services, research, corporate governance, technical operations or any other disciplines related to the Company's business and its operations.
- The Committee shall keep Board Diversity Policy in mind while recommending a candidate for appointment as Director.
- The number of companies in which the candidate holds directorship should not exceed the number prescribed under the Act or under the Listing Regulations.
- The candidate should not hold directorship in any of the competitor companies and should not have any conflict of interest with the Company.
- The candidate proposed to be appointed as Independent Director, should not have any direct or indirect material pecuniary relationship with the Company and must satisfy the requirements imposed under the Act and the Listing Regulations including registration in the data bank of Independent Directors as prescribed under Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014, as amended.
- The candidate should also have the ability to exercise sound business judgement, demonstrate leadership or prominence in a specified field, willingness to devote the required time and possess integrity and moral reputation.

In terms of requirement of the Listing Regulations, the Board has identified the following skills / expertise / competencies of the Directors as given below:

Skills & Description:

Name of the Director	Mr. Samir D Shah	Mrs. Tanvi S Shah	Mrs. Swati J Shah	Mr. Ankur A Dave	Mr. Priyank L Sancheti	Mr. Parshwa K Shah
Strategy Development and Insight: Developing long-term strategies to sustainably grow business, profitably and competitively, in a highly regulated and fast changing environment.	✓	✓	✓	✓	✓	✓
Business Leadership and management: Leading complex organizations with understanding of changes in external environment, business development and competitive landscape.	✓	✓	✓	✓	✓	✓
Pharma Business: Expertise on pharma business matters including unmet medical needs of patients / healthcare systems / healthcare professionals, competitive landscape in pharma business, pharma regulations, emerging business opportunities and risks	✓	✓	x	✓	x	x
Finance and Accounts: Understanding of accounting and financial statements	✓	✓	✓	✓	✓	✓
Governance, Risk and Compliance: Understanding of the governance principles, Board accountability, internal control and regulatory environment, risk management in a large complex organization and emerging local and global trends.	✓	✓	✓	✓	✓	✓

Remuneration to Executive Directors

The Nomination and Remuneration Committee recommends to the Board the remuneration payable to the Managing Director, Whole-time Directors and the Key Managerial Personnel. The elements of remuneration package include salary, benefits, retiral, performance linked incentives, etc. and is decided based on the performance, Company policy and benchmarks.

Annual increments are recommended by the Nomination and Remuneration Committee to the Board for approval within the salary range approved by the Shareholders and in line with the Nomination and Remuneration Policy.

The details of remuneration paid to the Managing Director / Whole-time Directors during the Financial Year ended March 31, 2026 are given below:

Name	Designation	Salary (Rs. in Lakhs)	Perquisites (Rs. in Lakhs)	Commission (Rs. in Lakhs)	Total (Rs. in Lakhs)
Samir Dilipkumar Shah	Managing Director	60.00	-	-	60.00

Remuneration to Non-Executive Directors

The Non-Executive Directors are not paid remuneration in any form during the year under review. During the year, there were no pecuniary relationships or transactions between the Company and any of its Non-Executive Directors. Also, there are no performance linked incentives, service contracts or stock options, therefore, disclosures with respect to said clause is not applicable during the year under review.

Details of sitting Fees paid to the Non-Executive Directors for attending the Board and Committee Meetings during the financial year 2025-26:

S.N.	Name of Directors	Sitting Fees paid (Rs. in Lakhs)
1.	Mr. Ankur Amiram Dave	-
2.	Mr. Parshwa Kaushal Shah	-
3.	Mr. Priyank Lalitbhai Sancheti	-

Performance Evaluation:

The Company follows a structured assessment process for evaluation of performance of the Board, Committees of the Board and individual performance of each Director including the Chairman based on the criteria approved by the Nomination and Remuneration Committee. The Chairman of the Board leads the exercise of the Performance Evaluation with the Company Secretary, assisting him.

The evaluation is based on parameters like level of participation of the Directors, knowing of the roles and responsibilities of Directors, understanding of the business and competitive environment in which the Company operates, understanding of the strategic issues and challenges for the Company, etc. The performance of the Independent Directors is also evaluated taking into account the time devoted, strategic guidance to the Company, advice given for determining important policies, external expertise provided and independent judgment that contributes objectively to the Board's deliberation.

The performance evaluation of the Board is carried out taking into account the various parameters like composition of Board, process of appointment to the Board, common understanding amongst Directors of their role and responsibilities, timelines and content of Board papers, strategic directions, advice and decision making, etc. The Board also notes the actions undertaken, pursuant to the outcome of previous evaluation exercises. Each Committee's self-assessment is carried out based on the degree of fulfillment of the key responsibilities as outlined by its terms of reference.

The evaluation of individual Directors is on parameters such as attendance, contribution, independent judgement, etc.

For the year ended March 31, 2026, Board evaluation exercise was completed by the Company internally, which included the evaluation of the Board as a whole, Board Committees and peer evaluation of the Directors. The evaluation forms were circulated to the Board Members. Each Director completed the evaluation form and shared feedback. The feedback scores as well as qualitative comments were then shared with the Nomination and Remuneration Committee and were presented to the Board by the Chairman of the Board. The feedback on Committee Evaluation was shared by the Committee Chairperson / Chairman with the Committee Members. The outcome and action points were discussed by the Board in February 2026. The Chairman of the Board and the Chairperson of the Nomination and Remuneration Committee briefed the Board on the overall outcome. The Chairman held individual meetings with each Director as a part of self-appraisal and peer-group evaluation.

Stakeholders Relationship Committee:

As on March 31, 2026, the Stakeholders Relationship Committee comprises 3 (three) Directors of which, all of them are Non-Executive Directors and the Chairperson is an Independent Director.

The role of the Stakeholders Relationship Committee includes:

1. Resolving the grievances of security holders of the Company.
2. Reviewing the measures taken for effective exercise of voting rights by shareholders.
3. Reviewing of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent (RTA).
4. Reviewing various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants / annual reports / statutory notices by the shareholders of the Company.

Constitution of the Stakeholders Relationship Committee and attendance details during the Financial Year ended March 31, 2026, is given below:

S.N.	Name of Director	DIN	Position
1	Mr. Ankur Dave	01059786	Chairman / Independent Director
2	Mr. Priyank Lalitbhai Sancheti	09784354	Member / Independent Director
3	Mrs. Tanvi Shah	08192047	Member / Non-Executive Director

One meeting of the Stakeholders Relationship committee was held during the year. The date on which the said meeting was held: 14th February, 2026.

S.N.	Name of Member	No of Meetings held	No. of Meetings attended
1	Mr. Ankur Dave	1	1
2	Mr. Priyank Lalitbhai Sancheti	1	1
3	Mrs. Tanvi Shah	1	1

Ms. Puneeta Sharma, Company Secretary of the Company acts as the Secretary and Compliance Officer to the meetings of the Stakeholders Relationship Committee.

During the Financial Year, no complaints were received from Shareholders as on March 31, 2026.

Risk Management Committee:

Under Regulation 21 of the SEBI (LODR) Regulations, 2015, the Company does not fall under the top 1000 entities, which has to mandatorily constitute a Risk Management Committee. However, the Company has the procedure for risk assessment and minimization.

Code of Conduct and Business Ethics:

The Company has adopted a Code of Conduct and Business Ethics for Directors and Senior Management of the Company, as required under Regulation 17(5)(a) of the Listing Regulations. The Company has received confirmations from the Directors and Senior Management regarding compliance with the Code for the year ended March 31, 2026.

A certificate from the Managing Director to this effect is attached to this Report.

The Code has been displayed on the Company's website at https://medicointercontinental.com/wp-content/uploads/2026/05/Code-of-Conduct_F.pdf

Whistle Blower Policy:

As required under Listing Regulations, the Company has a Whistle Blower Policy which has been displayed on its website at <https://medicointercontinental.com/wp-content/uploads/2026/05/MIL-Whistle-Blower-Policy.pdf>

Code of Conduct for Prevention of Insider Trading:

As required by the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has adopted "Code of conduct to Regulate, Monitor and Report trading by insiders in securities of Medico Intercontinental Limited." The Company Secretary acts as the Compliance Officer. The Code of Conduct is applicable to all Directors and designated persons of the Company who are expected to have access to unpublished price sensitive information relating to the Company. The Code of Conduct lays down guidelines, which advises them on procedures to be followed and disclosures to be made, while dealing with securities of the Company and cautions them of the consequences of violations.

Related Party Transactions:

During the year under review, there were material transactions or arrangements entered into between the Company and its Promoters, Directors or their Relatives or the Management, Subsidiaries, Joint Venture etc. which shall not have any potential conflict with the interests of the Company at large.

All the Related Party Transactions were in the ordinary course of business and at arm's length, approved by the Audit Committee and Board in line with the Company's policy on Related Party Transactions. Policy on transactions with related parties has been displayed on the Company's website at https://medicointercontinental.com/wp-content/uploads/2026/05/Policy_Related-Party-Transactions_F.pdf. The Audit Committee has granted omnibus approval for related party transactions in the ordinary course of business. The same are reviewed on a quarterly basis by the Audit Committee. Transactions with related parties, including the promoter / promoter group which hold(s) more than

10% shareholding in the Company, have been disclosed in the Annual Accounts. All Material Related Party Transactions defined as per the Listing Regulations were approved by the shareholders of the Company.

The details of related party transactions are presented in Note No. 29 to Annual Accounts in the Annual Report.

Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under regulation 32 (7A) of SEBI listing regulations:

Not Applicable

General Body Meetings:

The location, time of Annual General Meetings held during the last three years:

Financial Year	Date	Time	Location	No. of Special Resolutions Passed
April to March 2025	30th September, 2025	02:00 PM	At Registered Office - through Video Conferencing facility	Six
April to March 2024	27th September, 2024	02:00 PM	At Registered Office - through Video Conferencing facility	0
April to March 2023	30th June, 2023	12:00 PM	At Registered Office - through Video Conferencing facility	Three

All the resolutions set out in the respective Notices were passed by the Shareholders.

- Whether any Special Resolution passed last year through postal ballot - details of voting pattern – Not Applicable.
- Person who conducted the postal ballot exercise – Not Applicable.
- Whether any special resolution is proposed to be conducted through postal ballot – Not Applicable.
- Procedure for Postal Ballot: Not Applicable.

Means of Communication:

Quarterly, Half-Yearly and Annual Results of the Company are published in newspapers, Financial Express in English and Gujarati Language. These results are promptly submitted to the Stock Exchanges facilitating them to display the same on their website.


The Company's results are available on the Company's website at <https://medicointercontinental.com/investors/financials/>

General Shareholder Information:

AGM Date, Time and Venue:	Wednesday, September 30, 2026 at 02:00 p.m. through Video Conferencing facility
Financial Year:	April to March
First Quarter Results:	1st Fortnight of August, 2026
Second Quarter & Half yearly Results:	1st Fortnight of November, 2026
Third Quarter Results:	1st Fortnight of February, 2026
Fourth Quarter & Annual Results:	2nd Fortnight of May, 2027
Dates of Book Closure:	Thursday, September 24, 2026 to Wednesday, September 30, 2026 (both days inclusive)
Dividend Payment Date:	Not Applicable
Listing on Stock Exchanges:	The Company's Shares are listed on the Stock Exchange mentioned below and accordingly the Company has paid the Listing Fees to them for the Financial Year 2026-27. - BSE Limited (BSE) Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001.
Stock Code:	539938
ISIN No.:	INE858Q01019

Market Price Data: High and Low during each month in the financial year 2025-26:

Month	High Price (Rs.)	Low Price (Rs.)
April, 2025	43.00	34.70
May, 2025	41.80	35.75
June, 2025	43.00	34.00
July, 2025	40.99	36.01
August, 2025	38.99	32.71
September, 2025	39.50	33.15
October, 2025	39.44	31.30
November, 2025	38.10	29.30
December, 2025	40.45	26.00
January, 2026	43.00	33.40
February, 2026	39.00	31.39
March, 2026	34.99	25.39

Stock Performance in comparison to BSE Sensex during the Financial 2025-26:

Series 1 refer to the Company: Medico Intercontinental Limited

Series 2 refer to BSE: Bombay Stock Exchange

Note: Closing Price of April, 2026 has been taken as Base price 100 and accordingly adjusted the price of other Months for the Company and BSE.

Registrars and Share Transfer Agents: Purva Sharegistry (India) Pvt. Ltd,
 9, Shiv Shakti Ind. Estt. J.R. Boricha Marg,
 Lower Parel (East), Mumbai, Maharashtra – 400011
 Tel: 022 – 2301 2518
 Email: support@purvashare.com

Share Transfer System:

Shares in physical form should be lodged for transfer at the office of the Company's Registrar & Transfer Agent. Share transfers are registered and returned generally within fifteen days from the date of receipt if the relevant documents are complete in all respects. As per directives issued by SEBI, it is compulsory to trade in the Company's equity shares in dematerialized form. Effective April 1, 2019, transfer of shares in physical form has ceased. Shareholders who had lodged their request for transfer prior to March 31, 2019 and, have received the same under objection can re-lodge the transfer request after rectification of the documents. Request for transmission of shares and dematerialization of shares will continue to be accepted. The Company obtains a certificate from Practicing Company Secretaries as per the requirement of Regulation 40(9) of Listing Regulations and same is filed with the Stock Exchanges.

However, SEBI had introduced a special, time-bound window from July 7, 2025 to January 6, 2026, for the re-lodgment of physical share transfer requests that were previously rejected or returned before April 1, 2019. This initiative allowed shareholders to transfer and dematerialize shares that faced procedural or documentation issues, aiming to resolve long-standing legacy, non-disputed ownership cases. In order to further facilitate the investors to get rightful access to their securities, SEBI has opened another special window for transfer and dematerialization of physical securities which were sold / purchased before April 1, 2019. This special window is open for a period of 1 (one) year from February 5, 2026 to February 4, 2027 and is available for such transfer requests which were previously submitted and were rejected or returned before April 1, 2019 due to deficiency of documents, process or otherwise. The investors who are eligible for this are requested to take advantage of this special window and have the shares transferred in their name(s).

In terms of the Listing Regulations, shares of the Company can only be transferred in dematerialized form. Further, SEBI vide its circular No. SEBI/HO/MIRSD_RTAMB/P/CIR/2022/8 dated January 24, 2022, mandated all the listed Companies to issue securities in dematerialized form only, while processing the service request for issue of duplicate certificate, claim from Unclaimed Suspense Account, endorsement, sub-division / splitting of securities certificate, consolidation of securities certificates / folios, transmission and transposition.

In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialization, Members are advised to dematerialize the shares held by them in physical form.

Transfer of shares to Ministry of Corporate Affairs - Investor Education and Protection Fund ('IEPF') Authority: Not Applicable for the period under review.

Saksham Niveshak: The IEPF Authority, under the aegis of MCA, in order to reduce the volume of unclaimed dividend / shares transferred to IEPF Authority, launched Saksham Niveshak – a 100-day nationwide campaign from July 28, 2025 to November 6, 2025 to encourage investors to update their records and claim their entitlements.

Authority, ensure timely updation of KYC details and bank account information with the Registrar and Share Transfer Agent, opt for electronic mode of communication for prompt receipt of corporate communications. Your Company continues to uphold the principles of transparency and investor protection in all its engagements with the stakeholders.

Transfer of shares to Unclaimed Suspense Account: Not applicable for the period under review

Dispute Resolution Mechanism (SMART Online Dispute Resolution [ODR]):

SEBI vide its circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/ CIR/2022/76 dated May 30, 2022, issued a Standard Operating Procedure ('SOP') for dispute resolution under the Stock Exchange Arbitration Mechanism for disputes between a listed Company and / or Registrar and Share Transfer Agent and its shareholder(s) / investor(s). Further, SEBI vide its circular No. SEBI/HO/OIAE/OIAE_IAD3/P/CIR/2023/195 dated July 31, 2023, introduced a mechanism to streamline and strengthen the existing dispute resolution in the Indian Securities market.

This mechanism enhanced the degree of regulatory supervision by SEBI over disputes between aggrieved parties and the ODR order is binding on both the parties to the dispute.

Pursuant to the above-mentioned circulars, the aggrieved party can initiate the mechanism through the ODR portal, after exercising the primary options to resolve the issue directly with the Company and through the SCORES platform.

Distribution of Shareholding:

S.N.	Category (Equity Shares)	No. of Shareholders	% of Shareholders	No. of Shares held	% Shareholding
1	1 to 500	3374	82.45	347457	3.47
2	501 to 1000	306	7.48	242067	2.42
3	1001 to 5000	298	7.28	714134	7.14
4	5001 to 10000	49	1.20	347100	3.47
5	10001 to 100000	60	1.47	2213369	22.13
6	100001 and above	5	0.12	6135873	61.36
TOTAL		4,092	100.00	1,00,00,000	100.00

Category wise Shareholding Pattern:

S.N.	Category	No. of Shares	% of Voting Strength
1	Promoters	57,14,510	57.15
2	Resident – Individual	35,40,683	35.41
3	NRI	28,578	0.29
4	HUF	5,31,958	5.31
5	Body Corporate	36,012	0.36
6	Clearing Member	1,47,788	1.47
7	LLP	471	0.01
TOTAL		1,00,00,000	100.00

Dematerialization of shares and liquidity:

The process of conversion of shares from physical form to electronic form is known as dematerialization. For dematerializing the shares, the Shareholder has to open a demat account with a Depository Participant (DP). The Shareholder is required to fill in a Demat Request Form and submit the same along with the Share Certificate(s) to the DP. The DP will allocate a demat request number and shall forward the request physically and electronically, through NSDL/CDSL to the R&T Agent. On receipt of the demat request, both physically and electronically and after verification, the Shares are dematerialized, and an electronic credit of shares is given in the account of the Shareholder.

The Company's Shares are available for trading in the depository systems of both the National Securities Depository Limited (NSDL) and Central Depository Services Limited (CDSL). As on 31st March, 2026, 99,06,928 Equity shares of the Company, forming 99.07% of total shareholding stands dematerialized. As on 31st March, 2026, the promoters and promoters group holding 57,14,510 shares (100%) are held in dematerialized form.

Outstanding Global Depository Receipts or American depository Receipts or Warrants or any Convertible Instruments, Conversion Date and likely impact on equity; The Company has not issued GDR/ADR/Warrants or any convertible security.

Commodity price risk or foreign exchange risk and hedging activities; Not Applicable

Plant Location: Not Applicable

Address for correspondence:

RTA: Purva Sharegistry (India) Pvt. Ltd, 9, Shiv Shakti Ind. Estt. J.R. Boricha Marg, Lower Parel (East), Mumbai, Maharashtra – 400011, Tel: 022 – 2301 2518, Email: support@purvashare.com

Registered Office of Company: 1-5th floor, Adit Raj Acade Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad, Gujarat, 380015. Email: mail@medicointercontinental.com, Tel: 079 2674 2739.

Shareholders holding shares in Electronic Mode should address all their correspondence to their respective depository participant.

List of all credit ratings obtained by the entity along with any revisions thereto during the relevant financial year, for all debt instruments of such entity or any fixed deposit programmes or any scheme or proposal of the listed entity involving mobilization of funds, whether in India or abroad: Not Applicable

Other Disclosures and Affirmations:

- a) As required by Regulation 17(8) of the Listing Regulations, the Chief Executive Officer and the Chief Financial Officer have submitted a Certificate to the Board in the prescribed format for the Financial Year ended March 31, 2026. The Certificate has been reviewed by the Audit Committee and taken on record by the Board.
- b) There were no instances of non-compliance nor have any penalties, strictures been imposed by Stock Exchanges or SEBI or any other statutory authority during the last three years on any matter related to the capital markets.
- c) The Company does have 4 Wholly Owned subsidiaries and 1 Joint Venture. Further, Company has invested 51% in a Company having unique product portfolio so as to make it subsidiary of the Company. The name of the Company is Calborn Lifescience Private Limited. Company does not have any associate companies during the period under review. The Company has in place the Policy on Material Subsidiary and same is available on the website at <https://medicointercontinental.com/investors/policies/>
- d) The Company has not raised any funds in the Financial Year ended March 31, 2026.
- e) The Company has obtained a certificate from M/s. Agarwal & Mehta Company Secretaries LLP, as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 confirming that none of the Directors on Board of the Company have been debarred or disqualified from being appointed or continuing as directors of companies by SEBI / Ministry of Corporate Affairs or any such statutory authority, which forms part of this Report.
- f) The Company has paid Rs. 4,25,000/- as total fees for all services provided by M/s. V Goswami & Co, Chartered Accountants in the Financial Year ended March 31, 2026.
- g) During the year 2026, the Company did not receive any complaint of alleged sexual harassment. As on March 31, 2026 no complaints related to sexual harassment are pending for disposal.
- h) During the year, the Company has not provided any loans and advances in the nature of loans to firms / companies in which directors are interested.
- i) The Company has complied with the requirements as mentioned in Schedule V, Para C, sub-paras (2) to (10) of the Listing Regulations.
- j) The Company has complied with all the requirements as specified in the Regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the Listing Regulations.

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

[Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,
The Members
Medico Intercontinental Limited

We have examined the relevant disclosures provided by the Directors (as enlisted in Table A) to Medico Intercontinental Limited having CIN L24100GJ1984PLC111413 and registered office at 1-5th Floor, Adit Raj Arcade Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad, Gujarat, 380015 (hereinafter referred to as 'the Company') for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para C clause 10(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information, based on (i) Documents available on the website of the Ministry of Corporate Affairs (MCA) (ii) Verification of Directors Identification Number (DIN) status on the website of the MCA, and (iii) disclosures provided by the Directors to the Company, we hereby certify that none of the Directors on the Board of the Company (as enlisted in Table A) have been debarred or disqualified from being appointed or continuing as Directors of the Companies by the Securities and Exchange Board of India, MCA or any such other statutory authority as on March 31, 2026.

TABLE A

S.N.	Name of the Directors	Director Identification Number (DIN)	Date of Appointment in Company
1	Mr. Samir Dilipkumar Shah	03350268	14/08/2018
2	Mrs. Tanvi Samirbhai Shah	08192047	14/08/2018
3	Mr. Ankur Amiram Dave	01059786	23/03/2019
4	Mrs. Swati Jay Shah	08420884	29/05/2019
5	Mr. Priyank Lalitbhai Sancheti	09784354	14/11/2022
6	Mr. Parshwa Kaushal Shah	07400081	10/05/2024

General Disclaimer: Our Analysis for this certificate does not covers the verification of criteria pertaining to appointment as an Independent Director under Section 149 and criteria pertaining to appointment as Managing Director under section 196 and Schedule V of the Companies Act, 2013.

For, Agarwal & Mehta
Company Secretaries LLP
ICSI Unique Code No.: L2018GJ004600

Sd/-
YASH MEHTA
PARTNER
FCS: 12143;
COP: 16535

Date : 14.08.2026
Place: Ahmedabad

PEER REVIEW No.: 6717/2025
UDIN: F012143H001113606

COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE

To,
The Members,
Medico Intercontinental Limited

We have examined the compliance of conditions of Corporate Governance by Medico Intercontinental Limited, for the year ended 31st March, 2026 as stipulated in Regulations [17, 17A, 18, 19, 20, 21, 22, 23, 24A, 25, 26, 27 and clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46 and para C , D and E of Schedule V] of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (collectively referred to as "SEBI Listing Regulations, 2015").

The compliance of conditions of Corporate Governance is the responsibility of the Company's management. Our examination was limited to the procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations, 2015.

We state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

PROOF

For, Agarwal & Mehta
Company Secretaries LLP
ICSI Unique Code No.: L2018GJ004600

Date : 14.08.2026
Place: Ahmedabad

Sd/-
YASH MEHTA
PARTNER
FCS: 12143;
COP: 16535
PEER REVIEW No.: 6717/2025
UDIN: F012143H001113639

DECLARATION BY THE MANAGING DIRECTOR UNDER CLAUSE 17(5) OF SEBI (LODR) REGULATIONS, 2015

In accordance with Regulation 17(5)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board Members and Senior Management Personnel of the Company have confirmed compliance with the Code of Business Conduct and Ethics for the financial year ended March 31, 2026.

For Medico Intercontinental Limited

**Sd/-
Samir D Shah
Managing Director
DIN: 03350268**

Date: 14/08/2026

CEO and CFO Certification

The Board of Directors
Medico Intercontinental Limited
 Ahmedabad.

Dear Members of the Board,

We, Mr. Dilipkumar Bhogilal Shah, Chief Executive Officer, and Mr. Jay Sharadkumar Shah, Chief Financial Officer of Medico Intercontinental Limited, to the best of our knowledge and belief, certify that:

1. We have reviewed the Balance Sheet as at March 31, 2026, Statement of Profit and loss, the Statement of Changes in Equity and the Statement of Cash Flows for the year ended, and a summary of the significant accounting policies and other explanatory information of the Company, and the Board's report for the year ended March 31, 2026.
2. These statements do not contain any materially untrue statement or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. The financial statements, and other financial information included in this report, present in all material respect a true and fair view of the Company's affairs, the financial condition, results of operation and cash flows of the Company as at, and for, the periods presented in this report, and are in compliance with the existing accounting standards and / or applicable laws and regulations.
4. There are no transactions entered into by the Company during the year that are fraudulent, illegal or violate the Company's Code of Conduct and Ethics, except as disclosed to the Company's auditors and the Company's audit committee of the Board of Directors.
5. We are responsible for establishing and maintaining disclosure controls and procedures and internal controls over financial reporting for the Company, and we have:
 - a. Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared.
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with Indian Accounting Standards (Ind AS).
 - c. Evaluated the effectiveness of the Company's disclosure, controls and procedures.

- d. Disclosed in this report, changes, if any, in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal year that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
6. We have disclosed, based on our most recent evaluation of the Company's internal control over financial reporting, wherever applicable, to the Company's auditors and the audit Committee of the Company's Board (and persons performing the equivalent functions):
 - a. Any deficiencies in the design or operation of internal controls, that could adversely affect the Company's ability to record, process, summarize and report financial data, and have confirmed that there have been no material weaknesses in internal controls over financial reporting including any corrective actions with regard to deficiencies.
 - b. Any significant changes in internal controls during the year covered by this report.
 - c. All significant changes in accounting policies during the year, if any, and the same have been disclosed in the notes to the financial statements.
 - d. Any instances of significant fraud of which we are aware, that involve the Management or other employees who have a significant role in the Company's internal control system.
7. We affirm that we have not denied any personal access to the audit committee of the Company (in respect of matters alleged misconduct) and we have provided protection to whistleblowers from unfair termination and other unfair or prejudicial employment practices.
8. We further declare that all Board members and senior management personnel have affirmed compliance with the Code of Conduct and Ethics for the year covered by this report.

Place : Ahmedabad
Date : 14/08/2026

PROOF

Sd/-
Dilipkumar Shah
Chief Executive Officer

Sd/-
Jay Sharadkumar Shah
Chief Financial Officer

INDEPENDENT AUDITORS' REPORT ON STANDALONE FINANCIAL STATEMENTS

TO THE MEMBERS OF
MEDICO INTERCONTINENTAL LIMITED

Report on the Standalone Financial Statements

We have audited the accompanying Standalone Financial Statements of **MEDICO INTERCONTINENTAL LIMITED** ("the Company"), which comprise the Balance Sheet as at 31st March, 2026, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the Standalone Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (hereinafter referred to as "the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, (hereinafter referred to as "Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (hereinafter referred to as "SAs"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (hereinafter referred to as "ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Key Audit Matters

Key Audit Matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter	How our audit addressed the key audit matter
Revenue recognition as per Ind AS 115	Our audit procedures included the following:
Refer to Note - 1 (Significant Accounting Policies) and Note - 1.10 (Revenue from operations) of the financial statements.	We evaluated the design and tested operating effectiveness of the relevant controls with respect to revenue recognition including those relating to cut off at year end;
The Company's revenue is principally derived from sale of various medicine products.	We assessed the appropriateness of the revenue recognition accounting policies in line with Ind AS 115 "Revenue from Contracts with Customers";
In accordance with Ind AS 115, revenue from sale of goods is recognized when control of the products being sold is transferred to the customer and when there are no unfulfilled obligations. The performance obligations in the contracts are fulfilled at the time of dispatch, delivery or upon formal customer acceptance depending on terms of contract with the customer. Revenue is measured at fair value of the consideration received or receivable after deduction of any trade / volume discounts and taxes or duties collected.	We performed substantive testing of revenue transactions, recorded during the year by testing the underlying documents which included goods dispatch notes, shipping documents and customer acknowledgments, as applicable;
We identified revenue recognition as a key audit matter since revenue is significant to the financial statements and is required to be recognized as per the requirements of applicable accounting framework.	We tested manual journal entries posted to revenue to identify unusual items;
	We tested, on a sample basis, specific revenue transactions recorded before and after the financial year end date including examination of credit notes issued after the year end to determine whether the revenue has been recognized in the appropriate financial period.
	Based on the above stated procedures, no significant exceptions were noted in revenue recognition.

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India (Indian GAAPs), including the Accounting Standards ('Ind AS') specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

This responsibility also includes the maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding of the assets of the Company and for preventing and detecting the frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of internal financial control, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- o Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- o Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances; Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- o Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- o Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may

cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- o Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the Directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure – B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
 - g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended. In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
 - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:

- o The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements. Refer Note 27 to the standalone Ind AS financial statements
- o The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- o There were no any amounts required to be transferred, to the Investor Education and Protection Fund by the Company.
- o The final dividend paid by the Company during the year in respect of the same declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend.
- o a. The respective Managements of the company and its subsidiaries which are incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and brief belief, no funds (which are material either individually or in aggregate) have been advanced or loaned or invested (either from the borrowed funds or share premium or any other sources or kind of funds) by the Company or any such of subsidiaries to or in any other person or entity including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company or any of such subsidiaries ("Ultimate beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate beneficiaries.
- b. The respective Management of the Company and its subsidiaries which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of the knowledge and belief no funds (which are material either individually or in the aggregate) have been received by the company or any of subsidiaries from any person or entity, including foreign entity ("Funding parties") with the understanding, whether recorded in writing or otherwise, that the Company or any of such subsidiaries shall directly or indirectly, lend or invest in other persons or entities identified in any manner what's the whatsoever by or on behalf of the funding party ("Ultimate beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- c. Based on audit procedures that have been considered reasonable and appropriate in the circumstances performed by us on the Company and its subsidiaries which are companies incorporated in India whose financial statements have been audited under the Act, nothing has come to our notice that has caused us to believe that the representations are under sub clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)

Sd/-
VIPUL GOSWAMI
(Partner)
Mem. No.: 119809
UDIN : 26119809NQIVQC8702
Date : 22/05/2026
Place: Ahmedabad

Annexure “A” to the Independent Auditor’s Report

(Referred to in paragraph 1 under “Report on Other Legal and Regulatory Requirement of our report of even date to the members of **MEDICO INTERCONTINENTAL LIMITED** on the Standalone Financial Statements for the year ended 31st March, 2026).

On the basis of such checks as we considered appropriate and in terms of the information and explanations given to us, we state that:

- (i) (a) (A) The company is maintaining proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;
(B) The company is maintaining proper records showing full particulars of intangible assets;
- (b) As explained to us, the Property, Plant and Equipment have been physically verified by the management at reasonable intervals; and there were no material discrepancies were noticed on such verification and if so, and the same have been properly dealt with in the books of account;
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the company, the title deeds of immovable property held in the name of company.
- (d) The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year;
- (e) As explained to us, there are no proceedings have been initiated during the year or are pending against the Company as at March 31, 2026 for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder;
- (ii) (a) Physical verification of inventory has been conducted at reasonable intervals by the management and in our opinion, the frequency, coverage and procedure of such verification by the management is appropriate; No discrepancies of 10% or more in the aggregate for each class of inventory were noticed and they have been properly dealt with in the books of account;
- (b) During the year, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets; and the quarterly returns or statements as required, filed by the company with such banks or financial institutions are in agreement with the books of account of the Company;
- (iii) The year the company has made investments in Subsidiary Company as covered in register-maintained u/s 189 of the Companies Act, 2013: In respect of which
 - (a) During the year, the company has provided loans or advances in the nature of loans, or stood guarantee, or provided security to entity as below:

(In Lakhs)

Particulars	Guarantee	Loans	Security	Advances in nature of loans
Aggregate amount granted/provided during the year:				
— Wholly Owned Subsidiaries/ Subsidiaries	2891.83	2521.51		
— Joint Ventures / Associates				
— Other parties				
Balance outstanding as at March 31, 2026:				
— Wholly Owned Subsidiaries/ Subsidiaries	3342.83	2521.51		
— Joint Ventures / Associates				
— Other parties				

- (b) In our opinion, the investments made and the terms and conditions of the grant of loans, during the year, prima facie, not prejudicial to the Company’s interest;

- (c) In respect of loans granted by the Company, the schedule of repayment of principal and payment of interest has been stipulated and the repayments of principal amounts and receipts of interest are generally been regular as per stipulation;
- (d) There are no overdue amounts in respect of the loan granted to a body corporate listed in the register maintained under section 189 of the Act;
- (e) No loan granted by the Company which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the over dues of existing loans given to the same parties;
- (f) The Company has not been granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment during the year. Hence, reporting under clause 3(iii)(f) is not applicable.
- (iv) In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made.
- (v) In our opinion and according to the information and explanations given to us, the Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Companies Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- (vi) As informed to us, the maintenance of cost records has not been specified by the Central Government under section 148(1) of the Companies Act, 2013 for the business activities carried out by the Company. Thus, reporting under clause 3(vi) of the order is not applicable to the Company.
- (vii) (a) The company is generally regular in depositing the undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Wealth Tax, Goods and Services Tax, Custom Duty, Excise Duty and other statutory dues, as applicable, with the appropriate authorities in India;
- (b) According to the information and explanations given to us and based on audit procedures performed by us, no undisputed amounts payable in respect of these statutory dues were outstanding on the last day of the financial year concerned for a period of more than six months from the date they became payable.
- (c) Information and explanations given to us and the records of the Company examined by us, there are dues of income tax or goods and service tax, provident fund, employees' state insurance, income tax, sales tax, service tax, custom duty, excise duty, value added tax, Cess and other statutory dues which have not been deposited on account of any dispute.

Name of the Statute	Nature of dues	Forum where the dispute is pending	Year to which it pertains	Amount (Rs. in lakhs)
The Goods and Service Tax Act	GST	COMMISSIONER (APPEALS)	2020-21	9.44
The Goods and Service Tax Act	GST (APPEALS)	COMMISSIONER	2019-20	18.20
The Goods and Service Tax Act	GST	COMMISSIONER (APPEALS)	2018-19	9.63

- (viii) According to the records of the company examined by us and as per the information and explanation given to us, there were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- (ix) (a) According to the records of the company examined by us and as per the information and explanations given to us, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any financial institution or banks or lender;
- (b) According to the records of the company examined by us and as per the information and explanations given to us, The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority;

- (c) According to the records of the company examined by us and as per the information and explanations given to us, the Term loans were applied for the purpose for which the loans were obtained;
- (d) According to the records of the company examined by us and as per the information and explanations given to us, on an overall examination of the financial statements of the Company, no funds raised on short-term basis have been used for long-term purposes by the Company;
- (e) As we informed that the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures;
- (f) According to the records of the company examined by us and as per the information and explanations given to us, the Company has not raised loans during the year on the pledge of securities held in its subsidiaries or associate companies. Hence, the requirement to report on clause (ix) (f) of the Order is not applicable to the Company.
- (x) (a) According to the information and explanations given to us and based on our examination of the records of the company, the Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year.
- (b) According to the information and explanations given to us and based on our examination of the records of the company during the year, the Company has not made any preferential allotment of equity shares during the current financial year.
- (xi) (a) According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit;
- (b) According to the information and explanations given to us, during the year and upto the date of this audit report, no report under sub-section (12) of section 143 of the Companies Act, 2013 has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;
- (c) According to the information and explanations given to us, during the year there are no whistle blower complaints received by the company during the year.
- (xii) The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.
- (xiii) According to the information and explanations given to us and based on our examination of the records of the company, transactions with the related parties, are in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable and details of such transactions have been disclosed in the Standalone Financial Statements as required by the applicable accounting standards.
- (xiv) (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business;
- (b) We have considered the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.
- (xv) In our opinion during the year, the Company has not entered into any non-cash transactions with its directors or persons connected with its directors. Hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable;
- In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable.
- (xvii) In our opinion, there is no cash loss in the financial year and in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors of the Company during the year.
- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on

the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- (xx) (a) According to the information and explanations given to us and based on our examination of the records of the company, there are no unspent amounts that are required to be transferred to a fund specified in Schedule VII to the companies Act (the Act), in compliance with second proviso to sub section 5 of section 135 of the Act;
- (b) In our opinion, there are no unspent amounts in respect of ongoing projects, that are required to be transferred to a special account in compliance of provision of sub section (6) of section 135 of Companies Act.
- (xix) The reporting under clause 3(xix) of the Order is not applicable in respect of audit of standalone financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)

Sd/-
VIPUL GOSWAMI
(Partner)
Mem. No.: 119809
UDIN : 26119809NQIVQC8702
Date : 22/05/2026
Place: Ahmedabad

PROOF

Annexure “B” to the Independent Auditor’s Report

(Referred to in paragraph 2 (f) under “Report on Other Legal and Regulatory Requirement of our report of even date)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013

We have audited the Internal Financial Controls over Financial Reporting of **MEDICO INTERCONTINENTAL LIMITED** as on 31st March, 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls

Over Financial Reporting (the "Guidance Note") and the Standards on Auditing deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A Company's Internal Financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)**

**Sd/-
VIPUL GOSWAMI
(Partner)
Mem. No.: 119809
UDIN : 26119809NQIVQC8702
Date : 22/05/2026
Place: Ahmedabad**

STANDALONE BALANCE SHEET AS AT 31 March, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	Note	As at 31 March, 2026	As at 31 March, 2025
ASSETS:			
Non-Current Assets			
(a) Property, Plant & Equipment	2.1	152.45	167.93
(b) Investment Property	2.2	.00	271.00
(c) Financial Assests			
(i) Investments	3.1	1241.53	718.73
(ii) Loans	3.2	2521.51	.00
(d) Deferred Tax Assets (Net)	4	2.75	.97
(e) Other non current Assets	5	108.00	1030.69
Total Non-Current Assets		4026.24	2189.32
Current Assets			
(a) Inventories	6	211.46	294.15
(b) Financial Assests			
(i) Trade Receivables	7	1793.49	2277.47
(ii) Cash and Cash Equivalents	8	216.00	141.77
(iii) Loan	9	0.00	100.80
(c) Other Current Assets	10	494.78	873.62
Total Current Assets		2715.73	3687.81
TOTAL ASSETS		6741.98	5877.13
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share capital	11	1000.00	1000.00
(b) Other Equity	12	3084.51	2866.15
Total Shareholders' Funds		4084.51	3866.15
Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	13.1	1496.55	1277.05
(ii) Other Financial Liabilities	14	.00	29.32
(b) Long term Provisions	18.1	15.36	9.27
Total Non-Current Liabilities		1511.91	1315.64
Current Liabilities			
(a) Financial Liabilities\			
(i) Borrowings	13.2	118.17	44.53
(ii) Trade Payables	15		
Due to Micro and Small Enterprises		440.17	132.67
Due to others		465.11	425.98
(b) Other Current Liabilities	16	107.04	67.11
(c) Current Tax Liabilities (net)	17	14.12	24.47
(d) Short term Provisions	18.2	.94	.59
Total Current Liabilities		1145.56	695.35
TOTAL EQUITY AND LIABILITIES		6741.98	5877.13
		-	0.00

Basis of preparation, measurement and Significant Accounting Policies
The accompanying notes are an integral part of these Financial Statements

1

1 to 39

As per our report of even date
For V. GOSWAMI & CO,
Chartered Accountants
FRN : 0128769W
Sd/-
Vipul Goswami
Partner
M.No.: 119809
Place : Ahmedabad
Dated : 22/05/2026
UDIN : 26119809NQIVQC8702

For and on behalf of the board
Medico Intercontinental Limited

Sd/-
Tanvi Shah
Chairperson
DIN:-08192047
Sd/-
Jay Shah
Chief Financial officer
PAN No.: CZOPS1007A

Sd/-
Samir Shah
Managing Director
DIN:-03350268
Sd/-
Puneeta Sharma
Company Secretary
PAN No.: CXOPS0548E

STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st March, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	Note	Year ended 31st March 2026	Year ended 31st March 2025
INCOME			
Revenue From Operations	19	5446.08	6712.98
Other Income	20	234.54	50.77
Total Income		5680.62	6763.75
Expenses			
Purchases of Stock in Trade	21	4486.22	5444.92
Changes In Inventories	22	82.69	162.74
Employee Benefits Expense	23	246.03	174.06
Depreciation and Amortization Expense	2	69.35	55.57
Finance Costs	24	166.83	67.22
Other Expenses	25	317.86	501.68
Total Expenses		5368.98	6406.20
Profit before Exceptional Items and Tax		311.64	357.55
Exceptional Items			
Bad Debts		0	0
Profit before Tax		311.64	357.55
Tax Expense:			
- Current Tax		95.07	94.44
- Deferred Tax		-1.79	6.54
Profit for the year ended (A)		218.36	256.58
OTHER COMPREHENSIVE INCOME			
Items that will not be reclassified subsequently to profit or loss		0	0
Items that will be reclassified subsequently to profit or loss		0	0
OTHER COMPREHENSIVE INCOME FOR THE YEAR (B)		0	0
TOTAL COMPREHENSIVE INCOME FOR THE YEAR (A+B)		218.36	256.58
Earnings Per Equity Share of face value of Rs. 10/- each			
Basic and Diluted (Rs.)	26	2.18	2.57
Basis of preparation, measurement and Significant Accounting Policies	1		
The accompanying notes forms an integral part of the Financial Statements	1 TO 39		

As per our report of even date

For V. GOSWAMI & CO,

Chartered Accountants

FRN : 0128769W

Sd/-

Vipul Goswami

Partner

M.No.: 119809

Place : Ahmedabad**Dated : 22/05/2026****UDIN : 26119809NQIVQC8702****For and on behalf of the board****Medico Intercontinental Limited**

Sd/-

Tanvi Shah

Chairperson

DIN:-08192047

Sd/-

Jay Shah

Chief Financial officer

PAN No.: CZOPS1007A

Sd/-

Samir Shah

Managing Director

DIN:-03350268

Sd/-

Puneeta Sharma

Company Secretary

PAN No.: CXOPS0548E

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31st March 2026	As At 31st March 2025
A. CASH FLOW FROM OPERATING ACTIVITIES :		
a) Net Profit/(Loss) before tax	311.64	357.55
b) OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	311.64	357.55
Adjustments for:		
Depreciation & Amortization	69.35	55.57
Finance Costs	166.83	67.22
Gratuity Expenses	6.45	2.77
Profit on Sale of Asset	-35.85	0.00
Interest Income & Dividend Income	-172.31	-31.94
Loss on Sale Motor car	0.00	.98
CASH GENERATED FROM OPERATIONS	346.11	452.15
Adjustments for		
Decrease/(Increase) in Inventories	82.69	162.74
Decrease/(Increase) in Trade Receivables	483.97	-784.96
Decrease/(Increase) in Other Current Assets	378.84	-862.02
Increase/(Decrease) Non- Current Financial Liabilities	-29.32	29.32
Increase/(Decrease) in Trade Payables	346.63	365.19
Increase/(Decrease) in Current Financial Liabilities-Borrowings	0.00	0.00
Increase/(Decrease) in Other Current Liabilities	39.93	59.24
CASH GENERATED FROM OPERATING ACTIVITIES	1648.85	-578.33
Income Tax Paid Net	-105.42	-99.71
NET CASH FROM/(USED IN) OPERATING ACTIVITIES (A)	1543.43	-678.03
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase of Fixed Assets	-41.44	-188.35
Purchase of Investment Property	-198.00	-274.34
Decrease/(Increase) in Investment	-522.80	-298.54
Sales Of Motor Car	.00	.32
Interest and Dividend income received	172.31	31.94
Sales Of Property	492.41	0.00
Other Non-Current Assets	922.70	251.13
NET CASH FROM/(USED IN) INVESTING ACTIVITIES (B)	825.18	-477.83
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issuance of Share Capital	0.00	0.00
Increase/(Decrease) in Loan and advances	-2420.71	-100.80
Increase/(Decrease) in Borrowings	219.51	1197.25
Proceed from /(Repayment) of short term borrowing net	73.64	27.87
Finance costs paid	-166.83	-67.22
Dividend Paid	0.00	0.00
NET CASH FROM/(USED IN) FINANCING ACTIVITIES (C)	-2294.39	1057.09
NET INCREASE IN CASH AND CASH EQUIVALENTS (A+B+C)	74.22	-98.77
CASH AND CASH EQUIVALENTS (At the beginning of the year)	141.77	240.54
CASH AND CASH EQUIVALENTS (At the end of the year)	216.00	141.77

- The above cash flow statement has been prepared under the "Indirect Method" as set out in Ind AS 7, 'Statement of Cash Flows'.
- Previous Year's figure have been regrouped, rearranged, wherever necessary, to correspond with the current year's classification/disclosure.

As per our report of even date
For V. GOSWAMI & CO,
Chartered Accountants
FRN : 0128769W
Sd/-
Vipul Goswami
Partner
M.No.: 119809
Place : Ahmedabad
Dated : 22/05/2026
UDIN : 26119809NQIVQC8702

For and on behalf of the board
Medico Intercontinental Limited

Sd/-
Tanvi Shah
Chairperson
DIN:-08192047
Sd/-
Jay Shah
Chief Financial officer
PAN No.: CZOPS1007A

Sd/-
Samir Shah
Managing Director
DIN:-03350268
Sd/-
Puneeta Sharma
Company Secretary
PAN No.: CXOPS0548E

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026**STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31ST MARCH, 2026**

(Rs. in Lakhs unless otherwise stated)

	As at 31st March, 2026	As at 31st March, 2025
A. EQUITY SHARE CAPITAL		
Balance at the beginning of the reporting year		
Equity shares of Rs.10/- each issued, subscribed and paid-up	1000.00	1000.00
Changes in Equity Share capital during the year	.00	.00
Balance at the end of the reporting year	1000.00	1000.00

B. OTHER EQUITY

	Reserves and Surplus		Items of Other Comprehensive Income (OCI)	Total
	Securities Premium	Retained Earnings	NA	
Balance as at 1st April, 2024	1819.07	790.50	0.00	2609.57
Securities Premium Received /Profit for the year	0.00	256.58	0.00	256.58
Expenses on issue of equity shares	0.00	0.00	-	-
Dividend Paid during the year	0.00	-	0.00	-
Total comprehensive income for the year	1819.07	1047.07	0.00	2866.15
Balance as at 31st March, 2025	1819.07	1047.07	0.00	2866.15
Balance as at 1st April, 2025	1819.07	1047.07	0.00	2866.15
Profit for the year	-	218.36	0.00	218.36
Expenses on issue of equity shares	-	-		
Dividend Paid during the year	-	-		
Total comprehensive income for the year	1819.07	1265.43	0.00	3084.51
Balance as at 31st March, 2026	1819.07	1265.43	0.00	3084.51

As per our report of even date

For V. GOSWAMI & CO,

Chartered Accountants

FRN : 0128769W

Sd/-

Vipul Goswami

Partner

M.No.: 119809

Place : Ahmedabad

Dated : 22/05/2026

UDIN : 26119809NQIVQC8702

For and on behalf of the board**Medico Intercontinental Limited**

Sd/-

Tanvi Shah

Chairperson

DIN:-08192047

Sd/-

Jay Shah

Chief Financial officer

PAN No.: CZOPS1007A

Sd/-

Samir Shah

Managing Director

DIN:-03350268

Sd/-

Puneeta Sharma

Company Secretary

PAN No.: CXOPS0548E

STANDALONE NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2026

NOTE - 1.

1.01 Company overview

MEDICO INTERCONTINENTAL LIMITED ("the Company") was incorporated on August 14, 1984 having its Registered Office at 1-5th Floor, Adit Raj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad - 380015, Gujarat. The Company is into the business of trading of Pharmaceutical Products.

Basis of preparation and Significant Accounting Policies

1.02 Statement of Compliance

The financial statements of the Company have been prepared in accordance with the Indian Accounting Standards (IND AS) as per the Companies (Indian Accounting Standards) Rules, 2015 as amended and notified under Section 133 of the Companies Act, 2013 ("the Act") and other relevant provisions of the Act. The financial statements have been statements are consistent with those followed in the previous year.

1.03 Basis of preparation and presentation

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

Recent accounting pronouncements

New and amended Ind ASs effective from April 01, 2025

The Ministry of Corporate Affairs (MCA) notifies new standards | amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. During the year, the MCA has amended the Ind AS as below:

Ind AS 1 – Presentation of Financial Statements:

The amendments clarify requirements relating to classification of liabilities as current or non-current, including the effect of covenants and the Company's right to defer settlement. The amendments also introduce specific disclosure requirements where liabilities arising from loan arrangements are classified as non-current and the Company's right to defer settlement is subject to compliance with covenants within twelve months after the reporting period.

Ind AS 7 – Statement of Cash Flows and Ind AS 107 – Financial Instruments: Disclosures:

The amendments introduce disclosure requirements in respect of supplier finance arrangements, including information about the terms and conditions, carrying amounts of related financial liabilities, amounts for which suppliers have received payment from finance providers, ranges of payment due dates and the effect of non-cash changes. Supplier finance arrangements are also relevant to the Company's liquidity-risk disclosures.

Ind AS 12 – Income Taxes:

The amendments relating to International Tax Reform – Pillar Two Model Rules introduce a mandatory temporary exception from recognising and disclosing deferred tax assets and liabilities related to Pillar Two income taxes and introduce additional disclosures relating to Pillar Two income taxes, where applicable.

Ind AS 21 – The Effects of Changes in Foreign Exchange Rates:

The amendments provide guidance for assessing whether a currency is exchangeable into another currency and for estimating the spot exchange rate where exchangeability is lacking. Additional disclosures are required in such circumstances.

The Company has evaluated the applicability of the above amendments. Based on the nature of the Company's transactions, arrangements and operations, the amendments did not have a material impact on recognition and measurement. The Company has incorporated the additional disclosures required by the applicable amendments.

1.04 Use of estimates

The preparation of the financial statements in conformity with IND AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets,

liabilities, income and expenses. Actual results may differ from those estimates. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognized in the periods in which the results are known / materialize.

1.05 Current versus Non Current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when it:

- is expected to be realised or intended to be sold or consumed in the normal operating cycle;
- is held primarily for the purpose of trading;
- is expected to be realised within twelve months after the reporting period; or
- is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when it:

- is expected to be settled in the normal operating cycle;
- is held primarily for the purpose of trading;
- is due to be settled within twelve months after the reporting period; or
- the Company does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

The classification of liabilities is based on the rights that exist at the end of the reporting period. Covenants with which the Company is required to comply on or before the end of the reporting period are considered in assessing whether the Company has the right to defer settlement. Covenants with which the Company is required to comply only after the reporting period do not affect classification at the reporting date but may require

Additional disclosure.

Deferred tax assets and liabilities are classified as non-current.

The operating cycle of the Company is twelve months.

1.06 Property, plant and equipment and other intangible assets

Recognition and measurement:

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The residual value, useful life and method of depreciation of Property, Plant and Equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in statement of profit or loss.

Depreciation and amortization:

Depreciation, on fixed assets, based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013, on Written Down Value (WDV) method. Depreciation on additions during the year is provided on prorata time basis.

1.07 Inventories

Inventories are valued at the lower of cost and the net realizable value after providing for obsolescence and other losses, where considered necessary. Cost of inventory includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition, valued and verified by the managements at regular interval.

1.08 Cash and cash equivalents (for purposes of Cash Flow Statement)

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

1.09 Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

1.10 Revenue Recognition

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates, GST and amounts collected on behalf of third parties.

Sale of products

Timing of recognition- Revenue from sale of products is recognized when control of the products is transferred to customers based on the terms of sale.

Measurement of revenue- Revenue from sales is based on the price specified in the sales contracts, net of all expected discounts and returns in relation to sales made until the end of the reporting period.

No element of financing is deemed present as the sales are made with credit terms consistent with market practices. A receivable is recognized when the goods are dispatched, delivered or upon formal customer acceptance depending on terms of contract with the customer.

Dividend and interest income

Dividend income is recognised when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend.

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Other income

Other incomes are accounted on accrual basis except specifically stated on cash basis.

1.11 Employee benefits

Defined benefit plan

Gratuity:

Gratuity liability is a defined benefit obligation and is computed on the basis of an actuarial valuation by an actuary appointed for the purpose as per projected unit credit method at the end of each financial year. The liability or asset recognized in the Standalone Balance Sheet in respect of defined benefit gratuity plan, is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The liability so provided is represented by creation of separate fund and is used to meet the liability as and when it become due for payment in future. Any shortfall in the value of assets over the defined benefit obligation is recognized as a liability with a corresponding charge to the Standalone Statement of Profit and Loss.

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows with reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation.

The net interest cost is calculated by applying the discount rate at the beginning of the period to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the Standalone Statement of Profit and Loss.

Re-measurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur directly in other comprehensive income. They are included in retained earnings in the Statement of changes in equity and in the Standalone Balance Sheet.

Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognized immediately in profit or loss as past service cost.

Defined contribution plan

Contributions to defined contribution schemes such as contribution to provident fund, superannuation fund, employees' state insurance corporation, national pension scheme and labour welfare fund are charged as an expense to Standalone Statement of Profit and Loss based on the amount of contribution required to be made as and when services are rendered by the employees. The above benefits are classified as defined contribution schemes as the Company has no further defined obligations beyond the monthly contributions.

Short-term employee benefits

All employee benefits payable within 12 months of service such as salaries, wages, bonus, ex-gratia, medical benefits, etc, are recognized in the year in which the employees render the related service and are presented as current employee benefit obligations. Termination benefits are recognized as an expense as and when incurred. Short-term employee benefits are provided at undiscounted amount during the accounting period based on service rendered by employees.

Other long-term employee benefits

The liabilities for earned leave is not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. The benefits are discounted using the market yields at the end of the reporting period that have terms approximating to the terms of the related obligation. Re-measurements as a result of experience adjustments and changes in actuarial assumptions are recognized in profit or loss.

1.12 Borrowing costs

Borrowing costs include interest; amortization of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan. Borrowing costs, allocated to and utilized for qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset upto the date of capitalization of such asset is added to the cost of the assets. Capitalization of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

1.13 Earnings per Share

Basic earnings per share is computed by dividing the profit after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year.

1.14 Taxes on income

Current tax:

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax:

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

1.15 Contingent liabilities

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions, but are disclosed unless the possibility of outflow of resources is remote.

1.16 Contingent Asset

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company. The company does not recognize a contingent asset but discloses its existence in the financial statements.

1.17 Segment Reporting

An operating segment is component of the company that engages in the business activity from which the company earns revenues and incurs expenses, for which discrete financial information is available and whose operating results are regularly reviewed by the chief operating decision maker, in deciding about resources to be allocated to the segment and assess its performance. The company's chief operating decision maker is the Managing Director.

Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are disclosed as un-allocable.

Revenue and expenses directly attributable to segments are reported under each reportable segment. All other expenses which are not attributable or allocable to segments have been disclosed as un-allocable expenses.

The company prepares its segment information in conformity with the accounting policies adopted for preparing and presenting the financial statements of the company as a whole.

1.18 Leases:

As a lessee:

The Company assesses whether a contract is, or contains a lease, at inception of the contract. A contract is, or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: i) the contract involves the use of an identified asset ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and iii) the Company has the right to direct the use of the asset.

At the commencement date of the lease, the Company recognizes a right-of-use asset and a corresponding lease liability for all lease arrangements in which it is lessee, except for short-term leases (leases with a

term of twelve months or less), leases of low value assets and, for contract where the lessee and lessor has right to terminate a lease without permission from the other party with no more than an insignificant penalty. The lease expense of such short-term leases, low value assets leases and cancellable leases are recognized as an operating expense on a straight-line basis over the term of the lease.

At commencement date, lease liability is measured at the present value of the lease payments to be paid during non-cancellable period of the contract, discounted using the incremental borrowing rate. The right-of-use assets is initially recognized at the amount of the initial measurement of the corresponding lease liability, lease payments made at or before commencement date less any lease incentives received and any initial direct costs.

Subsequently the right-of-use asset is measured at cost less accumulated depreciation and any impairment losses. Lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using effective interest rate method) and reducing the carrying amount to reflect the lease payments made. The right-of-use asset and lease liability are also adjusted to reflect any lease modifications or revised in-substance fixed lease payments.

As a lessor:

Leases for which the Company is a lessor are classified as finance or operating leases. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

Income from operating leases where the Company is a lessor is recognized as income on a straight-line basis over the lease term unless the receipts are structured to increase in line with expected general inflation to compensate for the expected inflationary cost increases. The respective leased assets are included in the Balance Sheet based on their nature. Leases of property, plant and equipment where the Company as a lessor has substantially transferred all the risks and rewards are classified as finance lease. Finance leases are capitalized at the inception of the lease at the fair value of the leased property or, if lower, the present value of the minimum lease payments. The corresponding rent receivables, net of interest income, are included in other financial assets. Each lease receipt is allocated between the asset and interest income. The interest income is recognized in the Statement of Profit and Loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the asset for each period.

Under combined lease agreements, land and building are assessed individually.

1.19 Impairment of assets:

The carrying amount of assets are reviewed at each Balance Sheet date to assess if there is any indication of impairment based on internal | external factors. An impairment loss on such assessment is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount of the assets is net selling price or value in use, whichever is higher. While assessing value in use, the estimated future cash flows are discounted to the present value by using weighted average cost of capital. A previously recognized impairment loss is further provided or reversed depending on changes in the circumstances and to the extent that carrying amount of the assets does not exceed the carrying amount that will be determined if no impairment loss had previously been recognized.

1.20 Offsetting financial instruments:

Financial assets and liabilities are offset and the net amount is reported in the Balance Sheet where there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the assets and settle the liabilities simultaneously.

1.21 Dividend distribution to equity holders of the Company

The Company recognises a liability to make dividend distributions to equity holders of the Company when the distribution is authorised and the distribution is no longer at the discretion of the Company. As per the corporate laws in India, a distribution is authorised when it is approved by the shareholders. A corresponding amount is recognised directly in equity.

1.22 Investments and other financial assets

(i) Classification

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income, or through profit or loss), and
- those measured at amortized cost.

The classification depends on the entity's business model for managing the financial assets and the cash flows.

For assets measured at fair value, gains and losses will either be recorded in Statement of profit or loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Company has made an irrevocable election at the time of initial recognition to account for equity investment at fair value through other comprehensive income.

The Company reclassifies debt investments when and only when its business model for managing those assets changes.

(ii) Measurement

At initial recognition, the company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in profit or loss.

(iii) Debt instruments:

Subsequent measurement of debt instruments depends on the Company's business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Company classifies its debt instruments.

(iv) Amortized Cost:

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. A gain or loss on a debt investment that is subsequently measured at amortized cost and is not part of a hedging relationship is recognized in profit or loss when the asset is derecognized or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

(v) Fair value through other Comprehensive Income (FVOCI):

Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognized in profit and loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains/ (losses). Interest income from these financial assets is included in other income using the effective interest rate method.

(vi) Fair value through profit or loss:

Assets that do not meet the criteria for amortized cost or FVOCI are measured at fair value through profit or loss. A gain or loss on debt investment that is subsequently measured at fair value through profit or loss is recognized in profit or loss and presented net in the statement of profit and loss in the period in which it arises. Interest income from these financial assets is included in other income.

(vii) Financial liabilities:

Financial liabilities are subsequently carried at amortized cost using the effective interest method.

(viii) Investments in Subsidiaries:

Investments in subsidiaries, associates and joint ventures are carried at cost in the financial statements.

(ix) Equity Instruments:

An equity instrument is a contract that evidences residual interest in the assets of the company after

deducting all of its liabilities. Incremental costs directly attributable to the issuance of equity instruments are recognized as a deduction from equity instrument net of any tax effects.

1.23 Investments Property:

Investment Property is measured initially at cost including related transaction costs.

The cost comprises the purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for its intended use.

Subsequent expenditures are capitalized only when it is probable that future economic benefits associated with these will flow to the company and the cost of the item can be measured reliably.

Investment property is carried at cost less accumulated depreciation and impairment.

All day-to-day repair and maintenance expenditure are charged to the statement of profit and loss for the period during which such expenses are incurred.

Gains or losses arising from derecognition of investment property are measured as the difference between the net disposal proceeds and the carrying amount of the asset at the time of disposal and are recognized in the statement of profit and loss when the asset is derecognized.

Depreciation and amortization:

Depreciation, on Investment property, based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013, on Written Down Value (WDV) method. Depreciation on additions during the year is provided on prorata time basis.

PROOF

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026
NOTE - 2.1 : PROPERTY, PLANT AND EQUIPMENT:
(Rs. in Lakhs unless otherwise stated)

Particulars	Furniture and fixtures	Office Equipmrent	Plant & Machinery	Computer	Vehicle	Total
Year ended March 31, 2025						
Opening Gross Carrying Amount	29.10	1.65	.47	29.50	18.81	79.53
Additions	2.00	-	-	3.12	183.23	188.35
Disposals	-	-	-	-	-1.30	-1.30
Closing Gross Carrying Amount	31.10	1.65	.47	32.61	200.74	266.58
Accumulated Depreciation and Impairment						
Opening Accumulated Depreciation	9.84	1.35	.45	18.78	15.99	46.41
Depreciation Charge during the year	5.47	.19	-	4.98	41.59	52.23
Closing Accumulated Depreciation and Impairment	15.30	1.54	.45	23.76	57.58	98.64
Net Carrying Amount	15.79	.11	.02	8.85	143.16	167.93
Year ended March 31, 2026						
Opening Gross Carrying Amount	31.10	1.65	.47	32.61	200.74	266.58
Additions	37.83	.08	-	3.53	-	41.44
Disposals	-	-	-	-	-	-
Closing Gross Carrying Amount	68.92	1.73	.47	36.15	200.74	308.01
Accumulated Depreciation and Impairment						
Opening Accumulated Depreciation	15.30	1.54	.45	23.76	57.58	98.64
Depreciation Charge during the year	7.96	.07	-	3.75	45.15	56.92
Closing Accumulated Depreciation and Impairment	23.26	1.61	.45	27.51	102.73	155.56
Net carrying amount	45.66	.12	.02	8.63	98.01	152.45

Additional Regulatory Information : CARO 3(i)(c)
i) Title deeds of Immovable Property not held in name of the Company

Relevant line item in Balance Sheet	Description of item of property	Gross Carrying Value	Title deeds held in the name of	Whether title deed holder is a promoter, director or relative of promoter/director or employee of promoter/director	Reasons for not being held in the name of the company*
NIL	NIL	NIL	NIL	NIL	NIL

*also indicate if in dispute

ii) Capital-Work-in Progress (CWIP) / Intangible assets under development (ITAUD)

CWIP/ITAUD	Amount in CWIP for a period of		
	Less than 1 year	2-3 years	More than 3 years
Projects in progress	Nil	Nil	Nil
Projects temporarily suspended	Nil	Nil	Nil

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026**NOTE - 2 : PROPERTY, PLANT AND EQUIPMENT: (CONTD.....)** (Rs. in Lakhs unless otherwise stated)**iii) Capital-Work-in Progress (CWIP)/ITAUD whose completion is overdue**

CWIP/ITAUD	To be completed in		
	Less than 1 year	2-3 years	More than 3 years
Project 1	Nil	Nil	Nil
Project 2	Nil	Nil	Nil

NOTE - 2.2 : INVESTMENT PROPERTY:

Particular	Office	Total
Year ended March 31, 2025		
Opening Gross Carrying Amount	-	-
Additions	274.34	274.34
Disposals	0.00	0.00
Closing Gross Carrying Amount	274.34	274.34
Accumulated Depreciation and Impairment		
Opening Accumulated Depreciation	-	-
Adjustment during the year	3.34	3.34
Depreciation Charge during the year	-	-
Closing Accumulated Depreciation and Impairment	3.34	3.34
Net Carrying Amount	271.00	271.00
Year ended March 31, 2026		
Opening Gross Carrying Amount	274.34	274.34
Additions	198.00	198.00
Disposals	456.57	456.57
Closing Gross Carrying Amount	15.77	15.77
Accumulated Depreciation and Impairment		
Opening Accumulated Depreciation	3.34	3.34
Depreciation Charge during the year	12.43	12.43
Closing Accumulated Depreciation and Impairment	15.77	15.77
Net Carrying Amount	-	-

2.2A The Company has elected to measure all its investment properties at acquisition cost of assets.**2.2B** Fair value of investment properties

Particular	2025-26	2024-25
Investment properties	198.00	274.34

Refer note no. 30 for disclosure on fair value.

Estimation of fair value:

The Company obtains independent valuation report for its investment property once in every three years. For the current year's fair value, as per acquisition value of assets for year 2024-25.

2.2C Amount recognised in Profit or Loss for Investment Properties

Particulars	2025-26	2024-25
Rental Income	8.69	0
Direct/Indirect operating expenses (including repairs and maintenance) arising from investment property that generated rental income during the period;	11.32	0
Depreciation	12.43	3.34
NET INCOME	-15.06	-3.34

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026 Number of Shares	As At 31.03.2026	As At 31.03.2025 Number of Shares	As At 31.03.2025
NOTE - 3-1 : NON - CURRENT INVESTMENT:				
Investment in Equity Instruments in Subsidiaries Company (Unquoted)				
EVAGRACE PHARMA PVT LTD (Equity Shares of Face Value Rs. 10 each)	10000	1.00	10000	1.00
RITZ FORMULATIONS PVT LTD (RFPL) (Equity Shares of Face Value Rs. 10 each)	25000	32.95	25000	32.95
SUNGRACE PHARMA PVT LTD (SPPL) (Equity Shares of Face Value Rs. 10 each)	26000	32.04	26000	32.04
AZILLIAN HEALTHCARE PVT LTD (Equity Shares of Face Value Rs. 10 each)	220000	354.20	220000	354.20
CALBORN LIFESCIENCE PVT LTD (Equity Shares of Face Value Rs. 10 each)	1978072	593.42		0.00
		1013.61		420.19
Joint venture/Associates/Other Investments				
Capital Investment in MEDICO LAB Partnership firm		227.92		298.54
		1241.53		718.73

(*) Refer Note 30 for financial Instruments and fair value and measurements

Particulars	As At 31.03.2026	As At 31.03.2025
-------------	---------------------	---------------------

3.2 - NON - CURRENT LOANS:

Unsecured Loan to Subsidiary (CALBORN LIFESCIENCE PVT LTD)	2521.51	0.00
Corporate unsecured loan provided to Subsidiary company on Interest and the same is repayable on demand.	2521.51	-
Unsecured loan received by the subsidiary has been utilized for its principal business activities		

NOTE - 4 - DEFERRED TAX ASSETS:

Deffered tax assets	2.75	.97
	2.75	.97

Note 4: Deferred Tax Assets :
a. Depreciation

Opening balance	.97	7.50
Total reversible timing difference in books maintained as per Companies Act 2013		
Depreciation as per Companies Act 2013	69.35	55.57
Total reversible timing difference in books maintained as per Income Tax Act 1961		
Depreciation as per Income Tax Act 1961	53.61	81.83
Net reversible timing difference (1) - (2)	15.74	-26.27

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
Note 4: Deferred Tax Assets : (Contd.....)		
b. Gratuity		
Closing Gratuity provision	16.30	9.85
Opening Gratuity provision	9.85	7.08
Net reversible timing difference (1) - (2)	6.45	2.77
Deferred tax asset recognised for the year (a+b)	22.19	-23.50
Add : Deferred tax income/(expense)	6.17	-6.54
LESS : Deferred tax income/(expense)	-4.39	-
Total	2.75	.97

NOTE - 5 - OTHER NON CURRENT ASSETS:

Advance For Purchase of New Office (Advance given for purchase office at SOLITAIRE CONNECT SCHEME in Ahmedabad office no 1110,1111,1112)	3.00	210.69
Advance For Purchase of Land (Advance given for Plot in SUN INDUSTRIAL PARK, SANAND, AHMEDABAD GUJARAT)	105.00	820.00
Total	108.00	1030.69

NOTE - 6 - INVENTORIES:

Finished Goods*	211.46	294.15
	211.46	294.15

*Valued at lower of cost and net realizable value

NOTE - 7 - TRADE RECEIVABLES:**UNSECURED, CONSIDERED GOOD**

Trade receivable	1793.49	2277.47
	1793.49	2277.47

Trade Receivables ageing schedule as at 31st March, 2026:

Particulars	Outstanding for following periods from due date of payment					
	Not Due	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More Than 3 Years
(i) Undisputed Trade receivables -considered good	1103.04	608.74	14.82	2.32	64.57	
(ii) Undisputed Trade receivables -considered doubtful						
(iii) Disputed trade receivables considered good						
(iv) Disputed trade receivables considered doubtful						

Trade Receivables ageing schedule as at 31st March, 2025:

Particulars	Outstanding for following periods from due date of payment					
	Not Due	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More Than 3 Years
(i) Undisputed Trade receivables -considered good	1702.61	508.55	8.02	16.66	41.62	
(i) Undisputed Trade receivables -considered doubtful						
(iii) Disputed trade receivables considered good						
(iv) Disputed trade receivables considered doubtful						

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
NOTE - 8 - CASH AND CASH EQUIVALENTS:		
Cash Balance		
Cash on Hand	3.52	5.66
Balances with Banks		
In Current Account and OD a/c*	1.03	1.03
Unpaid dividend accounts *	.11	.11
(*Current Account with ICICI Bank, Standard Chartered Bank & Kotak Mahindra Bank)		
Investment in Bank Fixed Deposit		
ICICI Bank Fixed Deposit	211.33	134.97
	216.00	141.77

NOTE - 9 - LOANS :

Loan Receivable considered Good - Unsecured		
Inter-Corporate Deposits	-	100.80
	-	100.80

NOTE - 10 - OTHER CURRENT ASSETS:

SECURITY DEPOSITS - BAJAJ FORMULATIONS	.75	.75
SECURITY DEPOSITS - EMBARK LIFESCIENCE PRIVATE LIMITED	.13	.13
GST RECEIVABLES	2.71	6.93
SECURITY DEPOSITS - ELVIA	.03	.03
SECURITY DEPOSITS - WINDLABS	.07	.07
PREPAID EXPENSES	1.39	.43
SECURITY DEPOSITS - TORRENT	.11	.11
LAXMI SYNTHETICS (SECURITY DEPOSIT, SURAT)	1.00	1.00
SECURITY DEPOSITS - UGVCL	.08	.08
GST TAX	3.44	2.48
ADVANCE TO SUNDRY CREDITOR FOR GOODS	476.40	838.87
ADVANCE FOR EXPENSES	8.67	22.75
	494.78	873.62

NOTE - 11 - EQUITY SHARE CAPITAL:
Authorized Capital:

2,00,00,000 (P.Y. 2,00,00,000) Equity Shares of Rs. 10/- each	2000.00	2000.00
---	---------	---------

Issued, Subscribed and Paid-up Capital:

1,00,00,000 (P.Y. 1,00,00,000) Equity Shares of Rs. 10/- each	1000.00	1000.00
	1000.00	1000.00

a. The Reconciliation of the number of Outstanding Shares as at 31st March 2026 and 31st March, 2025 is set out below:

Particulars	As at 31.03.2026		As at 31.03.2025	
	Number of Shares	Amount	Number of Shares	Amount
Shares outstanding at the beginning of the year	10,000,000	1000.00	10,000,000	1000.00
Add: Issue during the year	-	-	-	-
Shares outstanding at the end of the year	10,000,000	1000.00	10,000,000	1000.00

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
-------------	---------------------	---------------------

NOTE - 11 - EQUITY SHARE CAPITAL: (CONTD.....)**b. Rights, preferences and restrictions:**

The Company has only one class of Equity Shares having Par Value of Rs. 10/- per share. Each holder of equity share is entitled to same Rights based on the number of shares held.

(i) Equity shares:

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts and preference shares. The distribution will be in proportion to the number of equity shares held by the shareholders.

(ii) Dividend:

Unpaid dividend of F.Y 2022-23 of Rs. 11147/- is lying as bank balance in Divided Payable Bank Account and shown as other current liabilities.

c. Shares in the Company held by each shareholders holding more than 5% shares:

Name of Shareholders	No. of Shares Held	Percentage of holding	No. of Shares Held	Percentage of holding
SAMIR SHAH	46,40,113	46.40%	44,42,828	44.43%
DILIPKUMAR BHOGILAL SHAH	10,74,397	10.74%	10,74,397	10.74%

d. Details of promoters' shareholding percentage in the Company is as below:**Shares held by promoters at the end of the year 31st March 2026**

Sr. No.	Promoter Name	No. of Shares**	% of total shares**	% Change during the year***
1	SAMIR SHAH	46,40,113	46.40%	1.97%
2	DILIPKUMAR BHOGILAL SHAH	10,74,397	10.74%	0.00%
	Total		57.14%	

Shares held by promoters at the end of the year ending 31st March 2025

Sr. No.	Promoter Name	No. of Shares**	% of total shares**	% Change during the year***
1	SAMIR SHAH	44,42,828	44.43%	0.10%
2	DILIPKUMAR BHOGILAL SHAH	10,74,397	10.74%	0.00%
	Total		55.17%	

** Details shall be given separately for each class of shares.

*** Percentage change shall be computed with respect to the number at the beginning of the year or if issued during the year for the first time then with respect to the date of issue.]

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
NOTE - 12 - OTHER EQUITY:		
Retained Earnings		
Balance at the beginning of the year	1047.07	790.50
Profit for the year	218.36	256.58
Dividend Paid during the year	.00	.00
Balance at the end of the year	1265.43	1047.07
(Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, any transfers from or to other comprehensive income, dividends or other distributions paid to shareholders.)		
Securities Premium Account		
Balance at the beginning of the year	1819.07	1819.07
Add : Premium arising on shares issued during the year	-	-
Expenses on issue of equity shares	-	-
Balance at the end of the year	1819.07	1819.07
Total Other Equity	3084.51	2866.15

Nature and purpose of other reserves:

a) Securities premium

Securities premium is used to record the premium on issue of shares. The reserve is utilised in accordance with the provisions of the Companies Act, 2013.

b) Retained earnings

Retained earnings are the profits that the Company has earned till date, any transfers from or to other comprehensive income, dividends or other distributions paid to shareholders.

Particulars	As At 31.03.2026	As At 31.03.2025
-------------	---------------------	---------------------

NOTE - 13 - BORROWINGS:

13.1 NON-CURRENT LIABILITIES

Secured

a. From Standard Chartered Bank

Overdraft and Cash Credit-Standard Chartered Bank	1427.30	1224.25
---	---------	---------

Company availed Overdraft and Cash Credit from Standard Chartered Bank of Rs. 15,50,00,000/- against Hypothication of Stock & Book Debts

Company management given below collateral Security to Standard Chartered bank

- Property Located at Sub Plot no 3 Nr Swetanjali Society, Nr Sachin Tower road, Satellite , Ahmedabad owned by Managing Director Samir Shah
- Personal guarantee of Samir D Shah, Dilip Shah and Tanvi Shah
- Commercial office situated office no 501 , 5th floor, Aditraj Arcade, Nr Hetvi Tower, Sanjay Sachin tower road, Satellite, Ahmedabad-380015 owned by Medico Healthcare.
- Corporate Guarantee of Medico Healthcare.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
-------------	---------------------	---------------------

NOTE - 13 - BORROWINGS: (CONTD.....)**13.1 NON-CURRENT LIABILITIES****From ICICI Bank**

Overdraft against FD - ICICI Bank

69.25

52.80

From KOTAK MAHINDRA PRIME LTD.

Car Loan for Porche Car - Kotak Mahindra Prime Ltd.

-

-

(Against hypothecation of CAR)

b. Unsecured

Loan from Directors

-

-

1496.55**1277.05****13.2 CURRENT-LIABILITIES****Term Loan**

Current maturities of Long Term Debts

118.17

44.53

118.17**44.53****NOTE - 14 - OTHER FINANCIAL LIABILITIES:**

Security Rent Deposit - TVS MOTOR COMPANY LTD.

-

29.32

-

29.32**NOTE - 15 - TRADE PAYABLE:****Unsecured****Trade Payable***

- Outstanding dues of Micro and Small Enterprises (Refer note-30)

440.17

132.67

- Others for Goods and Expenses

465.11

425.98

905.28**558.65****Trade Payables ageing schedule: As at 31st March, 2026:**

Particulars	Outstanding for following periods from due date of payment				
	Not Dues	Less than 1 year	1-2 years	2-3 years	Total
(i) MSME	440.17	-	-		440.17
(ii) Others	452.32	12.79	-		465.11
(iii) Disputed dues- MSME					-
(iv) Disputed dues - Others					-

Trade Payables ageing schedule: As at 31st March, 2025:

Particulars	Outstanding for following periods from due date of payment				
	Not Dues	Less than 1 year	1-2 years	2-3 years	Total
(i) MSME	132.67	-	-		132.67
(ii) Others	413.53	12.45	-		425.98
(iii) Disputed dues- MSME					-
(iv) Disputed dues - Others					-

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
NOTE - 16 - OTHER CURRENT LIABILITIES:		
Statutory Dues - TDS	3.18	3.98
Provident Fund Payable	.42	.35
Professional Tax Payable	.07	.07
Employees' State Insurance Corporation Payable	.08	-
Telephone Exp Payable	.09	.08
GST Payable	7.88	7.51
Electricity Exp Payable	.12	.22
TCS Payable	-	.28
Audit fees Payable	1.06	.88
Unpaid dividend	.11	.11
Advance from Customers	94.03	53.63
	107.04	67.11
NOTE - 17 - CURRENT TAX LIABILITIES (NET):		
Provision for Tax	14.12	24.47
	14.12	24.47
NOTE - 18 - PROVISIONS:		
18.1 Long term provisions		
Gratuity provision	15.36	9.27
	15.36	9.27
18.2 Short term provisions		
Gratuity provision	.94	.59
	.94	.59
NOTE - 19 - REVENUE FROM OPERATIONS:		
Sales of Pharmaceutical Products	5446.08	6712.98
	5446.08	6712.98
NOTE - 20 - OTHER INCOME:		
Interest Income	161.90	23.23
Commission Income	4.19	8.62
OFFICE RENT (ARK)	8.69	-
Other Income	.72	-
MAINTANCE INCOME (OFFICE)	1.73	-
Interest Fd income	10.41	8.71
PROFIT ON SALE OF PROPERTY (ARK)	35.85	-
Profit from Partnership Firm - Medico lab	11.06	10.20
	234.54	50.77
NOTE - 21 - PURCHASE OF STOCK IN TRADE:		
Purchases	4486.22	5444.92
	4486.22	5444.92
NOTE - 22 - CHANGE IN INVENTORIES:		
Opening Stock	294.15	456.89
Less: Closing Stock	211.46	294.15
	82.69	162.74

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	Year ended 31.03.2026	Year ended 31.03.2025
NOTE - 23 - EMPLOYEE BENEFIT EXPENSE:		
Bonus	9.35	6.56
Provident Fund Expenses	2.40	2.19
Staff Welfare	5.80	1.95
Leave Encashment Expenses	5.43	4.38
Remuneration of Directors	60.00	60.00
Salary	156.23	96.21
Employees' State Insurance Corporation Expenses	.27	-
Sales Incentive Expenses.	.11	-
Gratuity Expenses	6.45	2.77
	246.03	174.06
NOTE - 24 - FINANCE COST:		
Interest Expenses	162.37	65.48
Bank Charges	4.46	1.74
	166.83	67.22
NOTE - 25 - OTHER EXPENSES:		
Listing Fees	3.25	3.25
Professional Fees	3.67	4.54
Auditors Remuneration (For Statutory audit)	4.25	3.50
ROC Filing Fees	.07	7.64
Office Rent Expenses	6.00	6.00
Advertisement Expenses	14.28	6.93
Annual Issuer Fees	.54	.45
EGM/AGM Expenses	.31	.34
Freight Expenses	10.41	10.16
Freight Exp [OUTWARD] 5%	3.04	2.84
Freight Exp (OUTWARD)12%	.43	3.23
Freight Exp (OUTWARD)18%	6.18	.22
Godown Maintenance	.12	.14
Godown Rent	8.53	8.99
Cylinder Charges	.05	.03
Product Permission Charges	.05	.01
Plate Charges	-	-
Rounding Off (Other)	.00	.00
Sales Promotion	14.87	58.15
Share Transfer Agent Fees	.81	.89
Stationery & Printing Exp	1.44	2.33
Commission Exp	101.42	320.24
Conveyance [Petrol] Exp & Petrol & Diesel (BOLERO)	2.65	2.61
Electricity Expenses	1.91	1.92
Kasar & Discount	.02	.06
Licence Fees	.06	.07
Office & Canteen Expenses	2.59	2.41
Office [GODOWN] Misc. Exp.	20.05	5.96

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	Year ended 31.03.2026	Year ended 31.03.2025
NOTE - 25 - OTHER EXPENSES: (CONTD.....)		
Professional Tax (Firm)	.05	.05
Legal Exp	9.01	4.29
Municipal Tax	3.06	4.26
Trademark (Legal Exp)	.12	.03
Insurance Exp	26.76	7.55
Digital Sign Exp	.07	.02
FILM Fees	.10	.10
Computer Exp	2.00	1.44
Office Maintenance Exp	12.25	.93
Packing Exp	.02	.04
Postage & Courier Exp	9.50	12.05
Loss Motor Car	-	.98
Telephone Exp	1.71	2.01
Electric Repairing Exp	.13	.14
Machinery Repair Maintenance and Service Exp	.13	.20
Maintenance Exp (Software)	.18	.20
Tours & Travels Exp	30.09	11.94
Vehicle Exp	.54	.64
Inventory Charges	.06	-
ISO Certification Exp	-	.07
LEI Exp	.04	.04
Income Tax Exp	-	-
Office Safety Exp	-	.24
Membership Fees	.03	.07
Gst Exp	.49	.38
Stamp Duty Fees	-	-
Share Locking Exp	-	-
Late Fee Gst	.01	.01
Late Fee Amc	-	.00
DPCO Expenses	.48	-
Other Expenses	.04	-
Donation	14.00	1.08
	317.86	501.68

NOTE - 26 - EARNINGS PER SHARE (EPS):

a) Weighted Average Number of Equity Shares Outstanding during the year	1,00,00,000.00	1,00,00,000.00
b) Net Profit after tax available for Equity Shareholders	218.36	256.58
c) Basic and Diluted Earnings Per Share (Rs.)	2.18	2.57

The Company does not have any outstanding dilutive potential equity shares.

NOTE - 27 - CONTINGENT LIABILITIES:

Corporate guarantee to wholly owned subsidiary company	3342.83	451.00
Liabilities disputed - appeals filed with respect to		
Disputed GST tax(For the year 2018-19, 2019-20 and 2020-21)	37.28	27.64
	3380.11	478.64

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

NOTE - 28 - SEGMENTAL REPORTING:

(A) On the basis of Business Segments

Particulars	As at 31.03.2026		As at 31.03.2025	
	Trading	Total	Trading	Total
External Revenues	5680.62	5680.62	6763.75	6763.75
Internal Segment Revenues	0.00	0.00	0.00	0.00
Other Non-Allocable Income	0.00	0.00	0.00	0.00
Total Revenues	5680.62	5680.62	6763.75	6763.75
Less: Elimination	0.00	0.00	0.00	0.00
Total Revenues	5680.62	5680.62	6763.75	6763.75
External Expenses	5368.98	5368.98	6406.20	6406.20
Other Non-Allocable Expenses	0.00	0.00	0.00	0.00
Non Reportable Segment Revenue	0.00	0.00	0.00	0.00
Other Income	0.00	0.00	0.00	0.00
Interest Cost	0.00	0.00	0.00	0.00
Total Expenditure	5368.98	5368.98	6406.20	6406.20
Provision for Taxes/ Deferred Tax	93.28	93.28	100.97	100.97
NET PROFIT	218.36	218.36	256.58	256.58

Particulars	As at 31.03.2026		As at 31.03.2025	
	Trading	Total	Trading	Total
OTHER INFORMATION				
Segment Assets	6741.98	6741.98	5877.13	5877.13
Unallocable Corporate Assets	0.00	0.00	0.00	0.00
TOTAL ASSETS	6741.98	6741.98	5877.13	5877.13
Segment Liabilities	2657.47	2657.47	2010.98	2010.98
Unallocable Liabilities	0.00	0.00	0.00	0.00
TOTAL LIABILITIES	2657.47	2657.47	2010.98	2010.98
CAPITAL EXPENDITURE	-	-		
Segment Capital Expenditure	239.43	239.43	462.68	462.68
Unallocable Capital Expenses	0.00	0.00	0.00	0.00
TOTAL CAPITAL EXPENDITURE	239.43	239.43	462.68	462.68
DEPRECIATION & AMORTIZATION	-	-		
Segment Depreciation & Amortisement	69.35	69.35	55.57	55.57
Unallocated Depreciation & Amortisement	0.00	0.00	0.00	0.00
TOTAL DEPRECIATION & AMORTISEMENT	69.35	69.35	55.57	55.57

(B) Other Disclosures:-

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (IND AS-108) taking into account the organization structure as well as the differential risks and returns of these Segments.
2. The Company has disclosed Business Segment as the Primary Segment.
3. The Segment Revenues, Results, Assets and Liabilities include the respective amount identifiable to each of the segment and amounts allocated on a reasonable basis.

Note:- Above details complied by the Management and relied upon by the Auditors.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 29 - RELATED PARTY DISCLOSURES NATURE OF RELATIONSHIP AND TRANSACTION WITH RELATED PARTIES:

1 Related Parties and their Relationship:

a) Wholly Owned Subsidiary Companies

- 1 Evagrace Pharma Private Limited
- 2 Ritz Formulations Private Limited
- 3 Sungrace Pharma Private Limited
- 4 Azillian Healthcare Private Limited

b) Subsidiary Companies:

Calborn Lifescience Private Limited

c) Joint Venture

- 1 Medico Lab

d) Key Management Personnel:

Mr. Samir D Shah	Managing Director
Mr. Jay S Shah	Chief Financial Officer
Mr. Dilipkumar B Shah	Chief Executive Officer
Ms. Puneeta Sharma	Company Secretary & Compliance Officer

e) Independent and Non-Executive Directors:

Mr. Ankur A Dave	Independent Director
Mr. Priyank L Sancheti	Independent Director
Mr. Parshwa Shah	Independent Director
Mrs. Tanvi S Shah	Non-Executive Director
Mrs. Swati V Shah	Non-Executive Director

f) Relatives of Key Management Personnel:

Name	Relationship
Mrs. Tanvi S Shah	Wife of Mr. Samir Shah
Ms. Diya S Shah	Daughter of Mr Samir Shah and Mrs. Tanvi S Shah

g) Enterprises over which key management personnel are able to exercise significant influence:

Name of enterprise	Director/Partner/Employee
Medico Healthcare	Partnership firm in which Mr. Samir Shah & Mr. Dilipkumar Shah are Partners
Oxford Pharma	Partnership firm in which Mr. Samir Shah is Partner
Flora Marketing	Proprietorship firm in which Mrs. Tanvi Shah is Proprietor
Kingston Infracon	Partnership firm in which Mr. Samir Shah & Mr. Dilipkumar Shah are Partners
Kingston Café	Proprietorship firm in which Mr. Samir Shah is Proprietor

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 29 - RELATED PARTY DISCLOSURES NATURE OF RELATIONSHIP AND TRANSACTION WITH RELATED PARTIES: (CONTD.....)

2(a) Related Party Transactions entered during the year: (Rs. in Lakhs unless otherwise stated)

Particulars	Enterprises trusts over which significant influence exercised by key management personnel		Subsidiary Company		Key Managerial Personnel		Joint Venture		Other Related Parties		Total	
	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025
Purchase of goods	410.26	485.82	1035.71	48.64	0.00	0.00	27.26	8.40	0.00	0.00	1473.23	542.86
Purchase of fixed assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Sale of goods	579.24	526.88	620.96	539.43	0.00	0.00	300.43	307.64	0.00	1750.45	1500.63	3124.39
Rent/Vehicle Hire Charges paid	8.83	8.83	0.00	0.00	3.00	3.00	0.00	0.00	0.00	0.00	11.83	11.83
Dividend received	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Interest received	0.00	0.00	133.07	0.00	0.00	0.00	25.91	12.34	0.00	0.00	158.99	12.34
Sale Promotion	0.00	47.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	47.03
Staff Welfare	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Loans given	0.00	0.00	2388.44	0.00	0.00	0.00	8.47	286.20	0.00	0.00	2396.91	286.20
Loans repaid back	0.00	0.00	0.00	0.00	-	.16	105.00	-	0.00	0.00	105.00	.16
Share Capital	0.00	0.00	593.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	593.42	0.00
Remuneration on A/c of Salary & Perquisites	0.00	0.00	0.00	0.00	84.87	83.34	0.00	0.00	0.00	0.00	84.87	83.34

2(b) Balance Outstanding at the end of the Financial Year:

Particulars	Enterprises trusts over which significant influence exercised by key management personnel		Subsidiary Company		Key Managerial Personnel		Joint Venture		Other Related Parties		Total	
	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025
Receivable/(Payable) on account of goods sale/ services rendered/ received	56.55	494.39	-328.05	54.75	-3.69	-3.37	46.91	62.59	0.00	295.07	-228.28	903.42
Receivable on account of Security deposit/Prepaid Lease	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payable on account of Loans Given	0.00	0.00	2521.51	0.00	0.00	0.00	227.92	298.54	0.00	0.00	2749.43	298.54
Payable on account of Share capital	0.00	0.00	593.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	593.42	0.00
Corporate Guarantee	0.00	0.00	3342.83	451.00	0.00	0.00	0.00	0.00	0.00	0.00	3342.83	451.00

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 30 - FAIR VALUE MEASUREMENTS:

a. Financial instruments by category:

(Rs. in Lakhs unless otherwise stated)

Particulars	As at March 31, 2026		As at March 31, 2025	
	FVOCI	Amortised cost	FVOCI	Amortised cost
Financial Assets				
Investments				
- Equity / Pref Instruments	0.00	1013.61	0.00	420.19
- Joint ventures/Associates	0.00	227.92	0.00	298.54
Loan- Non current	0.00	2521.51	0.00	0.00
Trade Receivables	0.00	1793.49	0.00	2277.47
Cash and Cash Equivalents	0.00	216.00	0.00	141.77
Loan- current	0.00	0.00	0.00	100.80
Total Financial Assets	0.00	5772.53	0.00	3238.77
Financial Liabilities				
Borrowings	0.00	1614.72	0.00	1321.58
Other Financial Liabilities	0.00	0.00	0.00	29.32
Total Financial Liabilities	0.00	1614.72	0.00	1350.90

b. Fair value hierarchy:

Financial Assets and Liabilities measured at Fair Value - 31st March, 2026	Note No.	Level 1	Level 2	Level 3	Total
Financial Assets					
Investments					
- Equity / Pref instruments	-	0.00	0.00	0.00	0.00
Total Financial Assets	-	0.00	0.00	0.00	0.00
Financial, Non Financial Assets and Liabilities measured at Amortised Cost - 31st March, 2026	Note No.	Level 1	Level 2	Level 3	Total
Financial Assets					
Investments					
- Equity / Pref Instruments	3.1	0.00	0.00	1013.61	1013.61
- Joint ventures/Associates	3.1	0.00	0.00	227.92	227.92
Loans	3.2	0.00	0.00	2521.51	2521.51
Trade Receivables	7	0.00	0.00	1793.49	1793.49
Cash and Cash Equivalents	8	0.00	0.00	216.00	216.00
Loans	9	0.00	-	-	-
Total Financial Assets	-	0.00	-	5772.53	5772.53
Non Financial Assets					
Investment properties	2.2	-	-	-	-
Total Financial Assets	-	-	-	-	-
Financial Liabilities					
Borrowings	12	0.00	0.00	1614.72	1614.72
Other Financial Liabilities	14	0.00	0.00	-	-
Total Financial Liabilities	-	0.00	-	1614.72	1614.72

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 30 - FAIR VALUE MEASUREMENTS: (CONTD.....)

b. Fair value hierarchy:

(Rs. in Lakhs unless otherwise stated)

Financial Assets and Liabilities measured at Fair Value - 31st March, 2025	Notes	Level 1	Level 2	Level 3	Total
Financial Assets					
Investments					
- Equity / Pref Instruments	0.00	0.00	0.00	0.00	
Total Financial Assets	-	0.00	0.00	0.00	
Financial Assets and Liabilities measured at Amortised Cost - 31st March, 2025	Notes	Level 1	Level 2	Level 3	Total
Financial Assets					
Investments					
- Equity / Pref Instruments	3.1	0.00	0.00	420.19	420.19
- Joint ventures/Associates	3.1	0.00	0.00	298.54	298.54
Trade Receivables	7	0.00	0.00	2277.47	2277.47
Cash and Cash Equivalents	8	0.00	0.00	141.77	141.77
Loans	9	0.00	0.00	100.80	100.80
Total Financial Assets	-	0.00	-	3238.77	3238.77
Non Financial Assets					
Investment properties	2.2	0.00	0.00	274.34	274.34
Total Financial Assets	-	0.00	-	274.34	274.34
Financial Liabilities					
Borrowings	12	0.00	0.00	1321.58	1321.58
Other Financial Liabilities	14	0.00	0.00	29.32	29.32
Total Financial Liabilities	-	0.00	-	1350.90	1350.90

*Fair Value of Instruments is classified in various fair value hierarchies based on the following three levels:

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques, which maximise the use of observable market data and rely as little as possible on entity specific estimates. If significant inputs required to fair value an instruments are observable, the instrument is included in Level 2.

Level 3: If one or more of the significant inputs are not based on observable market data, the instruments is included in level 3.

Management uses its best judgement in estimating the fair value of its financial instruments. However, there are inherent limitations in any estimation technique. Therefore, for substantially all financial instruments, the fair value estimates presented above are not necessarily indicative of the amounts that the Company could have realized or paid in sale transactions as of respective dates. As such, the fair value of financial instruments subsequent to the reporting dates may be different from the amounts reported at each reporting date.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 31 - FINANCIAL RISK MANAGEMENT:

The Company is exposed to market risk (fluctuation in foreign currency exchange rates, price and interest rate), liquidity risk and credit risk, which may adversely impact the fair value of its financial instruments. The Company assesses the unpredictability of the financial environment and seeks to mitigate potential adverse effects on the financial performance of the Company.

(A) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of currency risk, interest rate risk and price risk. Financial instruments affected by market risk include loans and borrowings, trade receivables and trade payables involving foreign currency exposure. The sensitivity analyses in the following sections relate to the position as at March 31, 2026 and March 31, 2025.

The sensitivity of the relevant profit or loss item is the effect of the assumed changes in respective market risks. This is based on the financial assets and financial liabilities held at March 31, 2026 and March 31, 2025.

(i) Foreign currency exchange rate risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company did not undertake any transactions in foreign currencies during the year ended March 31, 2026. Consequently, the Company has no outstanding receivables, payables, or underlying exposure to foreign currency risk as of March 31, 2026, and sensitivity analysis is not applicable.

ii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of change in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's debt obligations with floating interest rates. As the Company has certain debt obligations with floating interest rates, exposure to the risk of changes in market interest rates are dependent of changes in market interest rates. Management monitors the movement in interest rate and, wherever possible, reacts to material movements in such rates by restructuring its financing arrangement.

As the Company has no significant interest bearing assets, the income and operating cash flows are substantially independent of changes in market interest rates.

(B) Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Credit risk encompasses both, the direct risk of default and the risk of deterioration of credit worthiness.

Credit risk arises primarily from financial assets such as trade receivables, investments in mutual funds, cash and cash equivalent and other balances with banks.

In respect of trade receivables, credit risk is being managed by the company through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the company grants credit terms in the normal course of business. All trade receivables are also reviewed and assessed for default on a regular basis. The concentration of credit risk is limited due to the fact that the customer base is large.

(C) Liquidity risk

- a. Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities.
- b. Management monitors rolling forecasts of the Company liquidity position and cash and cash equivalents on the basis of expected cash flows. The Company takes into account the liquidity of the market in which it operates. In addition, the Company's liquidity management policy involves projecting cash flows in major currencies and considering the level of liquid assets necessary to meet these, monitoring balance sheet liquidity ratios against internal and external regulatory requirements and maintaining debt financing plans.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 31 - FINANCIAL RISK MANAGEMENT: (CONTD.....)

Maturities of financial liabilities:

The tables below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

(Rs. in Lakhs)

Particulars	As at March 31, 2026		
	< 1 year	>1 Year	Total
Non-derivatives financial liabilities	0.00	0.00	0.00
Borrowings	118.17	1496.55	1614.72
Trade payables	905.28	0.00	905.28
Other financial liabilities	0.00	0.00	0.00
Total	1023.45	1496.55	2520.00
Particulars	As at March 31, 2025		
	< 1 year	>1 Year	Total
Non-derivatives financial liabilities	0.00	0.00	0.00
Borrowings	44.53	1277.05	1321.58
Trade payables	558.65	0.00	558.65
Other financial liabilities	29.32	0.00	29.32
Total	632.50	1277.05	1909.55

NOTE - 32 - EMPLOYEE BENEFIT:

a) **Defined Contribution plan:**

Provident fund

State defined contribution plans

Employers' contribution to employees' state insurance

Employers' contribution to employees' pension scheme 1995

The provident fund and the state defined contribution plans are operated by the Regional Provident Fund Commissioner. Under the scheme, the Company is required to contribute a specified percentage of payroll cost to the retirement benefit scheme to fund the benefits. These funds are recognized by the income tax authorities. The contribution of the Company to the provident fund and other contribution plans for all employees is charged to the Standalone Statement of Profit and Loss.

The Company has recognized the following amounts in the Standalone Statement of Profit and Loss for the year.

(Rs. in Lakhs)

PARTICULAR	2025-26	2024-25
Contribution to Provident Fund	2.40	2.19
Total	2.40	2.19

Estimation of social security code:

The Parliament of India has approved the Code on Social Security, 2020 (the Code), which may impact the contributions by the Company towards provident fund, gratuity and ESIC. The Ministry of Labour and Employment, Government of India has released draft rules for the Code on November 13, 2020. Final rules are yet to be notified. The Company will assess the impact of the Code when it comes into effect and will record related impact, if any.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026
NOTE - 32 - EMPLOYEE BENEFIT: (CONTD.....)
b) Defined benefit plan:
Gratuity
(Rs. in Lakhs)

PARTICULAR	Current Period	Previous Period
Type of Benefit	Gratuity	Gratuity
Country	India	India
Reporting Currency	INR	INR
Reporting Standard	Indian Accounting Standard 19 (Ind AS 19)	Indian Accounting Standard 19 (Ind AS 19)
Funding Status	Unfunded	Unfunded
Starting Period	01-Apr-25	01-Apr-24
Date of Reporting	31-Mar-26	31-Mar-25
Period of Reporting	12 Months	12 Months
Reference ID	1228508	1030735
Assumptions (Previous Period)		
Expected Return on Plan Assets	N.A.	N.A.
Rate of Discounting	6.73%	7.19%
Rate of Salary Increase	7.00%	7.00%
Rate of Employee Turnover	7.00%	7.00%
Mortality Rate During Employment	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012-14 (Urban)
Assumptions (Current Period)		
Expected Return on Plan Assets	N.A.	N.A.
Rate of Discounting	7.24%	6.73%
Rate of Salary Increase	7.00%	7.00%
Rate of Employee Turnover	7.00%	7.00%
Mortality Rate During Employment	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012-14 (Urban)
	Current Period	Previous Period
Table Showing Change in the Present Value of Defined Benefit Obligation		
Present Value of Benefit Obligation at the Beginning of the Period	9.85	7.08
Interest Cost	0.66	0.51
Current Service Cost	3.32	1.69
Past Service Cost	-	-
Liability Transferred In/ Acquisitions	-	-
(Liability Transferred Out/ Divestments)	-	-
(Gains)/ Losses on Curtailment	-	-

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 32 - EMPLOYEE BENEFIT: (CONTD.....)

b) Defined benefit plan:

Gratuity

(Rs. in Lakhs)

PARTICULAR	Current Period	Previous Period
Table Showing Change in the Present Value of Defined Benefit Obligation		
(Liabilities Extinguished on Settlement)	-	-
(Benefit Paid Directly by the Employer)	-	-
(Benefit Paid From the Fund)	-	-
The Effect Of Changes in Foreign Exchange Rates	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic Assumptions	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	(0.82)	0.43
Actuarial (Gains)/Losses on Obligations - Due to Experience	3.28	0.14
Present Value of Benefit Obligation at the End of the Period	16.30	9.85

* The increase in salary was much higher compared to the assumed salary increase, resulting in a higher Defined Benefit Obligation & actuarial loss on obligations due to experience.

PARTICULAR	Current Period	Previous Period
Table Showing Change in the Fair Value of Plan Assets		
Fair Value of Plan Assets at the Beginning of the Period	-	-
Interest Income	-	-
Contributions by the Employer	-	-
Expected Contributions by the Employees	-	-
Assets Transferred In/Acquisitions	-	-
(Assets Transferred Out/ Divestments)	-	-
(Benefit Paid from the Fund)	-	-
(Assets Distributed on Settlements)	-	-
Effects of Asset Ceiling	-	-
The Effect of Changes In Foreign Exchange Rates	-	-
Return on Plan Assets, Excluding Interest Income	-	-
Fair Value of Plan Assets at the End of the Period	-	-
Amount Recognized in the Balance Sheet		
(Present Value of Benefit Obligation at the end of the Period)	(16.30)	(9.85)
Fair Value of Plan Assets at the end of the Period	-	-
Funded Status (Surplus/ (Deficit))	(16.30)	(9.85)
Net (Liability)/Asset Recognized in the Balance Sheet	(16.30)	(9.85)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026
NOTE - 32 - EMPLOYEE BENEFIT: (CONTD.....)
b) Defined benefit plan:
Gratuity
(Rs. in Lakhs)

PARTICULAR	Current Period	Previous Period
Net Interest Cost for Current Period		
Present Value of Benefit Obligation at the Beginning of the Period	9.85	7.08
(Fair Value of Plan Assets at the Beginning of the Period)	-	-
Net Liability/(Asset) at the Beginning	9.85	7.08
Interest Cost	0.66	0.51
(Interest Income)	-	-
Net Interest Cost for Current Period	0.66	0.51
Expenses Recognized in the Statement of Profit or Loss for Current Period		
Current Service Cost	3.32	1.69
Net Interest Cost	0.66	0.51
Past Service Cost	-	-
(Expected Contributions by the Employees)	-	-
(Gains)/Losses on Curtailments And Settlements	-	-
Net Effect of Changes in Foreign Exchange Rates	-	-
Expenses Recognized	3.98	2.20
Expenses Recognized in the Other Comprehensive Income (OCI) for Current Period		
Actuarial (Gains)/Losses on Obligation For the Period	2.46	0.57
Return on Plan Assets, Excluding Interest Income	-	-
Change in Asset Ceiling	-	-
Net (Income)/Expense For the Period Recognized in OCI	2.46	0.57
Balance Sheet Reconciliation		
Opening Net Liability	9.85	7.08
Expenses Recognized in Statement of Profit or Loss	3.98	2.20
Expenses Recognized in OCI	2.46	0.57
Net Liability/(Asset) Transfer In	-	-
Net (Liability)/Asset Transfer Out	-	-
(Benefit Paid Directly by the Employer)	-	-
(Employer's Contribution)	-	-
Net Liability/(Asset) Recognized in the Balance Sheet	16.30	9.85

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 32 - EMPLOYEE BENEFIT: (CONTD.....)

b) Defined benefit plan:

Gratuity

(Rs. in Lakhs)

PARTICULAR	Current Period	Previous Period
Category of Assets		
Government of India Assets	-	-
State Government Securities	-	-
Special Deposits Scheme	-	-
Debt Instruments	-	-
Corporate Bonds	-	-
Cash And Cash Equivalents	-	-
Insurance fund	-	-
Asset-Backed Securities	-	-
Structured Debt	-	-
Other	-	-
Total	-	-
Other Details		
No. of Members in Service	41	38
Per Month Salary For Members in Service	8.86	7.26
Weighted Average Duration of the Defined Benefit Obligation	11	12
Average Expected Future Service	10	10
Defined Benefit Obligation (DBO) - Total	16.30	9.85
Defined Benefit Obligation (DBO) - Due but Not Paid	-	-
Expected Contribution in the Next Year	-	-
Net Interest Cost for Next Year		
Present Value of Benefit Obligation at the End of the Period	16.30	9.85
(Fair Value of Plan Assets at the End of the Period)	-	-
Net Liability/(Asset) at the End of the Period	16.30	9.85
Interest Cost	1.18	0.66
(Interest Income)	-	-
Net Interest Cost for Next Year	1.18	0.66
Expenses Recognized in the Statement of Profit or Loss for Next Year		
Current Service Cost	4.37	3.32
Net Interest Cost	1.18	0.66
(Expected Contributions by the Employees)	-	-
Expenses Recognized	5.55	3.98

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 32 - EMPLOYEE BENEFIT: (CONTD.....)

b) Defined benefit plan:

Gratuity

(Rs. in Lakhs)

PARTICULAR	Current Period	Previous Period
Maturity Analysis of the Benefit Payments		
Projected Benefits Payable in Future Years From the Date of Reporting		
1st Following Year	0.94	0.59
2nd Following Year	1.00	0.65
3rd Following Year	1.06	0.65
4th Following Year	1.09	0.68
5th Following Year	1.26	0.70
Sum of Years 6 To 10	6.80	3.45
Sum of Years 11 and above	27.14	16.28
Sensitivity Analysis		
Defined Benefit Obligation on Current Assumptions	16.30	9.85
Delta Effect of +1% Change in Rate of Discounting	(1.43)	(0.90)
Delta Effect of -1% Change in Rate of Discounting	1.67	1.06
Delta Effect of +1% Change in Rate of Salary Increase	1.66	1.05
Delta Effect of -1% Change in Rate of Salary Increase	(1.44)	(0.90)
Delta Effect of +1% Change in Rate of Employee Turnover	(0.09)	(0.06)
Delta Effect of -1% Change in Rate of Employee Turnover	0.09	0.06

The sensitivity analysis have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

The sensitivity analysis presented above may not be representative of the actual change in the Defined Benefit Obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the Defined Benefit Obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same method as applied in calculating the Defined Benefit Obligation as recognized in the balance sheet.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

Notes:

Gratuity is payable as per entity's scheme as detailed in the report.

Actuarial gains/losses are recognized in the period of occurrence under Other Comprehensive Income (OCI).

All above reported figures of OCI are gross of taxation.

Salary escalation & attrition rate are considered as advised by the entity; they appear to be in line with the industry practice considering promotion and demand & supply of the employees.

Maturity Analysis of Benefit Payments is undiscounted cashflows considering future salary, attrition & death in respective year for members as mentioned above.

Average Expected Future Service represents Estimated Term of Post - Employment Benefit Obligation.

Weighted Average Duration of the Defined Benefit Obligation is the weighted average of cash flow timing, where weights are derived from the present value of each cash flow to the total present value.

Any benefit payment and contribution to plan assets is considered to occur end of the year to depict liability and fund movement in the disclosures.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 32 - EMPLOYEE BENEFIT: (CONTD.....)

b) Defined benefit plan:

Qualitative Disclosures

Para 139 (a) Characteristics of defined benefit plan

The entity has a defined benefit gratuity plan in India (unfunded). The entity's defined benefit gratuity plan is a final salary plan for employees.

Gratuity is paid from entity as and when it becomes due and is paid as per entity scheme for Gratuity.

Para 139 (b) Risks associated with defined benefit plan

Gratuity is a defined benefit plan and entity is exposed to the Following Risks:

Interest rate risk: A fall in the discount rate which is linked to the G.Sec. Rate will increase the present value of the liability requiring higher provision.

Salary Risk: The present value of the defined benefit plan liability is calculated by reference to the future salaries of members. As such, an increase in the salary of the members more than assumed level will increase the plan's liability.

Asset Liability Matching Risk: The plan faces the ALM risk as to the matching cash flow. entity has to manage pay-out based on pay as you go basis from own funds.

Mortality risk: Since the benefits under the plan is not payable for life time and payable till retirement age only, plan does not have any longevity risk.

Para 139 (c) Characteristics of defined benefit plans

During the year, there were no plan amendments, curtailments and settlements.

Para 147 (a)

Gratuity plan is unfunded.

NOTE - 33 - DISCLOSURE REQUIREMENT UNDER MSMED ACT, 2006:

The Company has certain dues to suppliers (trade and capital) registered under Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act). The disclosures pursuant to the said MSMED Act are as follows: The Company has certain dues to suppliers (trade and capital) registered under Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act). The disclosures pursuant to the said MSMED Act are as follows:

(Rs. in Lakhs unless otherwise stated)

Particulars	As at March 31, 2026	As at March 31, 2025
Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	440.17	132.67
Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	-	-
Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
Interest due and payable towards suppliers registered under MSMED Act, for payments already made	-	-
Further interest remaining due and payable for earlier years	-	-

Average credit period allowed by the supplier is generally time limit exceeding as mention under MSMED Act; however, no interest has been charged by the company during the period under consideration.

NOTE - 34: The Company has not taken or given any assets on lease during the current year.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026
NOTE - 35 - FINANCIAL RATIOS:

The ratios as per the latest amendment to Schedule III are as below:

	Ratio Analysis	Numerator	31-Mar-26	31-Mar-25	Diff	Variance (%)	Explanation of variance
1.	Current Ratio	Current Inventories Trade Receivables Cash and Bank balances Other Receivables/Accruals Loans and Advances Disposable Investments Any other current assets	2.37	5.31	(2.94)	(55.30)	Due to Increase creditors in
2	Debt Equity Ratio	Total Liabilities Total Outside Liabilities	0.65	0.52	0.13	25.08	Due to increase in liabilities
3	Debt Service Coverage Ratio (For Ind AS Companies Profit before OCI)	Net Operating Income Net Profit after tax + non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of fixed assets, etc.	2.73	1.76	0.97	54.76	Due to decrease in borrowings
4	Return on Equity Ratio	Profit for the period Net Profit after taxes - preference dividend (if any)	0.22	0.26	(0.04)	(14.90)	Due to decrease in profit margins
5	Inventory Turnover Ratio	Cost of Goods sold (Opening Stock + Purchases) – Closing Stock	18.07	14.93	3.14	21.02	Due to increase purchase as compared to last year
6	Trade Receivables Turnover Ratio	Net Credit Sales Credit Sales	2.68	3.56	(0.89)	(24.87)	Due to Increase debtors as compared to previous year
7	Trade Payables Turnover Ratio	Total Purchases Annual Net Credit Purchases	6.13	14.48	(8.35)	(57.67)	Due to Increase creditors in current year as compared to previous year
8	Net Capital Turnover Ratio	Net Sales Total Sales - Sales Return	3.47	2.24	1.23	54.61	Due to decrease current assets

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 35 - FINANCIAL RATIOS: (CONTD.....)

	Ratio Analysis	Numerator	31-Mar-26	31-Mar-25	Diff	Variance (%)	Explanation of variance
9	Net Profit Ratio	Net Profit Profit After Tax	0.04	0.04	0.00	4.90	Due to Increase net profit compare to previous year
10	Return on Capital employed	EBIT Profit before Interest and Taxes	0.09	0.08	0.00	4.29	Return on capital employed is increased due to increase in profit during the year
11	Return on Investment	Return/Profit/Earnings	0.22	0.26	(0.04)	(14.90)	Return on investment decreased during the year.

* Capital Employed could be treated three ways

Total Assets - Current Liabilities

Fixed Assets + Working Capital

Equity + Long Term Debt

*** ROI as per GN

$$ROI = \{MV(T1) - MV(T0) - \text{Sum}[C(t)]\}$$

$$\{MV(T0) + \text{Sum}[W(t) * C(t)]\}$$

where, T1 = End of time period

T0 = Beginning of time period

t = Specific date falling between T1 and T0

MV(T1) = Market Value at T1

MV(T0) = Market Value at T0

C(t) = Cash inflow, cash outflow on specific date

W(t) = Weight of the net cash flow (i.e. either net inflow or net outflow) on day 't', calculated as $[T1 - t] / T1$

Companies may provide ROI separately for each asset class (e.g., equity, fixed income, money market, etc.).

NOTE - 36 - OTHER STATUTORY INFORMATION:

- The Company is not declared wilful defaulter by any bank or financial institution or other lender
- The Company has not traded or invested in crypto currency or virtual currency during the financial year.
- The Company has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the year.
- No proceedings have been initiated or are pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made there under.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026**NOTE - 37 - RELATIONSHIP WITH STRUCK OFF COMPANIESL**

There were no transactions or balances with struck off companies

NOTE - 38 - FOREIGN CURRENCY EXPOSURE:

There was no foreign currency exposure as on March 31, 2026.

NOTE - 39: Previous year figures have been regrouped / reclassified wherever necessary to correspond with current year classification/disclosure.

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For V. GOSWAMI & CO,

Chartered Accountants

FRN : 0128769W

Sd/-

Vipul Goswami

Partner

M.No.: 119809

Place : Ahmedabad

Dated : 22/05/2026

UDIN : 26119809NQIVQC8702

For and on behalf of the board

Medico Intercontinental Limited

Sd/-

Tanvi Shah

Chairperson

DIN:-08192047

Sd/-

Jay Shah

Chief Financial officer

PAN No.: CZOPS1007A

Sd/-

Samir Shah

Managing Director

DIN:-03350268

Sd/-

Puneeta Sharma

Company Secretary

PAN No.: CXOPS0548E

PROOF

INDEPENDENT AUDITORS' REPORT ON CONSOLIDATED FINANCIAL STATEMENTS

TO THE MEMBERS OF MEDICO INTERCONTINENTAL LIMITED

Report on the Consolidated Financial Statements

We have audited the accompanying Consolidated Financial Statements of MEDICO INTERCONTINENTAL LIMITED ("the Holding company") and its subsidiary, joint venture (Holding Company and its subsidiary together referred to as "the Group", which comprise the consolidated Balance Sheet as at 31st March, 2026, the consolidated Statement of Profit and Loss, the consolidated Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (hereinafter referred to as "the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, (hereinafter referred to as "Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, the consolidated profit and total comprehensive income, consolidated changes in equity and its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (hereinafter referred to as "SAs"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (hereinafter referred to as "ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter	How our audit addressed the key audit matter
Revenue recognition as per Ind AS 115	Our audit procedures included the following:
Refer to Note - 1 (Significant Accounting Policies) and Note - 1.10 (Revenue from operations) of the financial statements.	We evaluated the design and tested operating effectiveness of the relevant controls with respect to revenue recognition including those relating to cut off at year end;
The Company's revenue is principally derived from sale of various medicine products.	We assessed the appropriateness of the revenue recognition accounting policies in line with Ind AS 115 "Revenue from Contracts with Customers";
In accordance with Ind AS 115, revenue from sale of goods is recognized when control of the products being sold is transferred to the customer and when there are no unfulfilled obligations. The performance obligations in the contracts are fulfilled at the time of dispatch, delivery or upon formal customer acceptance depending on terms of contract with the customer. Revenue is measured at fair value of the consideration received or receivable after deduction of any trade/volume discounts and taxes or duties collected.	We performed substantive testing of revenue transactions, recorded during the year by testing the underlying documents which included goods dispatch notes, shipping documents and customer acknowledgments, as applicable;
We identified revenue recognition as a key audit matter since revenue is significant to the financial statements and is required to be recognized as per the requirements of applicable accounting framework.	We tested manual journal entries posted to revenue to identify unusual items;
	We tested, on a sample basis, specific revenue transactions recorded before and after the financial year end date including examination of credit notes issued after the year end to determine whether the revenue has been recognized in the appropriate financial period.
	Based on the above stated procedures, no significant exceptions were noted in revenue recognition.

Other Information

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact.

We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Holding Company's Board of Directors is responsible for the matters in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Company in accordance with the accounting principles generally accepted in India (Indian GAAPs), including the Accounting Standards ('Ind AS') specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

This responsibility also includes the maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding of the assets of the Company and for preventing and detecting the frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of internal financial control, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- o Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- o Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances; Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- o Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- o Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- o Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

We did not audit the annual financial statements of four subsidiaries and one joint venture

1. EVAGRACE PHARMA PRIVATE LIMITED
2. RITZ FORMULATIONS PRIVATE LIMITED
3. SUNGRACE PHARMA PRIVATE LIMITED
4. AZILLIAN HEALTHCARE PRIVATE LIMITED
5. CALBORN LIFESCIENCE PRIVATE LIMITED
6. MEDICO LAB (Joint Venture)

included in the Statement, whose financial information reflects total assets of Rs. 7642.99 lakhs as at 31st March 2026, total revenues of Rs. 4728.10 lakhs, total net profit after tax of Rs. -1316.40 lakhs and cash flows (net) of Rs. 238.88 lakhs for the year ended on that date, as considered in the Statement. These annual financial statements have been audited by other auditors whose audit reports have been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the audit reports of such other auditors, and the procedures performed by us as stated in paragraph above.

Our opinion is not modified in respect of this with respect to our reliance on the work done by and the reports of the other auditors.

Report on other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including Other Comprehensive Income, Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.

- d) In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors of the Holding Company as on March 31, 2026 taken on record by the Board of Directors of the holding company and reports of the statutory auditors of its subsidiary company, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Group, joint venture and the operating effectiveness of such controls, refer to our separate Report in "Annexure – A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Group, joint venture internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended: In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - o the consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group, joint venture - (Refer Note 30 to the consolidated financial statements);
 - o The Group, joint venture did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - o There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Group.
 - o The final dividend paid by the Holding Company and its subsidiaries incorporated in India during the year in respect of the same declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend
 - o
 - a. The respective Managements of the company and its subsidiaries which are incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and brief belief, no funds (which are material either individually or in aggregate) have been advanced or loaned or invested (either from the borrowed funds or share premium or any other sources or kind of funds) by the Company or any such of subsidiaries to or in any other person or entity including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company or any of such subsidiaries ("Ultimate beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate beneficiaries.
 - b. The respective Management of the Company and its subsidiaries which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of the knowledge and belief no funds (which are material either individually or in the aggregate) have been received by the company or any of subsidiaries from any person or entity, including foreign entity ("Funding parties") with the understanding, whether recorded in writing or otherwise, that the Company or any of such subsidiaries shall directly or indirectly, lend or invest in other persons or entities identified in any manner what's the whatsoever by or on behalf of the funding party ("Ultimate beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - c. Based on audit procedures that have been considered reasonable and appropriate in the circumstances performed by us on the Company and its subsidiaries which are companies incorporated in India whose financial statements have been audited under the Act, nothing has come to our notice that has caused us to believe that the representations are under sub clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

2. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2020 (the "Order"/ "CARO") issued by the Central Government in terms of Section 143(11) of the Act, to be included in the Auditor's report, according to the information and explanation given to us, and based on the CARO reports issued by us for the Company and its subsidiaries included in the consolidated financial statements of the Company, to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks in these CARO reports.

**For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)**

**Sd/-
VIPUL GOSWAMI
(Partner)
Mem. No: 119809
UDIN: 26119809QXQRLT7422**

**Date: 22/05/2026
Place: Ahmedabad**

PROOF

Annexure “A” to the Independent Auditor’s Report

(Referred to in paragraph 1 (f) under “Report on Other Legal and Regulatory Requirement of our report of even date)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013

We have audited the internal financial controls over financial reporting of **MEDICO INTERCONTINENTAL LIMITED** (“the Holding Company”) and its subsidiary as of 31st March, 2026 in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Respective Board of Directors of the Holding Company and its subsidiary management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Holding Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting

to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company and its subsidiary, joint venture have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India

**For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)**

**Sd/-
VIPUL GOSWAMI
(Partner)
Mem. No: 119809
UDIN: 26119809QXQRLT7422**

**Date: 22/05/2026
Place: Ahmedabad**

PROOF

CONSOLIDATED BALANCE SHEET AS AT 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	Note	As at 31 March, 2026	As at 31 March, 2025
ASSETS			
Non-Current Assets			
(a) Property, Plant & Equipments	2.1	3682.96	357.02
(b) Intangible Assets	2.2	1419.57	113.01
(c) Investment Property	2.3	0.00	394.00
(d) Financial Assets			
(i) Investments	3.1	229.97	300.54
(ii) Loans	3.2	130.00	-
(iii) Other financial assets	3.3	18.62	-
(e) Deferred Tax Assets (Net)	4	0.00	0.00
(f) Other Non Current Assets	5	120.06	1047.44
Total Non-Current Assets		5601.19	2212.01
Current Assets			
(a) Inventories	6	1493.36	851.73
(b) Financial Assests			
(i) Trade Receivables	7	2741.60	3232.69
(ii) Cash and Cash Equivalents	8	596.08	224.42
(iii) Loan	9	0.00	100.80
(c) Other Current Assets	10	1293.59	1070.29
Total Current Assets		6124.63	5479.92
TOTAL ASSETS		11725.82	7691.94
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share capital	11	1000.00	1000.00
(b) Other Equity	12	3688.87	4008.94
(c) Non-controlling Interest		-1462.27	-
Total Shareholders' Funds		3226.60	5008.94
Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	13.1	4608.51	1347.25
(ii) Other Financial Liabilities	14	0.00	53.27
(b) Long term Provisions	20.1	32.31	22.77
(c) Deferred Tax Liabilities (Net)	4	84.28	12.01
(d) Other non-current liabilities	15	.30	.30
Total Non-Current Liabilities		4725.40	1435.60
Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	13.2	2103.90	345.13
(ii) Other Financial Liabilities	16	10.12	0.00
(iii) Trade Payables	17		
Due to Micro and Small Enterprises		124.62	151.97
Due to Others		1286.50	573.34
(b) Other Current Liabilities	18	167.59	99.80
(c) Current Tax Liabilities (net)	19	79.41	75.90
(d) Short term Provisions	20.2	1.67	1.26
Total Current Liabilities		3773.81	1247.40
TOTAL EQUITY AND LIABILITIES		11725.82	7691.94

Basis of preparation, measurement and Significant Accounting Policies
 The Accompanying Notes are an integral part of these Financial Statements

1

1 TO 45

As per our report of even date

For V. GOSWAMI & CO,

Chartered Accountants

FRN : 0128769W

Sd/-

Vipul Goswami

Partner

M.No. 119809

Place : Ahmedabad
Dated : 22/05/2026
UDIN : 26119809XQRLT7422
**For and on behalf of the board
 Medico Intercontinental Limited**

Sd/-

Tanvi Shah

Chairperson

DIN:-08192047

Sd/-

Jay Shah

Chief Financial Officer

PAN No.: CZOPS1007A

Sd/-

Samir Shah

Managing Director

DIN:-03350268

Puneeta Sharma

Company Secretary

PAN No.: CXOPS0548E

CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st March, 2026
 (Rs. in Lakhs unless otherwise stated except EPS)

Particulars	Note	Year ended 31.03.2026	Year ended 31.03.2025
INCOME			
Revenue From Operations	21	8408.41	9531.53
Other Income	22	127.04	41.71
Total Income		8535.46	9573.23
Expenses			
Cost of materials consumed	23	769.90	-
Purchases of Stock in Trade	24	5396.73	7252.23
Changes In Inventories	25	98.77	192.24
Employee Benefits Expense	26	876.57	465.99
Depreciation and Amortization Expense	2	542.75	78.69
Finance Costs	27	815.92	99.31
Other Expenses	28	968.85	802.66
Total Expenses		9469.49	8891.12
Profit before Exceptional Items and Tax		-934.04	682.11
Exceptional Items			
Bad Debts		0.00	0.00
Profit Before Tax		-934.04	682.11
Tax Expense:			
- Current Tax		188.59	175.44
- Deferred Tax		-13.52	11.15
Profit for the year ended (A)		-1109.10	495.53
OTHER COMPREHENSIVE INCOME			
Share of Profit/ (Loss) of Associates and Joint Ventures		11.06	10.20
Items that will not be reclassified subsequently to profit or loss		0.00	0.00
Items that will be reclassified subsequently to profit or loss		0.00	0.00
OTHER COMPREHENSIVE INCOME FOR THE YEAR (B)		11.06	10.20
TOTAL COMPREHENSIVE INCOME FOR THE YEAR (A+B)		-1098.04	505.73
NET PROFIT ATTRIBUTABLE TO :			
Owners of the Holding Company		-320.07	505.73
Non-Controlling Interest		-777.97	-
OTHER COMPREHENSIVE INCOME ATTRIBUTABLE TO :			
Owners of the Holding Company		-	-
Non-Controlling Interest		-	-
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO :			
Owners of the Holding Company		-320.07	505.73
Non-Controlling Interest		-777.97	-
Earnings Per Equity Share of face value of Rs. 10/-each Basic and Diluted (Rs.)	29	-3.20	5.06
Basis of preparation, measurement and Significant Accounting Policies	1		
The accompanying notes forms an integral part of the Financial Statements	1 TO 45		

As per our report of even date

For V. GOSWAMI & CO,

Chartered Accountants

FRN : 0128769W

Sd/-

Vipul Goswami

Partner

M.No. 119809

Place : Ahmedabad**Dated : 22/05/2026****UDIN : 26119809QXQRLT7422****For and on behalf of the board
Medico Intercontinental Limited**

Sd/-

Tanvi Shah

Chairperson

DIN:-08192047

Sd/-

Jay Shah

Chief Financial Officer

PAN No.: CZOPS1007A

Sd/-

Samir Shah

Managing Director

DIN:-03350268

Puneeta Sharma

Company Secretary

PAN No.: CXOPS0548E

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
A. CASH FLOW FROM OPERATING ACTIVITIES :		
a) Net Profit/ (Loss) before tax	-934.04	682.11
b) OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	-934.04	682.11
Adjustments For:		
Profit/Loss on Sale of Fixed Assets	-	-
Depreciation and Amortization	542.75	78.69
Finance costs	815.92	99.31
Gratuity Provision	9.95	9.18
Profit on Sale of Asset	-51.23	-
Loss on Sale Motor car	-	.98
Dividend Income	-24	-24
Interest Income	-39.24	-31.94
CASH GENERATED FROM OPERATIONS	343.87	838.09
Adjustments for		
Decrease/(Increase) in Inventories	-26.57	192.24
Decrease/(Increase) in Trade Receivables	-140.50	-912.07
Decrease/(Increase) in Short Term Loans and Advances	100.80	0.00
Decrease/(Increase) in Other Current Assets/Non Current Assets	1260.70	-923.05
Increase/(Decrease) in Provisions and Other Current Liabilities	-282.01	30.27
Decrease/(Increase) in Current Assets, Loans	0.00	-
Increase/(Decrease) in Trade Payables	678.13	275.13
Increase/(Decrease) Non- Current Financial Liabilities	-53.27	53.27
Increase/(Decrease) in Current Financial Liabilities-Borrowings	10.12	-
Increase/(Decrease) in Provisions	-	-
CASH GENERATED FROM OPERATING ACTIVITIES	1891.28	-446.12
Income Tax Paid Net	-183.72	-179.41
NET CASH FROM/(USED IN) OPERATING ACTIVITIES (A)	1707.56	-625.53
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase of Fixed Assets	-464.29	-192.99
Purchase of Investment Property	-198.00	-398.86
Sale of Motor Car	-	.32
Investment In Joint Venture/Associates (Net of Profit for the period)	81.68	-288.34
Deposits (Net)	-	0.00
Interest Income Received	39.24	31.94
Dividend Income	.24	.24
Sales Of Property	627.95	-
(Increase)/ Decrease in Financial Assets	134.38	-
(Increase)/ Decrease in Other Financial Asset	-1.31	-
Purchase of Investments and Intangible assets	-	-
Other non-current Assets	-	354.29
NET CASH FROM/(USED IN) INVESTING ACTIVITIES (B)	219.89	-493.40
C. CASH FLOW FROM FINANCING ACTIVITIES:		
Increase/(Decrease) in Loan and Advances	-	-100.80
Proceeds from Issuance of Share Capital	-	0.00
Proceeds from Issued/paid Capital	-	0.00
Proceeds from / (Repayment) of Borrowings Net	-664.08	1160.28
Proceeds from / (Repayment) of Short Term Borrowing Net	-75.79	46.67
Finance Costs paid	-815.92	-99.31
Dividend Paid	-	-
NET CASH FROM/(USED IN) FINANCING ACTIVITIES (C)	-1555.79	1006.83
NET INCREASE IN CASH AND CASH EQUIVALENTS	371.66	-112.10
CASH AND CASH EQUIVALENTS (At the beginning of the year)	224.42	336.52
CASH AND CASH EQUIVALENTS (At the end of the year)	596.08	224.42

- The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in Ind AS 7, 'Statement of Cash Flows'.
- Previous Year's figure have been regrouped, rearranged, wherever necessary, to correspond with the current year's classification/disclosure.en regrouped, rearranged, wherever necessary, to correspond with the current year's classification/disclosure.

As per our report of even date
For V. GOSWAMI & CO,
 Chartered Accountants
 FRN : 0128769W
 Sd/-
Vipul Goswami
 Partner
 M.No. 119809
Place : Ahmedabad
Dated : 22/05/2026
UDIN : 26119809QXQRLT7422

For and on behalf of the board
Medico Intercontinental Limited

Sd/-
Tanvi Shah
 Chairperson
 DIN:-08192047
 Sd/-
Jay Shah
 Chief Financial Officer
 PAN No.: CZOPS1007A

Sd/-
Samir Shah
 Managing Director
 DIN:-03350268
Puneeta Sharma
 Company Secretary
 PAN No.: CXOPS0548E

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

	As at 31st March, 2026	As at 31st March, 2025
A. EQUITY SHARE CAPITAL		
Balance at the beginning of the reporting year		
Equity shares of Rs.10/- each issued, subscribed and paid-up	1000.00	1000.00
Changes in Equity Share capital during the year	0.00	0.00
Balance at the end of the reporting year	1000.00	1000.00

B. OTHER EQUITY

Particulars	Reserves and Surplus			Items of Other Comprehensive Income(OCI)	Total
	Securities Premium Account	Retained Earnings	Capital Reserve	NA	
Balance as at 1st April, 2024	1878.96	1624.25		0.00	3503.21
Profit for the year	-	505.73		0.00	505.73
Securities Premium Account	-	-		0.00	-
Expenses on issue of equity shares	-			0.00	-
Dividend Paid during the year		-		0.00	-
Total Comprehensive Income for the year	1878.96	2129.98		-	4008.94
Balance As at 31st March, 2025	1878.96	2129.98		0.00	4008.94
Balance as at 1st April, 2025	1878.96	2129.98		0.00	4008.94
Profit / Loss for the year		-320.07		0.00	-320.07
Capital reserves		-	-		-
Securities Premium Account	-	-			-
Expenses on issue of equity shares	-				-
Dividend Paid during the year		-			-
Total Comprehensive Income for the year	1878.96	1809.91	-	-	3688.87
Balance as at 31st March, 2026	1878.96	1809.91	-	0.00	3688.87

As per our report of even date

For V. GOSWAMI & CO,

Chartered Accountants

FRN : 0128769W

Sd/-

Vipul Goswami

Partner

M.No. 119809

Place : Ahmedabad**Dated : 22/05/2026****UDIN : 26119809QXQRLT7422****For and on behalf of the board****Medico Intercontinental Limited**

Sd/-

Tanvi Shah

Chairperson

DIN:-08192047

Sd/-

Jay Shah

Chief Financial Officer

PAN No.: CZOPS1007A

Sd/-

Samir Shah

Managing Director

DIN:-03350268

Puneeta Sharma

Company Secretary

PAN No.: CXOPS0548E

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE NO. 1:

1.01 GROUP Overview

The Consolidated Financial Statements (hereinafter referred to as "financial statements") comprise financial statements of The **MEDICO INTERCONTINENTAL LIMITED** (the Parent), its subsidiaries (collectively referred to as Group) for the year ended March 31, 2026.

MEDICO INTERCONTINENTAL LIMITED ("the company") was incorporated on August 14, 1984 having its Registered Office at 1-5th Floor, Adit Raj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad - 380015, Gujarat. The Company is into the business of trading of pharmaceuticals products.

Basis of preparation and Significant Accounting Policies

1.02 Statement of Compliance

The financial statements of the Group have been prepared in accordance with the Indian Accounting Standards (IND AS) as per the Companies (Indian Accounting Standards) Rules, 2015 as amended and notified under Section 133 of the Companies Act, 2013 ("the Act") and other relevant provisions of the Act. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

1.03 Basis of preparation and presentation

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

Recent accounting pronouncements

New and amended Ind ASs effective from April 01, 2026

The Ministry of Corporate Affairs (MCA) notifies new standards | amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. During the year, the MCA has amended the Ind AS as below:

Ind AS 1 – Presentation of Financial Statements:

The amendments clarify requirements relating to classification of liabilities as current or non-current, including the effect of covenants and the Company's right to defer settlement. The amendments also introduce specific disclosure requirements where liabilities arising from loan arrangements are classified as non-current and the Company's right to defer settlement is subject to compliance with covenants within twelve months after the reporting period.

Ind AS 7 – Statement of Cash Flows and Ind AS 107 – Financial Instruments: Disclosures:

The amendments introduce disclosure requirements in respect of supplier finance arrangements, including information about the terms and conditions, carrying amounts of related financial liabilities, amounts for which suppliers have received payment from finance providers, ranges of payment due dates and the effect of non-cash changes. Supplier finance arrangements are also relevant to the Company's liquidity-risk disclosures.

Ind AS 12 – Income Taxes:

The amendments relating to International Tax Reform – Pillar Two Model Rules introduce a mandatory temporary exception from recognizing and disclosing deferred tax assets and liabilities related to Pillar Two income taxes and introduce additional disclosures relating to Pillar Two income taxes, where applicable.

Ind AS 21 – The Effects of Changes in Foreign Exchange Rates:

The amendments provide guidance for assessing whether a currency is exchangeable into another currency and for estimating the spot exchange rate where exchangeability is lacking. Additional disclosures are required in such circumstances.

The Company has evaluated the applicability of the above amendments. Based on the nature of the Company's transactions, arrangements and operations, the amendments did not have a material impact on recognition and measurement. The Company has incorporated the additional disclosures required by the applicable amendments.

1.04 Use of estimates

The preparation of the financial statements in conformity with IND AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from those estimates. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognized in the periods in which the results are known / materialize.

1.05 Current versus Non-Current classification

The Group presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when it:

- is expected to be realised or intended to be sold or consumed in the normal operating cycle;
- is held primarily for the purpose of trading;
- is expected to be realised within twelve months after the reporting period; or
- is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when it:

- is expected to be settled in the normal operating cycle;
- is held primarily for the purpose of trading;
- is due to be settled within twelve months after the reporting period; or
- the Company does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

The classification of liabilities is based on the rights that exist at the end of the reporting period. Covenants with which the Company is required to comply on or before the end of the reporting period are considered in assessing whether the Company has the right to defer settlement. Covenants with which the Company is required to comply only after the reporting period do not affect classification at the reporting date but may require

Additional disclosures.

Deferred tax assets and liabilities are classified as non-current.

The operating cycle of the Group is twelve months

1.06A Property, Plant and Equipments and other Intangible Assets

Recognition and measurement:

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in statement of profit or loss.

Depreciation and Amortization:

Depreciation, on fixed assets, based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013, on Written Down Value (WDV) method. Depreciation on additions during the year is provided on prorata time basis.

1.06B Investment Property:

Investment Property is measured initially at cost including related transaction costs.

The cost comprises the purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for its intended use.

Subsequent expenditures are capitalized only when it is probable that future economic benefits associated with these will flow to the company and the cost of the item can be measured reliably.

Investment property is carried at cost less accumulated depreciation and impairment.

All day-to-day repair and maintenance expenditure are charged to the statement of profit and loss for the period during which such expenses are incurred.

Gains or losses arising from derecognition of investment property are measured as the difference between the net disposal proceeds and the carrying amount of the asset at the time of disposal and are recognized in the statement of profit and loss when the asset is derecognized.

Depreciation and amortization:

Depreciation, on Investment property, based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013, on Written Down Value (WDV) method. Depreciation on additions during the year is provided on prorata time basis.

1.07 Inventories

Inventories are valued at the lower of cost and the net realizable value after providing for obsolescence and other losses, where considered necessary. Cost of inventory includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

1.08 Cash and Cash Equivalents (for purposes of Cash Flow Statement)

Cash comprises Cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

1.09 Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

1.10 Revenue Recognition

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates, GST and amounts collected on behalf of third parties.

Sale of Products

Timing of recognition - Revenue from sale of products is recognized when control of the products is transferred to customers based on the terms of sale.

Measurement of revenue - Revenue from sales is based on the price specified in the sales contracts, net of all expected discounts and returns in relation to sales made until the end of the reporting period.

No element of financing is deemed present as the sales are made with credit terms consistent with market practices. A receivable is recognized when the goods are dispatched, delivered or upon formal customer acceptance depending on terms of contract with the customer.

Dividend and interest income:

Dividend income is recognised when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend.

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate

that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Other income:

Other incomes are accounted on accrual basis except specifically stated on cash basis.

1.11 Employee benefits

Defined benefit plan

Gratuity:

Gratuity liability is a defined benefit obligation and is computed on the basis of an actuarial valuation by an actuary appointed for the purpose as per projected unit credit method at the end of each financial year. The liability or asset recognized in the Consolidated Balance Sheet in respect of defined benefit gratuity plan, is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The liability so provided is represented by creation of separate fund and is used to meet the liability as and when it become due for payment in future. Any shortfall in the value of assets over the defined benefit obligation is recognized as a liability with a corresponding charge to the Consolidated Statement of Profit and Loss.

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows with reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation.

The net interest cost is calculated by applying the discount rate at the beginning of the period to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the Consolidated Statement of Profit and Loss.

Re-measurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur directly in other comprehensive income. They are included in retained earnings in the Statement of changes in equity and in the Consolidated Balance Sheet.

Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognized immediately in profit or loss as past service cost.

Defined contribution plan:

Contributions to defined contribution schemes such as contribution to provident fund, superannuation fund, employees' state insurance corporation, national pension scheme and labour welfare fund are charged as an expense to Consolidated Statement of Profit and Loss based on the amount of contribution required to be made as and when services are rendered by the employees. The above benefits are classified as defined contribution schemes as the Company has no further defined obligations beyond the monthly contributions.

Short-term employee benefits:

All employee benefits payable within 12 months of service such as salaries, wages, bonus, ex-gratia, medical benefits, etc, are recognized in the year in which the employees render the related service and are presented as current employee benefit obligations. Termination benefits are recognized as an expense as and when incurred.

Short-term employee benefits are provided at undiscounted amount during the accounting period based on service rendered by employees.

Other long-term employee benefits:

The liabilities for earned leave are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. The benefits are discounted using the market yields at the end of the reporting period that have terms approximating to the terms of the related obligation. Re-measurements as a result of experience adjustments and changes in actuarial assumptions are recognized in profit or loss.

1.12 Borrowing Costs

Borrowing costs include interest; amortization of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs

in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan. Borrowing costs, allocated to and utilized for qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset upto the date of capitalization of such asset is added to the cost of the assets. Capitalization of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

1.13 Earnings Per Share

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year.

1.14 Taxes on income

Current tax:

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax:

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

1.15 Contingent Liabilities

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions, but are disclosed unless the possibility of outflow of resources is remote.

1.16 Contingent Asset

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company. The company does not recognize a contingent asset but discloses its existence in the financial statements.

1.17 Segment Reporting

An operating segment is component of the Group that engages in the business activity from which the Group earns revenues and incurs expenses, for which discrete financial information is available and whose operating results are regularly reviewed by the chief operating decision maker, in deciding about resources to be allocated to the segment and assess its performance. The Parent Company's chief operating decision maker is the Managing Director.

Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are disclosed as unallocable.

Revenue and expenses directly attributable to segments are reported under each reportable segment. All other expenses which are not attributable or allocable to segments have been disclosed as unallocable expenses.

The Group prepares its segment information in conformity with the accounting policies adopted for preparing and presenting the financial statements of the Group as a whole.

1.18 Leases:

As a lessee:

The Group assesses whether a contract is, or contains a lease, at inception of the contract. A contract is, or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: i) the contract involves the use of an identified asset ii) the Group has substantially all of the economic benefits from use of the asset through the period of the lease and iii) the Company has the right to direct the use of the asset.

At the commencement date of the lease, the Group recognizes a right-of-use asset and a corresponding lease liability for all lease arrangements in which it is lessee, except for short-term leases (leases with a term of twelve months or less), leases of low value assets and, for contract where the lessee and lessor has right to terminate a lease without permission from the other party with no more than an insignificant penalty. The lease expense of such short-term leases, low value assets leases and cancellable leases are recognized as an operating expense on a straight-line basis over the term of the lease.

At commencement date, lease liability is measured at the present value of the lease payments to be paid during non-cancellable period of the contract, discounted using the incremental borrowing rate. The right-of-use assets is initially recognized at the amount of the initial measurement of the corresponding lease liability, lease payments made at or before commencement date less any lease incentives received and any initial direct costs.

Subsequently the right-of-use asset is measured at cost less accumulated depreciation and any impairment losses. Lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using effective interest rate method) and reducing the carrying amount to reflect the lease payments made. The right-of-use asset and lease liability are also adjusted to reflect any lease modifications or revised in-substance fixed lease payments.

As a lessor:

Leases for which the Group is a lessor are classified as finance or operating leases. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

Income from operating leases where the Group is a lessor is recognized as income on a straight-line basis over the lease term unless the receipts are structured to increase in line with expected general inflation to compensate for the expected inflationary cost increases. The respective leased assets are included in the Balance Sheet based on their nature. Leases of property, plant and equipment where the Group as a lessor has substantially transferred all the risks and rewards are classified as finance lease. Finance leases are capitalized at the inception of the lease at the fair value of the leased property or, if lower, the present value of the minimum lease payments. The corresponding rent receivables, net of interest income, are included in other financial assets. Each lease receipt is allocated between the asset and interest income. The interest income is recognized in the Statement of Profit and Loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the asset for each period.

Under combined lease agreements, land and building are assessed individually.

1.19 Impairment of assets:

The carrying amount of assets are reviewed at each Balance Sheet date to assess if there is any indication of impairment based on internal / external factors. An impairment loss on such assessment is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount of the

assets is net selling price or value in use, whichever is higher. While assessing value in use, the estimated future cash flows are discounted to the present value by using weighted average cost of capital. A previously recognized impairment loss is further provided or reversed depending on changes in the circumstances and to the extent that carrying amount of the assets does not exceed the carrying amount that will be determined if no impairment loss had previously been recognized.

1.20 Offsetting financial instruments:

Financial assets and liabilities are offset and the net amount is reported in the Balance Sheet where there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the assets and settle the liabilities simultaneously.

1.21 Investments and other Financial Assets

(i) Classification

The Group classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income, or through profit or loss), and
- those measured at amortized cost.

The classification depends on the entity's business model for managing the financial assets and the cash flows.

For assets measured at fair value, gains and losses will either be recorded in Statement of profit or loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for equity investment at fair value through other comprehensive income.

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

(ii) Measurement

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in profit or loss.

(iii) Debt Instruments

Subsequent measurement of debt instruments depends on the Company's business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Group classifies its debt instruments.

(iv) Amortized cost:

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. A gain or loss on a debt investment that is subsequently measured at amortized cost and is not part of a hedging relationship is recognized in profit or loss when the asset is derecognized or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

(v) Fair value through other comprehensive income (FVOCI):

Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognized in profit and loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains/(losses). Interest income from these financial assets is included in other income using the effective interest rate method.

(vi) Fair value through profit or loss:

Assets that do not meet the criteria for amortized cost or FVOCI are measured at fair value through profit or loss. A gain or loss on debt investment that is subsequently measured at fair value through profit or loss is recognized in profit or loss and presented net in the statement of profit and loss in the period in which it arises. Interest income from these financial assets is included in other income.

(vii) Financial Liabilities

Financial liabilities are subsequently carried at amortized cost using the effective interest method.

(viii) Investments in Subsidiaries

Investments in subsidiaries, associates and joint ventures are carried at cost in the separate financial statements.

(ix) Equity Instruments

An equity instrument is a contract that evidences residual interest in the assets of the company after deducting all of its liabilities. Incremental costs directly attributable to the issuance of equity instruments are recognized as a deduction from equity instrument net of any tax effects.

1.22 Basis of Consolidation

The Parent Company consolidates entities which it owns or controls and applies equity method of accounting where the Company has significant influence over the other entity.

Consolidation of Subsidiary

The Parent Company controls an entity when it is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Power is demonstrated through existing rights that give the current ability to direct the relevant activities of the entity that significantly affect the entity's returns.

Subsidiary is consolidated from the date control commences until the date control ceases.

Consolidated Financial Statements combine like items of assets, liabilities, equity, income, expenses and cash flows of the Parent Company with those of the subsidiary. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognized in the consolidated financial statements at the acquisition date. Offset the carrying amount of the Parent Company's investment in subsidiary and the Parent Company's portion of the equity of each subsidiary. Intragroup transactions, balances and unrealized gains and losses on transactions between entities of group are eliminated. Intragroup losses may indicate an impairment that requires recognition in the consolidated financial statements. IND AS 12, Income taxes, applies to temporary differences that arise from the elimination of profit and losses resulting from intragroup transactions.

Consolidated Financial Statements are prepared using uniform accounting policies for like transactions and events in similar circumstances.

Non-Controlling Interests in the profit or loss and equity of subsidiary are shown separately in the consolidated financial statements of profit and loss and consolidated statement of changes in equity respectively.

Consolidation joint Venture

The consolidated financial statements include the parent company's share of assets, liabilities, income, and expenses of its joint ventures, consolidated using the proportionate consolidation method. The parent's share in each line item is determined based on its proportion of ownership interest as at the reporting date.

1.23 Investment in joint ventures:

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control.

The Group's investments in joint venture are accounted for using the proportionate consolidation method.

Under this method, the company includes its share of the assets, liabilities, income, and expenses of each joint venture, based on its ownership percentage, in the respective lines of the consolidated financial statements.

The company recognizes its share of each asset, liability, income, and expense from joint ventures in the consolidated accounts on a line-by-line basis, in proportion to its ownership or contractual share.

The company's consolidated balance sheet reflects its proportionate share of the joint ventures' assets and liabilities. Similarly, the consolidated statement of profit and loss reflects the company's proportionate share of revenue and expenses from joint ventures.

Intragroup balances and transactions, and any unrealized gains or losses arising from such transactions with joint ventures, are eliminated to the extent of the company's interest.

The company's share of each category (e.g., inventories, property, plant and equipment, trade receivables, payables, revenues, and costs) is presented within the corresponding line items of the consolidated statements.

The ownership percentage used for proportionate consolidation is reviewed annually and is determined as per joint venture agreements.

Assessment of joint control is done at the inception of the arrangement and whenever there is a change in rights or obligations.

PROOF

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT AND FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 2.1 : PROPERTY, PLANT AND EQUIPMENTS:

(Rs. in Lakhs unless otherwise stated)

Particulars	Laboratory Equipment	Furniture and fixtures	Office Equip-ments	Godown Building	Plant and Machinery	Electric Instalatio and Equipments	Computer	Vehicle	Land	Total
Year ended March 31, 2025										
Opening Gross Carrying Amount	-	46.75	11.55	75.78	18.91	-	48.11	194.18		395.30
Additions	-	4.00	.08	0.00	.69	-	5.00	183.23		192.99
Disposals	-	-	-	-	-	-	-	-1.30		-1.30
Closing Gross Carrying Amount	-	50.75	11.63	75.78	19.60	-	53.11	376.10		586.99
Accumulated Depreciation and Impairment										
Opening Accumulated Depreciation	-	23.37	8.18	23.43	10.73	-	33.03	57.55		156.28
Depreciation Charge during the year	-	6.04	.80	1.66	.99	-	6.66	57.54		73.69
Closing Accumulated Depreciation and Impairment	-	29.41	8.98	25.09	11.71	-	39.69	115.09		229.97
Net Carrying Amount	-	21.34	2.66	50.69	7.89	-	13.42	261.02		357.02
Year ended March 31, 2026										
Opening Gross Carrying Amount	50.29	76.78	22.92	1086.04	1988.81	90.72	65.57	376.10	437.98	4195.21
Additions	2.15	65.55	5.72	0.00	321.46	22.90	3.53	110.95		531.97
Disposals	-	-	-	-	-8.32	-80	-	-		-9.11
Closing Gross Carrying Amount	52.44	142.33	28.64	1086.04	2301.65	112.82	69.10	487.06	437.98	4718.06
Accumulated depreciation and impairment										
Opening Accumulated Depreciation	9.35	34.09	12.81	87.66	191.35	15.62	46.85	115.09	-	512.82
Depreciation Charge during the year	12.51	20.21	5.67	95.66	281.45	23.68	9.51	73.58	-	522.28
Closing Accumulated Depreciation and Impairment	21.86	54.30	18.48	183.32	472.80	39.30	56.36	188.67	-	1035.10
Net Carrying Amount	30.58	88.03	10.15	902.72	1828.85	73.52	12.74	298.39	437.98	3682.96
2.2 INTANGIBLE ASSETS										
Particulars								Goodwill	Projects in Progress	Total
Year ended March 31, 2025										
Opening Gross Carrying Amount	-	-	-	-	-	-	-	132.57		132.57
Additions	-	-	-	-	-	-	-	0.00		0.00
Disposals	-	-	-	-	-	-	-	0.00		0.00
Closing Gross Carrying Amount	-	-	-	-	-	-	-	132.57		132.57
Accumulated Depreciation and Impairment										
Opening Accumulated Depreciation	-	-	-	-	-	-	-	19.41		19.41
Depreciation Charge during the year	-	-	-	-	-	-	-	.15		.15
Closing Accumulated Depreciation and Impairment	-	-	-	-	-	-	-	19.56		19.56
Net Carrying Amount	-	-	-	-	-	-	-	113.01		113.01
Year ended March 31, 2026										
Opening Gross Carrying Amount	-	-	-	-	-	-	-	132.57	20.37	152.95
Additions	-	-	-	-	-	-	-	1305.65	-	1305.65
Disposals	-	-	-	-	-	-	-	0.00		0.00
Closing Gross Carrying Amount	-	-	-	-	-	-	-	1438.22	20.37	1458.60
Accumulated Depreciation and Impairment										
Opening Accumulated Depreciation	-	-	-	-	-	-	-	19.56	12.92	32.48
Depreciation Charge during the year	-	-	-	-	-	-	-	.11	6.43	6.54
Closing Accumulated Depreciation and Impairment	-	-	-	-	-	-	-	19.67	19.35	39.02
Net Carrying Amount	-	-	-	-	-	-	-	1418.55	1.02	1419.57

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT AND FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 2.1 : PROPERTY, PLANT AND EQUIPMENTS: (Contd.....)

(i) Title deeds of Immovable Property not held in name of the Company :

Relevant line item in Balance Sheet	Description of item of property	Gross Carrying Value	Title deeds held in the name of		Whether title deed holder in a promoter, director or relative of promoter / director or employees of promoter / director			Property held since which date	Reason for not being held in the name of the Company*	
PPE	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
Investment property	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
PPE retired from active use and held for disposal	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL

*also indicate if in dispute

(ii) Capital-Work-in Progress (CWIP) / Intangible assets under development (ITAUD) (Amount in Rs.)

CWIP/ITAUD	Amount in CWIP for a period of				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	-	-	NIL	-	-
Projects temporarily suspended	-	-	-	-	-

(iii) Capital-Work-in Progress (CWIP)/ITAUD whose completion is overdue (Amount in Rs.)

CWIP/ITAUD	To be completed in			
	Less than 1 year	1-2 years	2-3 years 3 years	More than
Project 1	-	-	Nil	-
Project 2	-	-	-	-

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 2.3 : INVESTMENT PROPERTY:

Particular	Office	Total
Year ended March 31, 2025		
Opening Gross Carrying Amount	-	-
Additions	398.86	398.86
Disposals	0.00	0.00
Closing Gross Carrying Amount	398.86	398.86
Accumulated Depreciation and Impairment		
Opening Accumulated Depreciation	-	-
Adjustment during the year	-	-
Depreciation Charge during the year	4.86	4.86
Closing Accumulated Depreciation and Impairment	4.86	4.86
Net Carrying Amount	394.00	394.00
Year ended March 31, 2026		
Opening Gross Carrying Amount	398.86	398.86
Additions	198.00	198.00
Disposals	576.72	576.72
Closing Gross Carrying Amount	20.13	20.13
Accumulated Depreciation and Impairment		
Opening Accumulated Depreciation	4.86	4.86
Depreciation Charge during the year	15.28	15.28
Closing Accumulated Depreciation and Impairment	20.13	20.13
Net Carrying Amount	-	-

2.3A The Company has elected to measure all its investment properties at acquisition cost of assets.

2.3B Fair value of investment properties

Particular	2025-26	2024-25
Investment properties	198.00	398.86

Refer note no. 31 for disclosure on fair value.

Estimation of fair value:

The Company obtains independent valuation report for its investment property once in every three years. For the current year's fair value, as per acquisition value of assets for year 2024-25.

2.3C Amount recognised in Profit or Loss for Investment Properties

Particulars	2025-26	2024-25
Rental Income	15.78	0
Direct/Indirect operating expenses (including repairs and maintenance) arising from investment property that generated rental income during the period;	11.32	0
Depreciation	20.13	4.86
NET INCOME	-15.67	-4.86

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
NOTE - 3 - NON-CURRENT INVESTMENTS:		
3.1 Other Investments		
ICICI Bank Fixed Deposit	0.00	0.00
In AMCO Bank Shares	2.00	2.00
In The Mehsana Urban Co-Op Bank Ltd Bank Shares	.05	0.00
	2.05	2.00
Joint venture/Associates/Other Investments		
Capital Investment in MEDICO LAB Partnership firm	227.92	298.54
	229.97	300.54
3.2 NON - CURRENT LOANS		
Other Loans and advances	130.00	0.00
	130.00	-
3.3 NON - CURRENT OTHER FINANCIAL ASSETS		
Security Deposits	18.62	0.00
	18.62	-
NOTE - 4 - DEFERRED TAX:		
Deferred Tax Liabilities	92.13	17.81
Deferred Tax Assets	7.84	5.80
Deferred Tax (Asset) / Liabilities	84.28	12.01
Note 4: Deferred Tax:		
a. Depreciation		
Opening balance	97.80	.86
Total reversible timing difference in books maintained as per Companies Act 2013		
Depreciation as per Companies Act 2013	542.75	78.69
Total reversible timing difference in books maintained as per Income Tax Act 1961		
Depreciation as per Income Tax Act 1961	454.17	129.69
Net reversible timing difference (1) - (2)	88.57	-51.00
b. Gratuity		
Closing Gratuity provision	33.98	24.03
Opening Gratuity provision	24.03	14.85
Net reversible timing difference (1) - (2)	9.95	9.18
Deferred tax asset recognised for the year (a+b)	98.52	-41.82
Add : Deferred tax income/(expense)	-19.01	11.15
Less: Deferred tax income/(expense)	5.49	0.00
Total	84.28	12.01

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
NOTE - 5 - OTHER NON-CURRENT ASSETS:		
Security Deposits	2.04	2.04
Advance for Purchase of New Office	3.00	210.69
(Advance given for purchase office at SOLITAIRE CONNECT SCHEME in Ahmedabad office no 1110 to 1112)		
Advance For Purchase of Land	105.00	820.00
(Advance given for Plot in SUN INDUSTRIAL PARK, SANAND, AHMEDABAD GUJARAT)		
Capital Advances	10.03	14.71
	120.06	1047.44

NOTE - 6 - INVENTORIES:

Raw Materials (Including stock in transit)*	159.04	-
Work-In-Progress*	290.91	-
Finished Goods*	1041.54	851.73
Stores And Spares/Packing Material*	1.86	-
	1493.36	851.73

*Valued at lower of cost and net realizable value

NOTE - 7 - TRADE RECEIVABLES:**UNSECURED, CONSIDERED GOOD**

Trade receivable	2741.60	3232.69
	2741.60	3232.69

Trade Receivables ageing schedule as at 31st March, 2026:

Particulars	Outstanding for following periods from due date of payment					
	Not Due	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More Than 3 Years
(i) Undisputed Trade receivables -considered good	1684.55	875.58	37.26	6.60	93.28	44.33
(ii) Undisputed Trade receivables -considered doubtful						
(iii) Disputed trade receivables considered good						
(iv) Disputed trade receivables considered doubtful						

Trade Receivables ageing schedule as at 31st March, 2025:

Particulars	Outstanding for following periods from due date of payment					
	Not Due	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More Than 3 Years
(i) Undisputed Trade receivables -considered good	2281.97	787.90	23.38	26.54	88.61	24.27
(ii) Undisputed Trade receivables -considered doubtful						
(iii) Disputed trade receivables considered good						
(iv) Disputed trade receivables considered doubtful						

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
NOTE - 8 - CASH AND CASH EQUIVALENTS:		
Cash Balance		
Cash on Hand	32.86	36.62
Balances with Banks		
IN Current Accounts and OD A/c*	351.78	52.72
Unpaid dividend accounts *	.11	.11
(*Current account with ICICI BANK AND STANDARD CHARTERED BANK AND KOTAK MAHINDRA BANK)		
Investment in Bank		
ICICI Bank Fixed Deposit	211.33	134.97
	596.08	224.42
NOTE - 9 - FINANCIAL ASSETS-LOAN :		
Loan Receivable considered Good - Unsecured		
Inter-Corporate Deposits	0.00	100.80
	0.00	100.80
NOTE - 10 - OTHER CURRENT ASSETS:		
SECURITY DEPOSITS - BAJAJ FORMULATIONS	.96	.90
SECURITY DEPOSITS - EMBARK LIFESCIENCE PRIVATE LIMITED	.17	.17
SECURITY DEPOSITS - ELVIA	.10	.10
SECURITY DEPOSITS - WINDLABS	.07	.07
SECURITY DEPOSITS - TORRENT	.11	.11
TDS RECEIVABLES	1.25	.01
PREPAID EXPENSES	11.05	3.00
ADVANCE TAX	25.00	37.00
ADVANCE TO SUPPLIERS FOR GOODS AND SERVICES	10.47	4.38
EMPLOYEE ADVANCES	-	-
GST RECEIVABLES	536.47	15.28
LAXMI SYNTHETICS (SECURITY DEPOSIT), SURAT	1.00	1.00
Preliminary Expenses	41.03	-
ADVANCES GIVEN FOR PURCHASE	576.74	907.33
ADVANCES GIVEN FOR EXPENSES	10.65	23.38
SECURITY DEPOSITS - UGVCL	.08	.08
ADVANCES FOR PURCHASE OF FIXED ASSETS	75.00	75.00
GST TAX	3.44	2.48
	1293.59	1070.29
NOTE - 11 - EQUITY SHARE CAPITAL:		
Authorized Capital:		
2,00,00,000 (P.Y. 2,00,00,000) Equity Shares of Rs. 10/- each	2000.00	2000.00
Issued, Subscribed and Paid-up Capital:		
1,00,00,000 (P.Y. 1,00,00,000) Equity Shares of Rs. 10/- each	1000.00	1000.00
	1000.00	1000.00

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

NOTE - 11 - EQUITY SHARE CAPITAL: (CONTD.....)

- a. The Reconciliation of the number of Outstanding Shares as at 31st March, 2026 and 31st March, 2025 is set out below:

Particulars	As at 31.03.2026		As at 31.03.2025	
	Number of Shares	Amount	Number of Shares	Amount
Shares outstanding at the beginning of the year	10,000,000	1000.00	10,000,000	1000.00
Add: issue during the year	-	.00	-	.00
Shares outstanding at the end of the year	10,000,000	1000.00	10,000,000	1000.00

- b. Rights, preferences and restrictions:

The Company has only one class of Equity Shares having Par Value of Rs. 10/- per share. Each holder of equity share is entitled to same Rights based on the number of shares held.

(i) **Equity shares:**

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts and preference shares. The distribution will be in proportion to the number of equity shares held by the shareholders.

(ii) **Dividend:**

Unpaid dividend of F.Y 2022-23 of Rs. 11147/- is lying as bank balance in Dividend Payable Bank Account and shown as other current liabilities.

- c. Shares in the Company held by each shareholders holding more than 5% shares:

Name of Shareholders	No. of Shares Held	Percentage of holding	No. of Shares Held	Percentage of holding
SAMIR SHAH	46,40,113	46.40%	44,42,828	44.43%
DILIPKUMAR BHOGILAL SHAH	10,74,397	10.74%	10,74,397	10.74%

- d. Shares held by promoters at the end of the year 31st March 2026:

Sr. No.	Promoter Name	No. of Shares**	% of total shares**	% Change during the year***
1	SAMIR SHAH	46,40,113	46.40%	1.97%
2	DILIPKUMAR BHOGILAL SHAH	10,74,397	10.74%	0.00%
Total			57.14%	

Shares held by promoters at the end of the year ending 31st March 2025:

Sr. No.	Promoter Name	No. of Shares**	% of total shares**	% Change during the year***
1	SAMIR SHAH	44,42,828	44.43%	0.10%
2	DILIPKUMAR BHOGILAL SHAH	10,74,397	10.74%	0.00%
Total			55.17%	

** Details shall be given separately for each class of shares

*** Percentage change shall be computed with respect to the number at the beginning of the year or if issued during the year for the first time then with respect to the date of issue.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
NOTE - 12 - OTHER EQUITY:		
Retained Earnings		
Balance at the beginning of the year	2129.98	1624.25
Profit for the year	-320.07	505.73
Capital reserves	-	-
Dividend Paid during the year	-	-
Balance at the end of the year	1809.91	2129.98
(Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, any transfers from or to other comprehensive income, dividends or other distributions paid to shareholders.)		
Securities premium		
Balance at the beginning of the year	1878.96	1878.96
Add : Premium arising on shares issued during the year	-	-
Expenses on issue of equity shares	-	-
Balance at the end of the year	1878.96	1878.96
TOTAL OTHER EQUITY	3688.87	4008.94

a. Retained earnings

Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, any transfers from or to other comprehensive income, dividends or other distributions paid to shareholders.

b. Securities premium

Securities premium is used to record the premium on issue of shares. The reserve is utilised in accordance with the provisions of the Companies Act, 2013.

c. Capital Reserve

Capital Reserve Capital Reserve was created through business combinations and shall be utilised as per the provisions of the Companies Act 2013.

NOTE - 13 - BORROWINGS:
13.1 Non-Current (Secured)
a. From
Standard Chartered Bank

1427.30

1224.25

Company availed Overdraft and Cash Credit from Standard Chartered Bank of Rs. 15,50,00,000/- against Hypothication of Stock & Book Debts.

Comapany management given below collateral Security to Standard Chartered bank:

1. Property Located at Sub Plot no 3 Nr Swetanjali Society, Nr Sachin Tower road, Satellite , Ahmedabad owned by Managing Director Samir Shah
2. Personal guarantee of Samir D Shah, Dilip Shah and Tanvi Shah
3. Commercial office situated office no 501 , 5th floor, Aditraj Arcade, Nr Hetvi Tower, Sanjay Sachin tower road, Satellite, Ahmedabad-380015 owned by Medico Healthcare.
4. Corporate Guarantee of Medico Healthcare.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2025

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2025	As At 31.03.2024
NOTE - 13 - BORROWINGS: (CONTD.....)		
13.1 Non-Current (Secured)		
From ICICI Bank		
Overdraft against FD - ICICI Bank	69.25	52.80
From MERCEDES -BENZ FINANCIAL SERVICE INDIA PVT LTD, CHENNAI		
MERCEDES -BENZ FINANCIAL SERVICE INDIA PVT LTD, CHENNAI	-	27.05
Secured Loan against Hypothecation of Vehicle from Mercedes-Benz Financial Services @ 9% repayable in 36 equal installment		
From The Mehsana Urban Co-Operative Bank Limited, Mehsana		
The Mehsana Urban Co-Operative Bank Limited -Term Loan-Building Construction	281.47	-
The Mehsana Urban Co-Operative Bank Limited -Term Loan-Machinery Purchase	669.57	-
Terms of Repayment:		
1. Term Loans from The Mehsana Urban Co-Operative Bank Limited is repayable in 72 Equal Monthly Instalments.		
Securities Offered - Primary Security		
i) Exclusive charge over Industrial Plot No. 3332 & 3333 situated at Chhatral Industrial Estate, Chhatral, Gandhinagar, Gujarat. Personal Guarantee of 1) Piyush Ranchhodbhai Patel, 2) Jay Sharadbhai Shah, 3) Samir Dilipbhai Shah, 4) Rajeshkumar Kantibhai Patel, 5) Mittallumar Naimeshbhai Patel, 6) Naimeshkumar Haribhai Patel & 7) Hemal Naranbhai Patel. Corporate Guarantee Of Medico Intercontinental Limited.		
Period and Amount of Default:		
Company has defaulted in their obligation of payment of EMI of both the Term Loans and the account has turned Sub-Standard Non Performing Asset. Overdue amount as on 31-03-2025 is of Rs. 1,20,81,747.		
From KOTAK MAHINDRA PRIME LTD		
Car Loan for Porche Car - Kotak Mahindra Prime Ltd	-	-
Car Loan for BMW Car - Kotak Mahindra Prime Ltd	.13	
Car Loan for Honda City Car - Kotak Mahindra Prime Ltd (Against hypothecation of CAR)	1.20	
From The Ahmedabad Mercantile Co-Operative Bank Limited		
Car Loan for xuv 700 Car - The Ahmedabad Mercantile Co-Operative Bank Limited (Against hypothecation of CAR)	15.10	
b. Term Loan		
Non-Current (Unsecured)		
Loans from Director	1098.77	43.15
Inter Corporate Deposits	194.56	-
Other loans and advances	851.17	-
	4608.51	1347.25

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
NOTE - 13 - BORROWINGS: (CONTD.....)		
13.2 Current (Secured)		
Term Loan		
Current Maturities of Long Term Debts	507.40	44.53
Working Capital		
Kotak Mahindra Bank (Refer Note No. (i) Below)	-	76.44
The Ahmedabad Mercantile Co-op Bank Limited (Refer Note No. (ii) and (iii) Below)	200.05	186.47
The Mehsana Urban Co-Operative Bank Limited (Refer Note No. (iv) Below)	1368.14	-
Current Maturities of Car Loan from MERCEDS -BENZ FINANCIAL SERVICE INDIA PVT LTD, CHENNAI	28.32	37.68
(i) Company has availed Cash Credit Limit and Term Loan from Kotak Mahindra Bank Limited of Rs. 2,00,00,000/- against Hypothecation of Stock & Book Debts.		
(ii) Company has availed Cash Credit and Term Loan from The Ahmedabad Mercantile Co-Operative Bank Limited of Rs. 1,09,00,000/- against Hypothecation of Stock & Book Debts.		
(iii) Company has availed Cash Credit and Term Loan from The Ahmedabad Mercantile Co-Operative Bank Limited of Rs. 1,42,00,000/- against Hypothecation of Stock & Book Debts.		
(iv) Overdraft Facility is Secured by Exclusive charge over Industrial Plot No. 3332 & 3333 situated at Chhatral Industrial Estate, Chhatral, Gandhinagar, Gujarat. Personal Guarantee of 1) Piyush Ranchhodbhai Patel, 2) Jay Sharadbhai Shah, 3) Samir Dilipbhai Shah, 4) Rajeshkumar Kantibhai Patel, 5) Mittallumar Naimeshbhai Patel, 6) Naimeshkumar Haribhai Patel & 7) Hemal Naranbhai Patel. Corporate Guarantee Of Medico Intercontinenatl Limited		
Borrowing from Others	-	-
	2103.90	345.13
NOTE - 14 - OTHER FINANCIAL LIABILITIES:		
Security Rent Deposit - TVS MOTOR COMPANY LTD	-	53.27
	-	53.27
NOTE - 15 - OTHER NON-CURRENT FINANCIAL LIABILITIES:		
Trade / Security Deposits Received	.30	.30
	.30	.30
NOTE - 16 - OTHER FINANCIAL LIABILITIES - CURRENT:		
HDFC Fortuner Car Loan	-	0.00
Kotak Mahindra Bank Term Loan	-	0.00
Kotak Mahindra Prime Limited (TUV Loan)	-	0.00
Interest accrued-The Mehsana Urban Co-Operative Bank Limited TERM LOAN	10.12	0.00
	10.12	0.00

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	As At 31.03.2026	As At 31.03.2025
-------------	---------------------	---------------------

NOTE - 17 - TRADE PAYABLES:**Unsecured**

Trade Payables*

- Outstanding dues of Micro and Small Enterprises (Refer Note 34)	124.62	151.97
- Others for Goods and Expenses	1286.50	573.34
	1411.12	725.31

Trade Payables ageing schedule: As at 31st March, 2026:

Particulars	Outstanding for following periods from due date of payment					Total
	Not Dues	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	124.62	-	-	-	-	124.62
(ii) Others	617.63	469.08	159.06	27.12	13.60	1286.50
(iii) Disputed dues- MSME					-	-
(iv) Disputed dues - Others					-	-

Trade Payables ageing schedule: As at 31st March, 2025:

Particulars	Outstanding for following periods from due date of payment					Total
	Not Dues	Less than 1 year	1-2 years	2-3 years		
(i) MSME	151.97	-	-	-		151.97
(ii) Others	555.47	17.87	-	-		573.34
(iii) Disputed dues- MSME						-
(iv) Disputed dues - Others						-

Particulars	As At 31.03.2026	As At 31.03.2025
-------------	---------------------	---------------------

NOTE - 18 - OTHER CURRENT LIABILITIES:

Audit fees Payable	1.76	1.48
Statutory dues - TDS	26.45	9.92
Provident Fund Payable	2.21	.59
Employees' State Insurance Corporation Payable	.25	-
Professional Tax Payable	.26	.15
Telephone Exp Payable	.09	.08
GST Payable	9.37	8.89
Payable for Expenses	80.79	62.38
Advances from Customers	46.18	15.68
Payable to Others	-	-
Electricity Expenses Payable	.12	.22
TCS Payable	-	.31
Dividend Payable	.11	.11
	167.59	99.80

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	Year ended 31.03.2026	Year ended 31.03.2025
NOTE - 19 - CURRENT TAX LIABILITIES (NET):		
Provision for Tax	79.41	75.90
	79.41	75.90
NOTE - 20- PROVISIONS:		
20.1 Long term provisions		
Gratuity provision	32.31	22.77
	32.31	22.77
20.2 Short term provisions		
Gratuity provision	1.67	1.26
	1.67	1.26
NOTE - 21 - REVENUE FROM OPERATIONS:		
Sales of Pharmaceutical Products	8408.41	9531.53
	8408.41	9531.53
NOTE - 22 - OTHER INCOME:		
Interest Income	41.84	23.23
Commission Income	5.40	9.52
OFFICE RENT (ARK)	15.78	0.00
MAINTANCE INCOME (OFFICE)	1.73	0.00
Other Income	1.77	.00
Interest Fd income	10.41	8.71
Dividend	.24	.24
PROFIT ON SALE OF PROPERTY (ARK)	49.88	
Profit from Partnership Firm - Medico lab	-	-
Bank Charges	-	.01
	127.04	41.71
NOTE - 23 - COST OF MATERIALS CONSUMED:		
Opening stock of Raw / Packing Materials	35.57	-
Add: Gross Purchase	895.24	-
	930.81	-
Less: Closing stock of Raw / Packing Materials	-160.91	-
	769.90	-
NOTE - 24 - PURCHASES OF STOCK IN TRADE:		
Purchases	5396.73	7252.23
	5396.73	7252.23
NOTE - 25 - CHANGE IN INVENTORIES:		
Opening Stock	1431.22	1043.97
Less: Closing Stock	1332.45	851.73
	98.77	192.24

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2025

(Rs. in Lakhs unless otherwise stated)

Particulars	Year ended 31.03.2025	Year ended 31.03.2024
NOTE - 26 - EMPLOYEE BENEFITS EXPENSE:		
Bonus	18.05	14.47
Provident Fund Exp	12.09	3.64
Staff Welfare	10.19	2.24
Leave Encashment Expenses	11.34	8.98
Remuneration of Directors	91.13	96.46
Salary	648.44	294.84
Sales Incentive	73.55	36.17
Employees' State Insurance Corporation Expenses	1.83	-
Gratuity	9.95	9.18
Arears (Salary)	-	-
	876.57	465.99
NOTE - 27 - FINANCE COSTS:		
Interest Expenses	794.65	96.48
Bank Charges	16.21	1.74
Processing Charges	4.66	1.09
Other Borrowing Costs	.40	-
	815.92	99.31
NOTE - 28 - OTHER EXPENSES:		
Listing Fees	3.25	3.25
Professional Fees	26.04	9.66
Auditors Remuneration (For statutory audit)		
- For Audit	6.25	5.30
ROC Filing Fees	.40	7.73
Office Rent Expenses	16.23	14.44
Advertisement Expenses	18.02	10.50
Amortization Of Preliminary Exp	20.61	
Annual Issuer Fees	.94	.81
Biomedical Waste Exp	.29	
Calibration Charges	5.81	
EGM/AGM Expenses	.31	.34
Factory Exp.	6.64	
Freight Expenses	54.51	52.80
Freight Exp [OUTWARD] 5%	3.80	3.42
Freight Exp (OUTWARD)12%	.68	6.05
Freight Exp (OUTWARD)18%	9.22	.24
GIDC EXP	6.99	
Godown Maintenance	.36	.38
Godown Rent	22.56	22.85
Ineligible Gst Credit Exp.	.21	
Plate Charges	.06	0.00
Product Permission Charges	.21	.01

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	Year ended 31.03.2026	Year ended 31.03.2025
NOTE - 28 - OTHER EXPENSES: (CONTD.....)		
Rounding Off (Other)	.00	.00
Sales Promotion	42.56	108.72
Share Transfer Agent Fees	.94	.97
Stationery & Printing Exp	7.79	4.61
Stationery & Printing Exp	.23	.27
Security Exp.	9.38	-
Commission Exp	227.72	412.74
Brokerage	-	2.66
Conveyance Petrol Exp	19.05	7.59
Electricity Expenses	105.37	5.96
Kasar & Discount	.14	.15
Licence Fees	.16	.16
Office & Canteen Expenses	4.31	3.92
Office [GODOWN] Misc. Exp.	30.81	11.70
Professional Tax (Firm)	.12	.12
Legal Exp	9.34	6.74
Municipal Tax	5.10	7.04
Celo Tape Printed	.65	.60
Trademark (Legal Exp)	1.02	1.79
Insurance Expenses	38.47	9.85
Digital Sign Exp	.09	.06
FILM Fees	.10	.10
Other Exp	4.31	.21
Computer Exp	3.97	3.60
Donation	14.00	1.44
Office Maintenance Exp	14.18	2.63
Packing Exp	5.27	2.95
Postage & Courier Exp	30.29	34.30
Loss Motor Car	-	.98
Sales Incentive Exp	-	1.26
Telephone Exp	3.06	4.28
Electric Repairing Exp	4.29	.49
Machinery Repair Maintenance and Service Exp	21.01	.54
Maintenance Exp (Software)	.32	.34
Repairs and Maintenance	.13	.39
Registration Fees	.80	-
Tours & Travels Exp	49.14	17.38
GST Fees	-	.09
Vehicle Exp	2.12	1.18
Office Expenses	2.67	2.35
Cylinder Expenses	.29	.14
Expired and Damaged Goods	.24	.54
Bad Debts	7.55	2.62

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in Lakhs unless otherwise stated)

Particulars	Year ended 31.03.2026	Year ended 31.03.2025
NOTE - 28 - OTHER EXPENSES: (CONTD.....)		
Discount	1.15	.23
Interest on TDS	-	-
Inventory Charges	.06	-
Testing Expenses	28.68	.02
Bank Charges & Bank Interest	.29	.28
ISO Certification Exp	-	.07
LEI Exp	.04	.04
Office Safety Exp	-	.24
Membership Fees	.06	.07
Gst Exp	.49	.43
DPCO Expenses	.48	0.00
Other Expenses	.15	
Water Bill Exp.	1.68	
Late Fee Gst	.01	.03
Late Fee Amc	-	.00
Contract Labour Exp	53.63	
Interest & Penalty Exp	2.37	-
Interest Custom Duty	.34	
Foreign Exchange Loss/(Gain)	9.06	
	968.85	802.66

NOTE - 29 - EARNINGS PER SHARE (EPS):

a) Weighted Average Number of Equity Shares Outstanding during the Year	1,00,00,000.00	1,00,00,000.00
b) Net Profit after Tax available for Equity Shareholders	-320.07	505.73
c) Basic and Diluted Earnings Per Share (Rs.)	-3.20	5.06

The Company does not have any outstanding dilutive potential Equity Shares.

NOTE - 30 - CONTINGENT LIABILITIES:

Corporate guarantee to wholly owned subsidiary company	3342.83	451.00
Liabilities disputed - appeals filed with respect to Disputed GST tax	37.28	27.64
	3380.11	478.64

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 31 - SEGMENTAL REPORTING:

(A) On the basis of Business Segments

Particulars	As at 31.03.2026		As at 31.03.2025	
	Trading	Total	Trading	Total
External Revenues	8535.46	8535.46	9573.23	9573.23
Internal Segment Revenues	0.00	0.00	0.00	0.00
Other Non-allocable Income	0.00	0.00	0.00	0.00
Total Revenues	8535.46	8535.46	9573.23	9573.23
Less: Elimination	0.00	0.00	0.00	0.00
Total Revenues	8535.46	8535.46	9573.23	9573.23
External Expenses	9469.49	9469.49	8891.12	8891.12
Other Non-Allocable Expenses	0.00	0.00	0.00	0.00
Non Reportable Segment Revenue	0.00	0.00	0.00	0.00
Other Income	0.00	0.00	0.00	0.00
Interest Cost	0.00	0.00	0.00	0.00
Total Expenditure	9469.49	9469.49	8891.12	8891.12
Provision for Taxes/ Deferred Tax	175.06	175.06	186.59	186.59
NET PROFIT/(LOSS)	-1109.10	-1109.10	495.53	495.53

Particulars	As at 31.03.2026		As at 31.03.2025	
	Trading	Total	Trading	Total
OTHER INFORMATION				
Segment Assets	11725.82	11725.82	7691.94	7691.94
Unallocable Corporate Assets	0.00	0.00	0.00	0.00
TOTAL ASSETS	11725.82	11725.82	7691.94	7691.94
Segment Liabilities	8499.22	8499.22	2683.00	2683.00
Unallocable Liabilities	0.00	0.00	0.00	0.00
TOTAL LIABILITIES	8499.22	8499.22	2683.00	2683.00
CAPITAL EXPENDITURE				
Segment Capital Expenditure	729.96	729.96	591.85	591.85
Unallocable Capital Expenses	0.00	0.00	0.00	0.00
TOTAL CAPITAL EXPENDITURE	729.96	729.96	591.85	591.85
DEPRECIATION & AMORTIZATION				
Segment Depreciation & Amortization	544.10	544.10	78.69	78.69
Unallocated Depreciation & Amortization	0.00	0.00	0.00	0.00
TOTAL DEPRECIATION & AMORTIZATION	544.10	544.10	78.69	78.69

(B) Other Disclosures :-

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (IND AS-108) taking into account the organization structure as well as the differential risks and returns of these segments.
2. The Company has disclosed Business Segment as the primary segment.
3. The Segment Revenues, Results, Assets and Liabilities include the respective amount identifiable to each of the segment and amounts allocated on a reasonable basis.

Note:- Above details complied by the Management and relied upon by the Auditors.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 32 - FAIR VALUE MEASUREMENTS:

(Rs. in Lakhs unless otherwise stated)

a. Financial instruments by category:

Particulars	As at March 31, 2026		As at March 31, 2025	
	FVOCI	Amortised cost	FVOCI	Amortised cost
Financial Assets				
Investments				
- Equity / Pref Instruments	0.00	2.05	0.00	2.00
Joint venture/Associates/Other Investments	0.00	227.92	0.00	298.54
Non Current Loans	0.00	130.00		-
Fixed Deposits with Bank	0.00	-	0.00	-
Trade Receivables	0.00	2741.60	0.00	3232.69
Cash and Cash Equivalents	0.00	596.08	0.00	224.42
Loans	0.00	-	0.00	100.80
Total Financial Assets	0.00	3697.65	0.00	3858.45
Financial Liabilities				
Borrowings	0.00	6712.42	0.00	1692.38
Other Financial Liabilities	0.00	10.12	0.00	53.27
Total Financial Liabilities	0.00	6722.54	0.00	1745.65

b. Fair value hierarchy:

Financial Assets and Liabilities measured at Fair Value - March 31 2026	Note No.	Level 1	Level 2	Level 3	Total
Financial Assets					
Investments					
- Equity / Pref Instruments		0.00	0.00	0.00	0.00
Total Financial Assets		0.00	0.00	0.00	0.00
Financial Assets and Liabilities measured at Amortised Cost - 31st March, 2026	Note No.	Level 1	Level 2	Level 3	Total
Financial Assets					
Investments					
- Equity / Pref Instruments	3.1	0.00	0.00	2.05	2.05
Joint venture/Associates/Other Investments	3.1	0.00	0.00	227.92	227.92
Non Current Loans	3.2			130.00	130.00
- Fixed Deposits with Bank	3.1	0.00	0.00	-	-
Trade Receivables	7	0.00	0.00	2741.60	2741.60
Cash and Cash Equivalents	8	0.00	0.00	596.08	596.08
Loans	9	0.00	0.00	-	-
Total Financial Assets		0.00	0.00	3697.65	3697.65
Non Financial Assets					
Investment properties	2.3	0.00	0.00	-	-
Total Non Financial Assets		0.00	0.00	-	-
Financial Liabilities					
Borrowings	12	0.00	0.00	6712.42	6712.42
Other Financial Liabilities	14	0.00	0.00	10.12	10.12
Total Financial Liabilities		0.00	0.00	6722.54	6722.54

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 32 - FAIR VALUE MEASUREMENTS: (CONTD.....) (Rs. in Lakhs unless otherwise stated)

b. Fair value hierarchy:

Financial Assets and Liabilities measured at Fair Value - 31st March, 2025	Notes No.	Level 1	Level 2	Level 3	Total
Financial Assets					
Investments					
- Equity / Pref Instruments		0.00	0.00	0.00	0.00
Total Financial Assets		0.00	0.00	0.00	0.00
Financial Assets and Liabilities measured at Amortised Cost - 31st March, 2025	Notes No.	Level 1	Level 2	Level 3	Total
Financial Assets					
Investments					
- Equity / Pref Instruments	3.1	-	-	2.00	2.00
Joint venture/Associates/Other Investments	3.1	-	-	298.54	298.54
- Fixed Deposits with Bank	3.1			-	-
Trade Receivables	7	-	-	3232.69	3232.69
Cash and Cash Equivalents	8	-	-	224.42	224.42
Loans	9	-	-	100.80	100.80
Total Financial Assets		-	-	3858.45	3858.45
Non Financial Assets					
Investment properties	2.3	-	-	398.86	398.86
Total Non Financial Assets				398.86	398.86
Financial Liabilities					
Borrowings	12	-	-	1692.38	1692.38
Other Financial Liabilities	14	-	-	53.27	53.27
Total Financial Liabilities		-	-	1745.65	1745.65

*Fair value of Instruments is classified in various fair value hierarchies based on the following three levels:

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques, which maximise the use of observable market data and rely as little as possible on entity specific estimates. If significant inputs required to fair value an instruments are observable, the instrument is included in Level 2.

Level 3: If one or more of the significant inputs are not based on observable market data, the instruments is included in level 3.

Management uses its best judgement in estimating the fair value of its financial instruments. However, there are inherent limitations in any estimation technique. Therefore, for substantially all financial instruments, the fair value estimates presented above are not necessarily indicative of the amounts that the Company could have realized or paid in sale transactions as of respective dates. As such, the fair value of financial instruments subsequent to the reporting dates may be different from the amounts reported at each reporting date.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026
NOTE - 33 - RELATED PARTY DISCLOSURES NATURE OF RELATIONSHIP AND TRANSACTION WITH RELATED PARTIES:
1 Related Parties and their Relationship:

a) Holding Company: Medico Intercontinental Limited

b) Key Management Personnel:

Mr. Samir D Shah	Managing Director
Mr. Jay S Shah	Chief Financial Officer
Mr. Dilipkumar B Shah	Chief Executive Officer
Ms. Puneeta Sharma	Company Secretary & Compliance Officer
Mr. Dilipkumar B Shah	Director
Mr. Sharad B Shah	Director
Mr. Ronak K Shah	Director
Mrs. Khushboo R Shah	Director
Mrs. Tanvi S Shah	Director
Mr. Krushant C Parekh	Director
Mr. Pavankumar R Varma	Director
Mr. Yogendra G Rathod	Director
Mr. Nilesh D patel	Director
Mr. . Paresh J patel	Director
Mr. Shailesh S Patel	Director

c) Independent and Non-Executive Directors:

Mr. Ankur A Dave	Independent Director
Mr. Priyank L Sancheti	Independent Director
Mr. Parshwa Shah	Independent Director
Mrs. Tanvi S Shah	Non-Executive Director
Mrs. Swati V Shah	Non-Executive Director

d) Enterprises over which key management personnel are able to exercise significant influence:

Name of enterprise	Director/Partner/Employee
Sungrace Pharma	Proprietorship Firm in which Mr. Ronak Shah is Proprietor
Oxford Pharma	Partnership Firm in which Mr. Samir Shah is Partner
Ritz Formulations Private Limited	Wholly Owned Subsidiary of Holding Company
Evagrace Pharma Private Limited	Wholly Owned Subsidiary of Holding Company
Azillian Healthcare Private Limited	Wholly Owned Subsidiary of Holding Company
Sungrace Pharma Private Limited	Wholly Owned Subsidiary of Holding Company
Calborn Lifescience Private Limited	Subsidiary Company
Medico Lab	Joint Venture
Flora Marketing	Proprietorship Firm in which Mrs. Tanvi Shah is Proprietor
Kingston Infracon	Partnership Firm in which Mr. Samir Shah & Mr. Dilipkumar Shah are Partners
Medico Healthcare	Partnership Firm in which Mr. Samir Shah & Mr. Dilipkumar Shah are Partners
Ritz Pharma	Partnership Firm in which Mr. Samir Shah & Mr. Dilipkumar Shah are Partners
Kingston Café	Proprietorship firm in which Mr. Samir Shah is Proprietor

e) Relatives of Key Managerial Personnel

Ms. Diya Samir Shah	Daughter of Tanvi Samir Shah & Samir Dilip Shah
Mrs. Vidhi K Parekh	Wife of Mr. Krushant Parekh
Mrs. ANJU P VARMA	Wife of Mr. Pavan Varma
Mrs. KRISHNA Y RATHOD	Wife of Mr. Yogendra Rathod
Mrs. Chetnaben P Patel	Wife Of Mr. Paresh Patel
Mr. Jyanti G patel	Father Of Mr. Paresh Patel
Mrs. Vasumatiben J patel	Mother Of Mr. Paresh Patel
Mr. Aum P Patel	Son of Mr. Paresh Patel

f) Others

Name of Related Party	Relationship
LYF Pharma Distributor	Enterprise in which Directors of Subsidiary Company is having significant influence

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026
NOTE - 33 - RELATED PARTY DISCLOSURES NATURE OF RELATIONSHIP AND TRANSACTION WITH RELATED PARTIES: (CONTD.....)
2(a) Related Party Transactions entered during the year: (Rs. in Lakhs unless otherwise stated)

Particulars	Enterprises trusts over which significant influence exercised by key management personnel		Key Managerial Personnel		Joint Venture Parties		Other Related		Total	
	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025
Purchase of Goods	856.23	892.48	-	-	27.60	8.49	-	-	883.83	900.97
Purchase of Fixed Assets	-	-	-	-	-	-	-	-	-	-
Sale of goods	861.07	784.76	-	-	300.62	308.16	-	1750.45	1161.69	2843.38
Rent/Vehicle Hire Charges paid	20.23	20.23	9.73	9.73	-	-	-	-	29.96	29.96
Interest Paid	-	-	18.17	4.75	-	-	33.81	-	51.99	4.75
Interest received	-	-	-	-	25.91	12.34	-	-	25.91	12.34
Sale Promotion Exp	2.26	80.84	-	-	-	-	-	-	2.26	80.84
Staff Welfar	-	-	-	-	-	-	-	-	-	-
OFFICE & CANTEEN	-	-	-	-	-	-	-	-	-	-
Capital contribution	-	-	-	-	8.47	286.20	-	-	8.47	286.20
Capital withdrawal	-	-	-	-	105.00	-	-	-	105.00	-
Loans Taken	-	-	640.01	-	-	-	-	-	640.01	-
Loans Repayment	-	-	4.50	2.84	-	-	-	-	4.50	2.84
Remuneration on A/c of Salary & Perquisites	-	-	178.09	155.53	-	-	58.13	38.36	236.22	193.89

2(b) Balance Outstanding at the end of the Financial Year:

Particulars	Enterprises trusts over which significant influence exercised by key management personnel		Key Managerial Personnel		Joint Venture		Other Related Parties		Total	
	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025	March 31,2026	March 31,2025
Receivable/ (Payable) on account of goods sale/services rendered/ received	172.17	654.88	-10.83	-6.52	46.89	62.59	-20.91	294.57	187.33	1005.52
Receivable on account of Security deposit/Prepaid Lease	-	-	-	-	-	-	-	-	-	-
Receivable on account of Capital contribution	-	-	-	-	227.92	298.54	-	-	227.92	298.54
Payable on account of Loans Taken	-	-	745.30	43.15	-	-	30.11	-	775.41	43.15
Corporate Guarantee	-	-	3342.83	451.00	-	-	-	-	3342.83	451.00

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTES - 34 - ADDITIONAL INFORMATION REGARDING SUBSIDIARIES COMPANIES, JOINT VENTURES, ASSOCIATES ENTITIES:

(Rs. in Lakhs unless otherwise stated)

YEAR 2024-25								
Name of the Entity	Net Assets, i.e. Total Assets minus Total Liabilities		Share in Profit or Loss		Share in Other Comprehensive Income		Share in Total Comprehensive Income	
	As % of Consoli- dated Net Assets	Amount	As % of Consoli- dated Profit or Loss	Amount	As % of Consoli- dated Profit or Loss	Amount	As % of Consoli- dated Profit or Loss	Amount
PARENT COMPANY								
Medico Intercontinental Limited	77.18%	3866.15	50.73%	256.58	0	0	50.73%	256.58
SUBSIDIARY COMPANIES								
Ritz Formulations Private Limited	4.01%	200.87	7.06%	35.70	0	0	7.06%	35.70
Sungrace Pharma Private Limited	4.08%	204.25	7.05%	35.67	0	0	7.05%	35.67
Evagrace Pharma Private Limited	1.82%	91.00	5.64%	28.51	0	0	5.64%	28.51
Azillian Healthcare PVT LTD	12.91%	646.68	29.52%	149.27	0	0	29.52%	149.27
MINORITY RESERVE SUBSIDIARY COMPANIES								
TOTAL	100.00%	5008.94	100.00%	505.73	%	0	100.00%	505.73
YEAR 2025-26								
Name of the Entity	Net Assets, i.e. Total Assets minus Total Liabilities		Share in Profit or Loss		Share in Other Comprehensive Income		Share in Total Comprehensive Income	
	As % of Consoli- dated Net Assets	Amount	As % of Consoli- dated Profit or Loss	Amount	As % of Consoli- dated Profit or Loss	Amount	As % of Consoli- dated Profit or Loss	Amount
PARENT COMPANY								
Medico Intercontinental Limited	126.59%	4084.51	-68.22%	218.36	0	0	-68.22%	218.36
SUBSIDIARY COMPANIES								
Ritz Formulations Private Limited	7.47%	240.90	-12.51%	40.03	0	0	-12.51%	40.03
Sungrace Pharma Private Limited	7.54%	243.33	-12.21%	39.08	0	0	-12.21%	39.08
Evagrace Pharma Private Limited	3.93%	126.95	-11.23%	35.94	0	0	-11.23%	35.94
Azillian Healthcare Private Limited	24.88%	802.92	-48.82%	156.24	0	0	-48.82%	156.24
Calborn Lifescience Private Limited	-70.41%	-2272.00	252.99%	-809.73	0	0	252.99%	-809.73
MINORITY RESERVE SUBSIDIARY COMPANIES								
TOTAL	100.00%	3226.60	100.00%	-320.07	0	0	100.00%	-320.07

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 35 - EMPLOYEE BENEFIT:

a) Defined Contribution plan:

Provident fund

State defined contribution plans

Employers' contribution to employees' state insurance

Employers' contribution to employees' pension scheme 1995

The provident fund and the state defined contribution plans are operated by the Regional Provident Fund Commissioner. Under the scheme, the Company is required to contribute a specified percentage of payroll cost to the retirement benefit scheme to fund the benefits. These funds are recognized by the income tax authorities. The contribution of the Company to the provident fund and other contribution plans for all employees is charged to the Consolidated Statement of Profit and Loss.

The Company has recognized the following amounts in the Consolidated Statement of Profit and Loss for the year

(Rs. in Lakhs)

PARTICULAR	2025-26	2024-25
Contribution to Provident Fund	12.09	3.64
Total	12.09	3.64

Estimation of social security code:

The Parliament of India has approved the Code on Social Security, 2020 (the Code), which may impact the contributions by the Company towards provident fund, gratuity and ESIC. The Ministry of Labour and Employment, Government of India has released draft rules for the Code on November 13, 2020. Final rules are yet to be notified. The Company will assess the impact of the Code when it comes into effect and will record related impact, if any.

b) Defined benefit plan:

Gratuity

(Rs. in Lakhs)

PARTICULAR	2025-26	2024-25
Type of Benefit	Gratuity	Gratuity
Country	India	India
Reporting Currency	INR	INR
Reporting Standard	Indian Accounting Standard 19 (Ind AS 19)	Indian Accounting Standard 19 (Ind AS 19)
Funding Status	Unfunded	Unfunded
Starting Period	01-Apr-25	01-Apr-24
Date of Reporting	31-Mar-26	31-Mar-25
Period of Reporting	12 Months	12 Months
Assumptions (Current Period)		
Expected Return on Plan Assets	N.A.	N.A.
Rate of Discounting	7.24%	6.73%
Rate of Salary Increase	7.00%	7.00%
Rate of Employee Turnover	7.00%	7.00%
Mortality Rate During Employment	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012-14 (Urban)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 35 - EMPLOYEE BENEFIT: (CONTD.....)

b) Defined benefit plan:

Gratuity

(Rs. in Lakhs)

PARTICULAR	Current Period	Previous Period
Table Showing Change in the Present Value of Defined Benefit Obligation		
Present Value of Benefit Obligation at the Beginning of the Period	24.03	14.85
Interest Cost	1.62	1.07
Current Service Cost	7.19	7.13
Past Service Cost	-	-
Liability Transferred In/ Acquisitions	-	-
(Liability Transferred Out/ Divestments)	-	-
(Gains)/ Losses on Curtailment	-	-
(Liabilities Extinguished on Settlement)	-	-
(Benefit Paid Directly by the Employer)	-	-
(Benefit Paid From the Fund)	-	-
The Effect Of Changes in Foreign Exchange Rates	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic Assumptions	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	(1.77)	0.86
Actuarial (Gains)/Losses on Obligations - Due to Experience	2.91	0.12
Present Value of Benefit Obligation at the End of the Period	33.98	24.03
Table Showing Change in the Fair Value of Plan Assets		
Fair Value of Plan Assets at the Beginning of the Period	-	-
Interest Income	-	-
Contributions by the Employer	-	-
Expected Contributions by the Employees	-	-
Assets Transferred In/Acquisitions	-	-
(Assets Transferred Out/ Divestments)	-	-
(Benefit Paid from the Fund)	-	-
(Assets Distributed on Settlements)	-	-
Effects of Asset Ceiling	-	-
The Effect of Changes In Foreign Exchange Rates	-	-
Return on Plan Assets, Excluding Interest Income	-	-
Fair Value of Plan Assets at the End of the Period	-	-
Amount Recognized in the Balance Sheet		
(Present Value of Benefit Obligation at the end of the Period)	(33.98)	(24.03)
Fair Value of Plan Assets at the end of the Period	-	-
Funded Status (Surplus/ (Deficit))	(33.98)	(24.03)
Net (Liability)/Asset Recognized in the Balance Sheet	(33.98)	(24.03)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 35 - EMPLOYEE BENEFIT: (CONTD.....)

b) Defined benefit plan:

Gratuity

(Rs. in Lakhs)

PARTICULAR	Current Period	Previous Period
Net Interest Cost for Current Period		
Present Value of Benefit Obligation at the Beginning of the Period	24.03	14.85
(Fair Value of Plan Assets at the Beginning of the Period)	-	-
Net Liability/(Asset) at the Beginning	24.03	14.85
Interest Cost	1.62	1.07
(Interest Income)	-	-
Net Interest Cost for Current Period	1.62	1.07
Expenses Recognized in the Statement of Profit or Loss for Current Period		
Current Service Cost	7.19	7.13
Net Interest Cost	1.62	1.07
Past Service Cost	-	-
(Expected Contributions by the Employees)	-	-
(Gains)/Losses on Curtailments And Settlements	-	-
Net Effect of Changes in Foreign Exchange Rates	-	-
Expenses Recognized	8.81	8.20
Expenses Recognized in the Other Comprehensive Income (OCI) for Current Period		
Actuarial (Gains)/Losses on Obligation For the Period	1.14	0.98
Return on Plan Assets, Excluding Interest Income	-	-
Change in Asset Ceiling	-	-
Net (Income)/Expense For the Period Recognized in OCI	1.14	0.98
Balance Sheet Reconciliation		
Opening Net Liability	24.03	14.85
Expenses Recognized in Statement of Profit or Loss	8.81	8.20
Expenses Recognized in OCI	1.14	0.98
Net Liability/(Asset) Transfer In	-	-
Net (Liability)/Asset Transfer Out	-	-
(Benefit Paid Directly by the Employer)	-	-
(Employer's Contribution)	-	-
Net Liability/(Asset) Recognized in the Balance Sheet	33.98	24.03
Category of Assets		
Government of India Assets	-	-
State Government Securities	-	-
Special Deposits Scheme	-	-
Debt Instruments	-	-
Corporate Bonds	-	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026**NOTE - 35 - EMPLOYEE BENEFIT: (CONTD.....)****b) Defined benefit plan:****Gratuity****(Rs. in Lakhs)**

PARTICULAR	Current Period	Previous Period
Cash And Cash Equivalents	-	-
Insurance fund	-	-
Asset-Backed Securities	-	-
Structured Debt	-	-
Other	-	-
Total	-	-
Other Details		
No. of Members in Service	98	83
Per Month Salary For Members in Service	19.56	15.18
Weighted Average Duration of the Defined Benefit Obligation	12	12
Average Expected Future Service	10	10
Defined Benefit Obligation (DBO) - Total	33.98	24.03
Defined Benefit Obligation (DBO) - Due but Not Paid	-	-
Expected Contribution in the Next Year	-	-
Net Interest Cost for Next Year		
Present Value of Benefit Obligation at the End of the Period	33.98	24.03
(Fair Value of Plan Assets at the End of the Period)	-	-
Net Liability/(Asset) at the End of the Period	33.98	24.03
Interest Cost	2.46	1.62
(Interest Income)	-	-
Net Interest Cost for Next Year	2.46	1.62
Expenses Recognized in the Statement of Profit or Loss for Next Year		
Current Service Cost	9.62	7.19
Net Interest Cost	2.46	1.62
(Expected Contributions by the Employees)	-	-
Expenses Recognized	12.08	8.81
Maturity Analysis of the Benefit Payments		
Projected Benefits Payable in Future Years From the Date of Reporting		
1st Following Year	1.67	1.26
2nd Following Year	2.04	1.38
3rd Following Year	2.45	1.57
4th Following Year	2.32	1.82
5th Following Year	2.62	1.73
Sum of Years 6 To 10	14.73	9.81
Sum of Years 11 and above	61.76	41.12

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 35 - EMPLOYEE BENEFIT: (CONTD.....)

b) Defined benefit plan:

Gratuity

(Rs. in Lakhs)

PARTICULAR	Current Period	Previous Period
Sensitivity Analysis		
Defined Benefit Obligation on Current Assumptions	33.98	24.03
Delta Effect of +1% Change in Rate of Discounting	(3.09)	(2.24)
Delta Effect of -1% Change in Rate of Discounting	3.66	2.67
Delta Effect of +1% Change in Rate of Salary Increase	3.64	2.63
Delta Effect of -1% Change in Rate of Salary Increase	(3.12)	(2.25)
Delta Effect of +1% Change in Rate of Employee Turnover	(0.22)	(0.20)
Delta Effect of -1% Change in Rate of Employee Turnover	0.21	0.22

The sensitivity analysis have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

The sensitivity analysis presented above may not be representative of the actual change in the Defined Benefit Obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the Defined Benefit Obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same method as applied in calculating the Defined Benefit Obligation as recognized in the balance sheet.

Notes :

Gratuity is payable as per entity's scheme as detailed in the report.

Actuarial gains/losses are recognized in the period of occurrence under Other Comprehensive Income (OCI). All above reported figures of OCI are gross of taxation.

Since it is the first year of the company's operations, we have considered the Current Service Cost to be the same as the Defined Benefit Obligation.

Salary escalation & attrition rate are considered as advised by the entity; they appear to be in line with the industry practice considering promotion and demand & supply of the employees.

Maturity Analysis of Benefit Payments is undiscounted cashflows considering future salary, attrition & death in respective year for members as mentioned above.

Average Expected Future Service represents Estimated Term of Post - Employment Benefit Obligation.

Weighted Average Duration of the Defined Benefit Obligation is the weighted average of cash flow timing, where weights are derived from the present value of each cash flow to the total present value.

Any benefit payment and contribution to plan assets is considered to occur at the end of the period to depict liability and fund movement in the disclosures.

Qualitative Disclosures	
Para 139 (a) Characteristics of defined benefit plan	
The Entity has a defined benefit gratuity plan in India (unfunded). The Entity's defined benefit gratuity plan is a final salary plan for employees. Gratuity is paid from entity as and when it becomes due and is paid as per entity scheme for Gratuity.	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

NOTE - 35 - EMPLOYEE BENEFIT: (CONTD.....)

Para 139 (b) Risks associated with defined benefit plan	
Gratuity is a defined benefit plan and entity is exposed to the Following Risks: Interest rate risk: A fall in the discount rate which is linked to the G.Sec. Rate will increase the present value of the liability requiring higher provision. Salary Risk: The present value of the defined benefit plan liability is calculated by reference to the future salaries of members. As such, an increase in the salary of the members more than assumed level will increase the plan's liability. Asset Liability Matching Risk: The plan faces the ALM risk as to the matching cash flow. Entity has to manage pay-out based on pay as you go basis from own funds. Mortality risk: Since the benefits under the plan is not payable for life time and payable till retirement age only, plan does not have any longevity risk.	
Para 139 (c) Characteristics of defined benefit plans	
During the year, there were no plan amendments, curtailments and settlements.	
Para 147 (a)	
Gratuity plan is unfunded.	

NOTE - 36 - FINANCIAL RISK MANAGEMENT:

The Group is exposed to market risk (fluctuation in foreign currency exchange rates, price and interest rate), liquidity risk and credit risk, which may adversely impact the fair value of its financial instruments. The Group assesses the unpredictability of the financial environment and seeks to mitigate potential adverse effects on the financial performance of the Company.

(A) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of currency risk, interest rate risk and price risk. Financial instruments affected by market risk include loans and borrowings, trade receivables and trade payables involving foreign currency exposure. The sensitivity analyses in the following sections relate to the position as at March 31, 2026 and March 31, 2025.

The sensitivity of the relevant profit or loss item is the effect of the assumed changes in respective market risks. This is based on the financial assets and financial liabilities held at 31st March, 2026 and 31st March, 2025.

(i) Foreign currency exchange rate risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company did not undertake any transactions in foreign currencies during the year ended March 31, 2026. Consequently, the Company has no outstanding receivables, payables, or underlying exposure to foreign currency risk as of March 31, 2026, and sensitivity analysis is not applicable.

(ii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of change in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's debt obligations with floating interest rates. As the Group has certain debt obligations with floating interest rates, exposure to the risk of changes in market interest rates are dependent of changes in market interest rates. Management monitors the movement in interest rate and, wherever possible, reacts to material movements in such rates by restructuring its financing arrangement.

As the Group has no significant interest-bearing assets, the income and operating cash flows are substantially independent of changes in market interest rates.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026
NOTE - 36 - FINANCIAL RISK MANAGEMENT: (CONTD.....)
(B) Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Credit risk encompasses both, the direct risk of default and the risk of deterioration of credit worthiness.

Credit risk arises primarily from financial assets such as trade receivables, investments in mutual funds, cash and cash equivalent and other balances with banks.

In respect of trade receivables, credit risk is being managed by the Group through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. All trade receivables are also reviewed and assessed for default on a regular basis. The concentration of credit risk is limited due to the fact that the customer base is large.

(C) Liquidity risk

- Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities.
- Management monitors rolling forecasts of the Company liquidity position and cash and cash equivalents on the basis of expected cash flows. The Company takes into account the liquidity of the market in which it operates. In addition, the Company's liquidity management policy involves projecting cash flows in major currencies and considering the level of liquid assets necessary to meet these, monitoring balance sheet liquidity ratios against internal and external regulatory requirements and maintaining debt financing plans.

Maturities of financial liabilities:

The tables below analyses the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

(Rs. in Lakhs)

Particulars	As at March 31, 2026		
	< 1 year	>1 Year	Total
Non-derivatives financial liabilities			
Borrowings	2103.90	4608.51	6712.42
Trade payables	742.25	668.87	1411.12
Other financial liabilities	10.12	0.00	10.12
Total	2856.27	5277.38	8133.66
Particulars	As at March 31, 2025		
	< 1 year	>1 Year	Total
Non-derivatives financial liabilities			
Borrowings	345.13	1347.25	1692.38
Trade payables	725.31	0.00	725.31
Other financial liabilities	0.00	0.00	0.00
Total	1070.44	1347.25	2417.69

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026**NOTE - 37 - DISCLOSURE REQUIREMENT UNDER MSMED ACT, 2006:**

The Group has certain dues to suppliers (trade and capital) registered under Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act). The disclosures pursuant to the said MSMED Act are as follows:

(Rs. in Lakhs unless otherwise stated)

Particulars	As at March 31, 2026	As at March 31, 2025
Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	124.62	151.97
Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	-	-
Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
Interest due and payable towards suppliers registered under MSMED Act, for payments already made	-	-
Further interest remaining due and payable for earlier years	-	-

Average credit period allowed by the supplier is generally exceed the time limit mention under MSMED Act, however no interest has been charged during the period under consideration.

NOTE - 38 - LIST OF JOINT VENTURES AND DESCRIPTION OF INTEREST:

Name of Joint Venture	Country of Incorporation	Proportion of Ownership Interest (%)	Nature of Business
MEDICOLAB	India	50%	Pharmaceutical products

The parent company have no share in contingent liabilities and capital commitments relating to joint ventures. There are no significant restrictions on the ability of a joint venture to transfer funds to the parent company.

NOTE - 39 - DETAILS OF SUBSIDIARY IS SET OUT BELOW:

Name of the entity	Relation	Place of business	For the year ended March 31, 2026	For the year ended March 31, 2025
EVAGRACE PHARMA PRIVATE LIMITED	Subsidiary	Ahmedabad	100%	100%
RITZ FORMULATIONS PRIVATE LIMITED	Subsidiary	Ahmedabad	100%	100%
SUNGRACE PHARMA PRIVATE LIMITED	Subsidiary	Ahmedabad	100%	100%
AZILLIAN HEALTHCARE PRIVATE LIMITED	Subsidiary	Ahmedabad	100%	100%
CALBORN LIFESCIENCE PRIVATE LIMITED	Subsidiary	Ahmedabad	51%	0%

NOTE - 40: The Group has not taken or given any assets on lease during the current year.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026
NOTE - 41 - FINANCIAL RATIOS:

The ratios as per the latest amendment to Schedule III are as below:

Sr. No.	Ratio Analysis	Numerator	Denominator	31-Mar-26	31-Mar-25	Variance (%)	Explanation of variance
1	Current Ratio	Current Assets	Current Liabilities	1.62	4.32	-62.39	The reduction in the Current Ratio is mainly attributable to higher utilization of working capital borrowings and increased trade creditors for financing the growth in business operations.
2	Debt Equity Ratio	Total Liabilities	Shareholder's Equity	2.08	0.34	515.72	The Debt-Equity Ratio increased from 0.34:1 to 2.08:1 primarily due to higher utilization of working capital borrowings and an increase in trade liabilities to support the expanded scale of business operations and higher inventory levels.
3	Debt Service Coverage Ratio	Net Operating Income	Debt Service	0.18	2.46	-92.74	'Decrease in DSCR due to higher side repayment of loans and interest
4	Return on Equity Ratio	Profit for the period	Avg. Shareholders' Equity	-1.11	0.50	-323.82	Return on equity decrease due to decrease in profit of the company
5	Inventory Turnover Ratio	Cost of Goods sold	Average Inventory	4.69	7.85	-40.26	Decrease in ratio due to higher inventory with lower input cost in current year
6	Trade Receivables Turnover Ratio	Net Credit Sales	Average Trade Receivables	2.82	3.43	-17.94	Decrease in ratio due to increase recovery in trade receivables.
7	Trade Payables Turnover Ratio	Total Purchases Payables	Average Trade	5.06	12.34	-59.01	Increase in Raw material prices, procured with advance payment
8	Net Capital Turnover Ratio	Net Sales Capital	Average Working	3.58	2.25	58.94	Increase ratio due to efficiency in utilization of working capital

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2025**NOTE - 41 - FINANCIAL RATIOS: (CONTD.....)**

The ratios as per the latest amendment to Schedule III are as below:

Sr. No.	Ratio Analysis	Numerator	Denominator	31-Mar-26	31-Mar-25	Variance (%)	Explanation of variance
9	Net Profit Ratio	Net Profit	Net Sales	-0.13	0.05	-353.54	Decrease in margin so ratio reduction in current year
10	Return on Capital employed	EBIT	Capital Employed *	-0.01	0.12	-112.14	Due to increase capital employed
11	Return on Investment	Return/Profit/ Earnings	Investment **	-1.11	0.50	-323.82	Increase in loss due to ration decline

NOTE - 42 - OTHER STATUTORY INFORMATION:

- The Company is not declared wilful defaulter by any bank or financial institution or other lender.
- The Company has not traded or invested in crypto currency or virtual currency during the financial year.
- The Company has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the year.
- No proceedings have been initiated or are pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made there under.
- In respect of Investment in subsidiary, the holding company has complied with the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013 read with Companies (Restrictions on number of Layers) Rules, 2017.

NOTE - 43 - RELATIONSHIP WITH STRUCK OFF COMPANIES:

There were no transactions or balances with struck off companies.

NOTE - 44 - FOREIGN CURRENCY EXPOSURE:

There was no foreign currency exposure as on March 31, 2026.

NOTE - 45 :

Previous year figures have been regrouped / reclassified wherever necessary to correspond with current year classification/disclosure.

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For V. GOSWAMI & CO,
 Chartered Accountants

FRN : 0128769W

Sd/-

Vipul Goswami

Partner

M.No. 119809

Place : Ahmedabad

Dated : 22/05/2026

UDIN : 26119809XQXRLT7422

For and on behalf of the board
Medico Intercontinental Limited

Sd/-

Tanvi Shah

Chairperson

DIN:-08192047

Sd/-

Jay Shah

Chief Financial Officer

PAN No.: CZOPS1007A

Sd/-

Samir Shah

Managing Director

DIN:-03350268

Puneeta Sharma

Company Secretary

PAN No.: CXOPS0548E

Book-Post

If Undelivered please return to :



MEDICO INTERCONTINENTAL LIMITED

CIN : L24100GJ1984PLC111413

Registered Office : 1-5th Floor, Adit Raj Arcade,
Nr. Karma Shreshtha Tower, 100 Ft Road, Satellite, Ahmedabad, Gujarat - 380015, India.